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Abstract
Molecular imaging is an emerging field that seeks to combine the mechanistic detail of biochemical assays
with the the broad phenotypic data obtained from non-invasive medical imaging. A cornerstone of molecular
imaging is the ability to chemically attach a contrast-inducing payload to a targeting ligand, a protein that
binds tightly and specifically to the targeted cell population. There are currently many approaches to
bioconjugation. Chemical approaches have broad applicability, but lack the site-specificity and efficiency
desired for contrast agent generation. Enzymatic techniques are quantitative, efficient, and site-specific, but
often have limited scope and can add significant bulk to the targeting ligand or require additional downstream
purification steps. In this work, we create a novel bioconjugation and protein purification technique, Sortase-
Tag Expressed Protein Ligation (STEPL). By fusing the active domain of S. aureus Sortase A to the targeting
ligand as part of a greater chimeric protein, we are able to combine protein purification and the C-terminal
bioconjugation of that protein into a single step. Using a mass-action kinetics model, we prove that this results
in a modular, efficient system capable of producing high-purity conjugated protein. We then use the system to
generate contrast agents for fluorescent and magnetic imaging studies. The modularity of the STEPL system
allows us to create an array of monospecific and bispecific targeting ligand dimers, linked by two different
spacer regions. The dimers' binding properties are probed and they are used to successfully bind and label
cells, with the bispecific proteins enhancing contrast of a cell line that is positive for both targets. Finally the
STEPL system is subjected to a number of directed evolution approaches and screened for a clone that could
further improve STEPL's efficiency and yield.
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ABSTRACT
THE DEVELOPMENT, USE, AND OPTIMIZATION OF SORTASE-TAG EXPRESSED
PROTEIN LIGATION
Robert L. Warden-Rothman
Dr. Andrew Tsourkas
Molecular imaging is an emerging field that seeks to combine the mechanistic detail of biochem-
ical assays with the the broad phenotypic data obtained from non-invasive medical imaging. A
cornerstone of molecular imaging is the ability to chemically attach a contrast-inducing payload to a
targeting ligand, a protein that binds tightly and specifically to the targeted cell population. There
are currently many approaches to bioconjugation. Chemical approaches have broad applicability, but
lack the site-specificity and efficiency desired for contrast agent generation. Enzymatic techniques
are quantitative, efficient, and site-specific, but often have limited scope and can add significant bulk
to the targeting ligand or require additional downstream purification steps. In this work, we create
a novel bioconjugation and protein purification technique, Sortase-Tag Expressed Protein Ligation
(STEPL). By fusing the active domain of S. aureus Sortase A to the targeting ligand as part of a
greater chimeric protein, we are able to combine protein purification and the C-terminal bioconjuga-
tion of that protein into a single step. Using a mass-action kinetics model, we prove that this results
in a modular, efficient system capable of producing high-purity conjugated protein. We then use the
system to generate contrast agents for fluorescent and magnetic imaging studies. The modularity
of the STEPL system allows us to create an array of monospecific and bispecific targeting ligand
dimers, linked by two different spacer regions. The dimers’ binding properties are probed and they
are used to successfully bind and label cells, with the bispecific proteins enhancing contrast of a cell
line that is positive for both targets. Finally the STEPL system is subjected to a number of directed
evolution approaches and screened for a clone that could further improve STEPL’s efficiency and
yield.
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Chapter 1
Introduction and Scope
The field of molecular imaging uses targeted contrast agents to study and diagnose disease [1].
By revealing the molecular basis of a disease, molecular imaging can help the medical community
understand what causes the disease, what treatment options are available, and how well a therapy
progresses. The workhorses of molecular imaging are targeted contrast agents, which can seek out
and interact with diseased cells in a specific fashion as well as influence some physical property on or
near the cells that can alter a medical imaging signal enough that a radiologist can pinpoint where
the contrast agent has found cells to bind. These two functions are usually mediated by separate
chemical entities, so the ability to efficiently link a targeting molecule to a contrast-producing payload
is a cornerstone of molecular imaging.
The importance of the linking reaction has led many groups to develop techniques that accom-
plish this goal. When both the targeting and contrast agents are small molecules, organic chemistry
provides a plethora of efficient linking reactions. However, the targeting ligands are often derived
from proteins, which makes the process much more complicated. A number of chemical crosslinking
approaches have been described that are capable of attaching a broad range of chemical function-
alities to a protein, but they generally suffer from inefficiency and random placement. Enzymatic
systems have produced better results because they tend to be site-specific, efficient, and stoichiomet-
ric, which are all important for generating imaging agents [2]. However, enzymes are often limited in
their substrates, add large amounts of bulk to the imaging agent, or require additional downstream
purifications.
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In this work, we develop and validate a novel, site-specific enzymatic ligation technique and il-
lustrate its applications to molecular imaging. We create a system that is both capable of accepting
most, if not all, categories of potential targeting proteins and payloads. In addition, our system
minimizes waste and avoids difficult purification workups, such as separating conjugated and uncon-
jugated proteins whose chemical differences may be as small as a single functional group. The use
of protein engineering and molecular biology tools enable us to build this ideal system.
This thesis is organized into six chapters. This first chapter provides a brief motivation and
summary of the other chapters. In Chapter 2, we review relevant literature pertaining to the fields
of molecular imaging, bioconjugation, and protein engineering. This will provide a solid background
for my thesis work, which lies at the intersection of all three fields. In Chapter 3, we describe Sortase-
Tag Expressed Protein Ligation (STEPL), a novel bioconjugation and protein expression technique,
which we believe has advantages over many existing bioconjugation technologies. In Chapter 4, we
use STEPL’s inherent modularity to create an array of dimeric targeting ligands and show how these
ligands enhance specificity in molecular imaging. In Chapter 5, we evaluate various strategies to
enhance STEPL through directed evolution. We then design and screen libraries to increase protein
yield. Finally, in Chapter 6, we review the thesis as a whole and discuss its contributions to the
fields of molecular imaging and bioconjugation. We will also describe opportunities to extend and
enhance the STEPL system for even broader applicability.
1.1 Literature Review
In Chapter 2, we briefly discuss topics relevant to this work.
Molecular Imaging
We describe the concepts underlying the field of molecular imaging as well as some of the pressing
medical issues that the field seems poised to solve. We detail the physical chemistry that drives
the five main imaging modalities and how contrast agents can be designed to influence their signals.
Emphasis is put on fluorescence and magnetic imaging, as they are used throughout this thesis. We
then discuss the concepts of passive and active targeting and how contrast agents are localized to
diseases. Next, we define biomarkers. Finally, we look at the emerging science of bispecific targeting
and its advantages over using a single ligand in particular scenarios.
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Targeting Proteins
This section details the origins of many of today’s targeting proteins, as well as the advantages
and downfalls of each technology. Emphasis is put on antibodies, and fragments thereof, as well as
scaffold-derived targeting ligands.
Bioconjugation
In an effort to establish the need for the novel bioconjugation system that is the centerpiece of this
thesis, we describe the history and current challenges in the field of bioconjugation. We discuss
traditional organic chemistry approaches to labeling proteins with bio-orthogonal functional groups.
We detail the mechanisms of these reactions and how the chemistries and proteins can be engineered
to produce better reactants. Additionally, we introduce the concept of “click chemistry,” a class
of efficient, biocompatible chemical reactions. Next, we discuss the use of enzymes to facilitate
bioconjugations. Careful attention is paid to the intein-based Expressed Protein Ligation system
and sortase-mediated transpeptidation, as these form the basis of our novel system.
Protein Engineering
Finally, we discuss the principles and techniques employed by the two schools of protein engineering,
rational design and directed evolution. We describe the power and precision of rational design
approaches, given there is enough known about the subject to use these techniques. Then we
describe the common methods used to evolve proteins by applying an artificial selective pressure to
create useful proteins even with very poor initial characterization.
1.2 Development and Validation of Sortase-Tag Expressed
Protein Ligation
In Chapter 3, we introduce Sortase-Tag Expressed Protein Ligation (STEPL). We discuss the new
technology’s design principles, optimal reaction conditions, and initial uses in molecular imaging.
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STEPL Design Strategy
Our novel bioconjugation system is driven by the desire to combine the best aspects of chemical and
enzymatic bioconjugation techniques while avoiding their downfalls. We accomplish this by using a
sortase domain in the same way that an intein is used in Expressed Protein Ligation. This results in
protein purification becoming dependent on bioconjugation, potentially yielding a pure, conjugated
protein directly off of the IMAC column. For each component of the STEPL system, we discuss the
choice of sequence and location within the chimeric protein.
Determining the Optimal STEPL Reaction
To validate and optimize the STEPL system, we generate an EGFP-STEPL chimera, which allows
us to quantitatively monitor the reaction by observing EGFP’s transfer from the metal resin to bulk
solution. This is first used to determine the optimal concentration for the necessary calcium trigger
ion in order to reduce unwanted random cleavage while maintaining enzyme activity. To optimize
the other elements of the reaction (time, temperature, and peptide concentration), a mass-action
kinetics model is described and fit to EGFP cleavage data. This allows us to determine the optimal
set of conditions for different desired outcomes.
Initial Applications
In order to prove STEPL’s utility in the context of molecular imaging, the system is used to express
small targeting ligands and conjugate fluorescent or chemically functionalized peptides to that ligand.
The fluorescent ligands are used directly for microscopy. The functionalized ligand is efficiently
attached to the surface of a magnetic nanoparticle. Both systems are assayed for their ability to
provide contrast by specifically labeling the cell population to which they are targeted.
1.3 Making Bi-specific Ligands with STEPL
In Chapter 4, we discuss how STEPL is an ideal system for quick and facile generation of useful
bispecific targeting ligands.
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Modular Protein Dimerization
STEPL is used to express two different targeting ligands and conjugate them to four different
functionalized peptides. Ligands bearing compatible chemistries are reacted with one another to
produce a panel of six dimeric ligands, which are confirmed by gel electrophoresis. We then discuss
the advantages STEPL has in dimer generation over other available technologies.
Increasing Contrast Agent Specificity
Wemeasure the differential ability of the monomer and dimer panel to bind and target cells displaying
one or both of the ligands’ antigens. These are then used as fluorescence contrast agents to specifically
label the double-positive cell population.
1.4 Enhancing STEPL Yield with Directed Evolution
In Chapter 5, we evaluate different systems for directed evolution that could be capable of enhancing
the STEPL reaction by decreasing cleavage during expression via altered calcium dependence. We
then discuss library designs and the results of screening those libraries by phage display.
Selecting an Evolution System
First, we explore the use of an E. coli display system. We describe potential display constructs
and screening protocols. Then we briefly consider a yeast display system and discuss why this is
sub-optimal. Finally, we look at the use of phage display by detailing a potential screening procedure
and the assays validating that screen.
Library Design
We discuss the different options available for library design. We explore the features within the
sortase enzyme’s structure that are known to bind the calcium ion and how the choice of degenerate
codons in that area could effect the enzyme’s structure and overall library size and health. Finally,
we look at different methods of generating the library and describe a way to accomplish this without
biasing the sequences toward wild-type.
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Screening Results
This section details our attempts at finding a better sortase domain through phage display. For each
library, we detail the conditions used for the positive and negative screens and the sequences that
the screen returns. We then clone the sequences into the EGFP-STEPL construct and assay them
for activity. For each round, we evaluate potential problems and justify changes that will be made
to the next round of library generation and screening.
1.5 Overall Discussion and Future Directions
Finally, in Chapter 6, we summarize the work presented in the previous chapters and discuss STEPL’s
place in the fields of molecular imaging and bioconjugate chemistry. We also describe future exten-
sions and applications of the technology that will increase its utility and broaden its impact.
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Chapter 2
Targeting Ligands in Molecular
Imaging
2.1 Molecular Imaging
The field of molecular imaging developed out of the desire to combine the advantages of medical
imaging and biochemical assays. While both imaging and biochemical assays are staples of modern
medicine and immensely powerful in their own right, neither can tell the whole story of a patient’s
disease state. Biochemical assays are performed ex vivo, requiring the removal of tissue from the
subject. The biopsy process irreversibly damages the cells and tissue in the sample and the subject.
It also only provides data from a very small portion of an organ at a single point in time, which is
problematic when assessing diseases that have a high degree of heterogeneity [3]. And while medical
imaging can describe the extent and phenotype of a disease, standard radiology can rarely uncover
the underlying mechanisms driving that disease [1]. Despite the limited information obtained by
standard imaging techniques, they are heavily relied on in the clinic.
One area where this information gap is especially pertinent is in cancer diagnosis. Although
cancer is classically thought of as a single disease, the scientific community has come to understand
that what we call “cancer” is really a collection of hundreds of unique proliferation diseases, each
with their own genetic causes, therapeutic interventions, and degrees of pathology [4]. Therefore,
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when imaging or another early detection method reveals a tumor, it is standard medical practice
to assume the worst possible cancer and begin treating that, even though the patient may have a
much milder disease [5]. This led to an overdiagnosis of tumors in recent years [6, 7, 8, 9, 10, 11].
Time and again, meta-analysis of tumor screening studies have shown that the once-touted “early
screening and diagnostics” recommended by oncologists and cancer advocates do more harm than
good [7]. Recently, the overdiagnosis controversy has spilled out of medical journals into mainstream
media [12, 13, 14]. One study casting doubt on the benefits of annual mammograms even landed
on the front page of The New York Times [15, 16]. That study followed 89,835 women over 25
years and found no significant reduction of the mortality rate between those who received yearly
mammograms and those who received yearly physicals. This problem is unlikely to go away unless
early detection screens begin yielding much more information.
This same problem is echoed in the increasingly specific indications for oncology therapeutics.
It is not uncommon for an antineoplastic drug to be effective in fewer than half of its recipients
[17]. This can make it incredibly difficult for a drug to pass clinical trials, requiring vast numbers
of patients to prove statistical efficacy. More importantly, low-response-rate drugs take a toll on
the health of nonresponders, both in unnecessary side effects and time not spent in an effective
therapeutic regimen. To combat these economic, regulatory, and human costs, many pharmaceutical
and biotechnology companies are using mechanistic knowledge about their drugs to target likely
responders by requiring the patients’ tumors to present specific biomarkers, molecular components
of the cells used to identify a specific disease [18, 19]. Use of biomarkers in Phase I and II clinical trials
nearly doubled between 2001 and 2009 [19], with more than 20% of those trials using a biomarker
as inclusion criteria [20]. The increasing popularity of targeted cancer therapies will require facile
and noninvasive ways to determine which patients fall under a drug’s dosing indications.
Molecular imaging stands to solve these problems by connecting the information derived from
fundamental cancer research with the utility and broad appeal of medical imaging. Rather than
imaging the electronic, nuclear, or physical structures inherent to biology, molecular imaging employs
man-made contrast agents that alter the image signal in their vicinity. The contrast agent is then
targeted to interact with a specific cellular phenotype. In this way, the contrast agent alters the
image only where cells exhibit that phenotype, making it possible to visualize microscopic pathology
at a macroscopic level.
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Figure 2.1: Fluorescence Guided Surgery. Injection of a fluorescent contrast agent allows a computer
to create a virtual model of the targeted tissue. That model is then superimposed on the real video
feed so that the surgeon can be sure they are resecting the entirety of the tissue. Reprinted from
[28] with permission from Elsevier.
2.1.1 Modalities
Molecular imaging contrast agents have been produced for all of the major imaging modalities:
fluorescence [21, 22], magnetic resonance [23], positron emission tomography/single-photon emission
computed tomography (PET/SPECT) [24], X-ray computed tomography (CT) [25], and ultrasound
[26]. There is no “ideal” modality. Each must be evaluated for its applicability based on the
resolution, sensitivity, and safety requirements of the project at hand. In this thesis, we label cells
with fluorescent and magnetic agents, which are described below.
Fluorescence
Fluorescence is a chemical phenomenon that occurs due to the excitation and relaxation of a
molecule’s electronic structure. When a compound interacts with a photon of compatible energy, the
electron in its highest occupied molecular orbital can be promoted to a higher-energy, unoccupied
molecular orbital. After promotion, it very quickly relaxes to the lowest vibrational state in the new
orbital, releasing the energy as heat. Even then, the heightened electronic state is unstable, and the
molecule will relax down to its ground state by converting the excess electronic energy into chemi-
cal, thermal, or radiant energy. Radiant energy release is observed as a photon. Thus, fluorescence
is when a compound releases a photon in response to photoexcitation. Due to the intermediate
vibrational relaxation, emitted photons usually have a lower energy than the exciting photon, a
phenomenon known as the Stokes shift [27]. By filtering out the high-energy photons, a clear image
can be obtained of the fluorophore’s location with an optical microscope or fluorescence scanner.
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In media that does not bend or scatter photons, fluorescence has the highest resolution of the
medical imaging modalities, as low as the wavelength of the emitted photon (and even more precise
with computer-aided ultra-resolution imaging), allowing the visualization of a wide range of biological
targets, from sub-cellular organelles to whole organs. Unfortunately, visible excitation photons are
readily absorbed and converted to heat in most biological tissues, limiting fluorescence to the top few
centimeters of tissue [29]. This makes the modality extremely useful for in vitro and small-animal
in vivo imaging, but greatly limits clinical use for diagnosis. However, one clinical application that
has recently emerged is fluorescence-guided surgery [28]. As shown in Figure 2.1, fluorescence and
white-light video feeds are overlayed on each other, allowing the surgeon to see the presence of a
fluorescent contrast agent in real-time. By showing surgeons the contrast agent, they are able to
remove all traces of a targeted cell population, even small tumor foci not visible to the human eye.
Magnetic Resonance
Magnetic Resonance Imaging (MRI) has become a mainstay of medical imaging due to its ability
to acquire high-resolution anatomical images without exposing the patient to ionizing radiation [1].
MR images are obtained by recording the bulk magnetic moment of water protons within a given
voxel. By carefully timing this measurement in relation to a series of applied magnetic fields, signal
differences can be observed between protons belonging to different tissues. MR contrast agents alter
how quickly the protons react to the external fields, resulting in a higher [30] or lower [31] signal
than the unlabeled tissue.
Higher signals, or positive contrast, are obtained with T1-weighted contrast agents, generally
Gd3+ [32]. The paramagnetic ion has seven unpaired electrons in the d-orbital, speeding up the
magnetic relaxation of coordinated water molecules. This results in more protons aligned with the
base magnetic field and a brighter image. Unfortunately, free Gd3+ is a potent calcium channel
inhibitor and is therefore highly toxic [33]. This can be mediated by chelating the ion with agents
such as diethylene triamine pentaacetic acid (DTPA) or 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA), which makes the Gd3+ biologically inert but also occupies seven of its eight
potential coordination sites. This greatly reduces the chelated ion’s ability to bind and relax nearby
water, requiring very high Gd3+ concentrations (10 - 100 µM) in order to produce contrast [34].
However, visible signal can be created by chelating many Gd3+ ions into dendrimer nanoparticles.
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Figure 2.2: SPIO-Mediated Tumor Contrast. MR images of mice before and after administration
of a Her2/neu targeted SPIO nanoparticle. Nanoparticle accumulation in the targeted tumor (B)
greatly decreases signal in the tumor tissue compared to the pre-administration image (A). Contrast
is not see on in the tumor that does not display Her2, either before (C) or after (D) administering
the nanoparticle. Arrows point to the location of the xenograft tumor. Adapted from [2] with
permission from John Wiley and Sons.
Our lab has loaded up to 300,000 Gd3+ ions onto a single dendrimer nanocluster, which successfully
labeled folate-receptor positive tumors in a murine model [35].
Lower signals, or negative contrast, are usually obtained with T2-weighted magnetic nanopar-
ticles, like superparamagnetic iron oxide (SPIO) crystals [32]. SPIO crystals align nearby water
protons to their own magnetic field, lowering the number aligned with the base magnetic field and
creating a darker image where SPIO is present, as shown in Figure 2.2. This effect can be en-
hanced by concentrating many SPIO crystals into the core of a nanoparticle [36]. Our lab also uses
SPIO particles, and has successfully labeled Her2-positive cells in vivo and in vitro on a number of
occasions [2, 37, 38, 39].
Nuclear Imaging
Radioactive nuclei can be detected using one of two techniques, positron emission tomography (PET)
or single-photon emission computed tomography (SPECT), depending on their decay mechanism.
For PET, radiohalides that undergo positron emission (β+) decay, like 18F and 64Cu, spontaneously
emit positrons. These quickly collide with their anti-particle, the electron, and annihilate, creating
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two 511 keV electrons traveling in exactly opposite directions. The electrons are detected and
their detection time and position are used to calculate their origin, thereby locating the agent that
produced them. By far, the most common PET agent used in the clinic is 18FDG, a glucose analog
that is taken up by cells with high metabolic activity. While a highly active glycolysis pathway is
unusual for healthy tissues, it is a common trait shared by many tumors, making 18FDG an effective
broad-spectrum tumor imaging agent [1]. The other nuclear imaging technology, SPECT, detects
radiohalides that decay by gamma emission, like 99mTc and 123I. Because these nuclei only emit
a single photon, their source’s position is harder to determine, making them orders of magnitude
less sensitive than PET agents. They also require halides with longer half-lives, further limiting
SPECT’s clinical relevance due to radio-exposure concerns [1].
X-ray computed tomography
Like a standard X-ray radiograph, X-ray computed tomography (CT) measures the attenuation of
high-energy X-ray photons while traveling through the patient’s body. However, CT is capable of
producing a three-dimensional reconstruction of the patient’s anatomy, making it much easier for
a radiologist to delineate anatomical structures. Because the ionization energy of iodine’s K-shell
electrons is similar to that of the X-ray photons, iodine has a large X-ray attenuation coefficient and
iodinated chemicals can be used to produce CT contrast [40]. These contrast agents generally have
low sensitivity, limiting their clinical utility due to the high amounts of iodinated contrast agent
necessary to alter the bulk X-ray attenuation of a tissue. CT is also limited by the number of times
a patient can be exposed to the ionizing X-ray photons in a given time period to minimize tissue
damage [1].
Ultrasound
Clinical ultrasound (US) detects the mechanical responses of biological tissues to high-frequency, 1 to
20 MHz, sound waves transmitted through that tissue. The US transducer emits a sonic pulse which
then travels along a straight line in the tissue. When that pulse reaches an interface between tissue
types, some of the mechanical energy is reflected back toward the transducer, which then detects the
reflection and calculates the distance to the interface based on the time it took to receive the signal.
The strength of the reflection is determined by the tissue types at the interface, allowing some level
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of delineation. Molecular contrast can be produced by targeted microbubbles, gas-filled liposomes
or polymerosomes. These bubbles can resonate with the US field, making them orders of magnitude
more reflective than normal tissues, enabling detection of micron-sized cell populations [1].
2.1.2 Targeting
Contrast agents need to be directed to their target cell population in some way. This can be
done passively or actively. Passive targeting relies solely on the physical properties of the agent
and target. The most common passive targeting approach utilizes the enhanced permeability and
retention (EPR) effect [41, 42]. The EPR effect is a phenomenon that occurs when a tumor induces
rapid angeogenesis to oxygenate its core. These blood vessels are made quickly and poorly, allowing
solutes in the blood to “leak” into the tumor interstitium. In addition, tumors generally have poor
lymphatic drainage, increasing the retention time of the solutes that leaked in from the blood. As a
whole, the EPR effect allows nanoparticles to “target” a tumor, simply because they preferentially
accumulate in that tissue.
In order for a nanoparticle to take advantage of the EPR effect, it must have a long circulation
time so that it can randomly leak into the tumor [43]. This can be achieved by coating the particle
with hydrophilic, biocompatible, inert materials, such as poly(ethylene glycol) (PEG). The sterics of
the PEG chains make it difficult for monocytes to phagocytose the particles, slowing their excretion.
Many groups have PEGylated their nanoparticles in order to target them via EPR [44, 45, 46].
A better approach for agents that require high concentrations for detection is active targeting.
Actively targeted agents rely on the contrast agent carrying a chemical group that binds tightly
and specifically to the target population. This binding event confers a few advantages on actively
targeted contrast agents. Active agents do not require poor lymphatic drainage to accumulate, as
their affinity to the tumor cells themselves prolongs their retention time [47]. They are able to
be internalized by recycled receptors, which greatly increases their local concentration and signal
contrast. On a decorated particle, the binding is multivalent, which can trigger internalization even
if the target biomarker is not recycled [48].
Targeting ligands can take a number of forms. Popular small-molecule targeting ligands include
folate [35, 38, 49, 50], estrone [51, 52], and TRX-20 [53, 54], which target cell surface folate receptors,
estrogen receptors, and chondroitin sulfate, respectively. These are easily attached by standard
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organic chemistry to nanoparticles or other contrast agents, making them an attractive choice. In
addition, due to their small size, a large number of small molecule ligands can be packed onto a
nanoparticle surface, increasing particle avidity and internalization.
However, small molecule ligands do not exist for most relevant biomarkers (including those
detailed in Section 2.1.3), so more complex targeting proteins are required. Protenaceous targeting
ligands must have a high affinity and specificity for their target biomarker. Sometimes these proteins
can be found in nature, such as using the epidermal growth factor to target the epidermal growth
factor receptor [55], but they are usually antibody derivatives or evolved binding scaffolds. Section
2.2 describes these proteins in detail. Attachment of proteins to the contrast agent is much more
difficult than to small molecules, but several strategies have emerged, which are discussed in Section
2.3. Although multivalency is also possible with protein-decorated nanoparticles, avidity is inhibited
at high protein densities and an optimal ligand density must be determined for each particle [38].
2.1.3 Biomarkers
A biomarker is any objectively measurable characteristic that gives insight into a biological process
or therapeutic response [56]. They can fall into one (or more) of four main categories. First are
diagnostic markers, which can be prognostic, indicating the presence or absence of disease, and/or
predictive, suggesting potential therapeutic treatments. Second, disease activity biomarkers report
the current disease severity, an important quantity when assessing therapeutic efficacy. Third,
drug effect biomarkers show how well a drug is interacting with its intended target and are used
to determine dosing. Note that this is not the same as a disease activity marker because a drug
reaching its target does not mean it will alter the course of the disease. Finally, there are drug kinetics
biomarkers, which measure prodrug processing and transport to the desired tissue. Biomarkers can
also be classified by their location in the tissue: genomic, cytoplasmic, cell surface, or systemic.
In molecular imaging, the focus is on diagnostic biomarkers, like those listed in Table 2.1 and
detailed below, that detect genomic or proteomic differences from healthy cells. In oncology, this
is often in the form of genetic amplifications, which lead to heightened levels of a protein in the
blood or on the surface of a cell. In situ hybridization, quantitative PCR, sequencing, ELISA, and
immunohistochemistry are commonly used to quantify the amount of biomarkers in patient samples.
These biomarker levels can be highly predictive of a patient’s response to a given drug, especially
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Table 2.1: Diagnostic Biomarkers
Marker Disease Type References
AFP Liver Cancer; Germ Cell Tumors Overexpression [57]
ALK Non-small cell lung cancer; anaplastic large cell lymphoma Splice Variants [58, 59]
B2M Multiple myeloma; Chronic Lymphocytic Leukemia; Peripheral Arterial Disease Overexpression [60]
BCR-ABL Chronic Myeloid Leukemia Translocation [59]
Beta-hCG Choriocarcinoma; Testicular Cancer Overexpression [61]
BRAF Cutaneous Melanoma; Colorectal Cancer Mutation [58, 59]
CA125 Ovarian Cancer Overexpression [62]
CA15-3 Breast Cancer Overexpression [63]
CA19-9 Pancreatic Cancer; Gallbladder Cancer; Bile Duct Cancer; Gastric Cancer Overexpression [64, 65]
CD20 Non-Hodgkin Lymphoma Overexpression [1]
CEA Breast Cancer; Colorectal Cancer Expression [1, 66]
CgA Neuroendocrine Tumors Overexpression [67]
Cytokeratin Pancreatic Cancer Splice Variants [68]
EGFR Mutliple Solid Tumors Overexpression; Mutations [1, 3, 56, 58, 59]
ER/PR Breast Cancer Overexpression [58, 59]
HE4 Ovarian Cancer Overexpression [66, 69]
Her2 Breast Cancer; Gastric Cancer Overexpression [1, 3, 58, 59]
Integrin αvβ3 Solid Tumors Overexpression [1]
KIT Gastrointestinal Stromal Tumor; Mucosal Melanoma Mutation [58, 59]
KRAS Colorectal Cancer; Non-Small Cell Lung Cancer Mutation [58, 59]
Mammaprint Breast Cancer Multiple Overexpressions [56]
MMP-2 Melanoma Activity [1, 70]
MMP-9 Melanoma Activity [1, 70]
Oncotype DX Breast Cancer Multiple Mutations [56, 59]
Ova1 Ovarian Cancer Multiple Overexpressions [66, 71]
PDGFR Malignant Pleural Mesothelioma Overexpression [72]
PK11195 Cerebral inflammation Expression [73]
PSA Prostate Cancer Overexpression [1]
Thyroglobulin Thyroid Cancer Overexpression [74]
uPA Breast Cancer Activity [75]
VEGFR Angiogenesis Overexpression [3, 70]
for targeted therapeutics [58]. Biomarkers that can be measured by immunohistochemistry, such
as cell-surface receptors, are prime candidates for molecular imaging because they are accessible to
targeting ligands [1].
EGFR
The epidermal growth factor receptor (EGFR) is the primary member of the ErbB family of receptor
tyrosine kinases, and plays an important role in cellular replication and differentiation [76]. Due to
its importance in regulating proliferation, overexpression of EGFR is common in many solid tumors,
including lung, breast, colorectal, and squamous cell tumors, among others [77]. Many studies have
targeted imaging agents and therapeutics to EGFR-positive tumors [78, 79].
Her2/neu
Human epidermal growth factor receptor 2 (HER2) is another receptor tyrosine kinase in the ErbB
family. It is overexpressed in approximately one third of all breast cancers due to an amplification
of the Her2/neu gene. This results in an overactive proliferation signal and generally aggressive
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cancers with poor clinical prognoses [80, 81]. Due to its extreme clinical relevance, a number of
therapeutics and diagnostics have appeared for Her2-positive tumors both in the clinic [82] and in
academia [83, 84, 85, 86].
2.1.4 Bispecific Ligands
Sometimes, one biomarker is not enough to selectively label a diseased cell. Many biomarkers, like
the ones described in the previous section, are displayed on a wide range of cells, both healthy and
diseased. And while the diseased cells may express the marker at a much higher level, even low
quantities of a surface receptor can mediate the uptake of a targeted particle [87]. One method to
further increase selectivity for a target cell population is to employ a bispecific ligand, a targeting
ligand that can bind to two different biomarkers. Many cancers express multiple disease biomarkers,
often in unusual combinations [88]. By requiring both markers, it is possible to greatly increase the
signal-to-noise ratio of a contrast agent or the therapeutic index of a pharmaceutical. For example,
Yan et al. targeted a 18F labeled bispecific peptide to GRPR (a marker of lung, colon, and prostate
cancers) and integrin αvβ3 (a general marker of solid tumors) [89]. They were then able to use
MicroPET to specifically label double positive PC-3 cells in a murine tumor model. In a different
study, Nie et al. targeted a PEG-PEI polyplex to the often-overexpressed transferrin receptor (TfR)
and integrin αvβ3 to deliver a luciferase gene. Not only did they see increased selectivity for tumor
cells, they also saw a synergistic effect, where the dual-targeted polyplex transfected cells more
efficiently that an equal dose of mixed TfR-targeted polyplex and integrin αvβ3-targeted polyplex
[90]. Synergy has been seen in a number of other studies, as well [91, 91, 92, 93].
A different application of bispecific ligands is to have one binding domain find a biomarker and
the other bind to the imaging agent/therapeutic itself. This is often done with bispecific antibodies
because the long circulation time and poor clearance of the antibody become problematic with toxic
imaging payloads [88]. For instance, Yazaki et al. made a bispecific antibody where one arm bound
the carcinoembryonic antigen (CEA) and the other variable domain bound the chelator DOTA [94].
They injected the antibody into nude mice bearing a CEA-positive tumor and allowed the antibody
to circulate, bind, and clear from the blood. They then gave an injection of 77Lu ·DOTA and allowed
that to bind and clear. Biodistribution studies showed that by using the pretargeting approach, the
group was able to increase the tumor-to-blood ratio of 77Lu from 3:1 with a directly labeled antibody
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to 199:1 with the pretargeted bispecific antibody.
Another use of bispecific ligands is to deliver agents across the blood-brain barrier. Unlike most
other tissues in the body, solutes in the blood do not easily diffuse into the brain. For example, IgG
content in the brain interstitial fluid is only 0.1%-0.7% of what is found in the blood [95]. This makes
it very hard to use molecular imaging to study neurological disorders. However, Yu et al. discovered
that a low-affinity protein targeted to the transferrin receptor was able to undergo transcytosis and
enter the brain compartment, so long as there is a sufficiently high dose of the agent in the blood
to drive binding on that side of the barrier [96]. By making bispecific antibodies with one arm
having a low affinity to transferrin receptor, they were able to separately image both the neuronal
marker NeuN and β-secretase in mouse brains (with the other arm of the antibody localizing to
those targets).
Bispecifics can also be used to crosslink two different cell types. This is most commonly done is the
context of bispecific T-cell engager (BiTE) ligands, which target CD3 on killer T-cells and a tumor
biomarker. Thus, the bispecific ligand recruits CD3+ cells to the tumor environment and activates
their cytolytic pathways. The first BiTE therapeutic, Blinatumomab, was recently approved for
use in the United States, in December 2014, for patients with Philadelphia-chromosome-negative
relapsed/refractory B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) [97]. It targets both
CD3 and CD19, a leukemia biomarker. Not only did the drug put most of its patients into complete
remission within the first treatment cycle, it also removed PCR-detectible traces of residual disease
in 78% of those patients [98]. If these results can be replicated in other tumor types, BiTE may
become a powerful new class of anti-cancer agents.
2.2 Classes of Targeting Proteins
Targeting proteins have a wide array of origins, which influences the final protein’s size, shape,
stability, and manufacturability. Just as there is no ideal imaging modality, there is no best targeting
ligand. Each one must be chosen for the desired application. Desirable targeting proteins will have
high affinity and selectivity for their targets, be small enough to allow polyvalency on a particle,
and simple enough to be produced robustly and cheaply.
Targeting proteins can be sorted into two major categories: those that are derived from antibodies
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and those that are evolved from a scaffold. Antibody-derived targeting proteins consist of portions of
an antibody that has been raised in an animal model. Scaffold-derived targeting proteins are derived
from mutated portions of natural structural or binding protein domains, such that they have a high
affinity for their new target and low affinity for their natural binding partners. Pertinent examples
of both are described below.
2.2.1 Antibodies
Antibodies, specifically IgGs, are the most common class of targeting protein. This is mainly due
to their high affinity and long history of utility in biomedical research [99, 100]. While costly
and complex to manufacture, the process of producing monoclonal antibodies from hybridomas has
been used since the late 1970s, diminishing these factors’ importance [101]. A larger problem to
molecular imaging and targeted therapeutics has been immunogenicity [102]. However, the steadily
dropping cost of DNA sequencing and rise of genetic engineering has made it possible to “humanize”
an antibody by cloning the antigen-binding regions of a non-human antibody into the human IgG
sequence [103]. The final factor to consider is size. Antibodies are the largest targeting proteins we
will discuss, with a hydrodynamic radius of about 5 nm [104]. This limits the number that can be
packed onto a nanoparticle, which may only have a radius of 20 or 30 nm itself [2]. It also gives
IgG a half-life in the blood of 23 days [105], much longer than is desirable for imaging applications
because of extended exposure to toxic imaging agents and prolonged times between imaging studies.
2.2.2 Antibody Fragments
Many of the problems with monoclonal antibodies can be avoided by using antibody fragments.
Protease digestions and molecular cloning have produced a plethora of antibody segments, which can
be seen in Figure 2.3. These smaller antibody pieces have many properties that are better suited to
imaging agents: faster clearance, improved tissue penetration, and increased tumor-to-blood ratios
[99]. However, these improvements are often counterbalanced by lower affinities, manufacturing
difficulties, slower uptake, and aggregation [106]. Still, antibody fragments have shown some clinical
success. Although scFvs were the first monovalent fragments to be developed, they are cleared
from the blood too fast to be good imaging agents on their own. They are ideal for nanoparticle
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Figure 2.3: Antibody Fragments. Protease digestion and recombinant DNA technologies can produce
many useful fragments of both standard and camelid IgGs. Adapted from [106] with permission from
DOVE Medical Press.
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Figure 2.4: Affibody Structure. A) The three-helix bundle structure of an affibody. The thirteen
mutable side chains are shown and their positions colored magenta. B) The mutated face of the
ZHer2 affibody forms the binding interface with the extracellular domain of Her2. The images are
produced using crystal structures determined by Eigenbrot et al. [107].
conjugations, though, as their small size allows for a much denser packing on the particle surface
than an antibody and the particle mass ensures longer circulation times. Diabodies and minibodies,
whose structures are detailed in Figure 2.3, seem to be big enough to have an acceptable half-life
and have been developed into clinically relevant PET/SPECT agents [1].
A currently emerging class of antibody fragments is derived from camelid, or heavy-chain, IgGs.
Usually produced by inoculating llamas, camelid IgGs lack a light chain, disulfides, and glycosylation,
making them much easier to manufacture. Due to the single-domain structure of the VHH region,
the antigen binding domain is much more soluble and can even be expressed in E. coli [106].
2.2.3 Affibodies
Affibodies are small (6.6 kDa) targeting proteins derived from a portion of S. aureus protein A
(SPA) that naturally binds IgG [108]. The 58-amino-acid B domain of SPA was mutated to increase
chemical stability, creating protein Z, shown in Figure 2.4A [109]. Protein Z has a number of useful
properties. The small size and lack of structural disulfides make affibodies ideal candidates for
expression in bacterial systems. Protein Z has also been shown to have remarkable heat resistance
and structural integrity, so much so that it has the fastest refolding time of any measured protein
at just 3 µs [110]. The small size also allows for high ligand to nanoparticle ratios, which increases
particle avidity and uptake [38].
Most importantly, thirteen of the amino acids on one face of protein Z can be simultaneously
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mutated to any other residue without altering the stability and structure of the protein [108]. This
allows the protein Z scaffold to be evolved to bind tightly to a target biomarker (see Section 2.4 for
details). These matured proteins are known as affibodies. Affibodies have been evolved to target a
wide array of biomarkers, including Her2, transferrin, amyloid β peptide, EGFR, Factor VIII, CD25,
HIV gp120, and CD28 [111]. They have very high affinities (in the mid- to low-nanomolar range) for
their targets. Affibodies have a standardized nomenclature of a capitol Z with the target molecule
as a subscript (ZTARGET).
An affibody often seen in the literature is ZHer2, which can be seen binding its target in Figure
2.4B. This affibody has been particularly useful due to its extremely high affinity (KD = 22pM,
[107]) and specificity for Her2. ZHer2 has proven highly successful in a large number of therapeutic,
imaging, and nanoparticle studies [2, 37, 38, 55, 112, 113, 114, 115].
2.2.4 Other Scaffolds
More than 50 different scaffold domains have been employed in creating targeting proteins over
the past few decades. Most of these scaffolds were never developed after their initial publication.
However, a few, like affibodies, have stood out in the literature and continue to be developed by labs
around the world [116].
Monobodies, also called Adnectins, are based on the 10th extracellular domain of human fi-
bronectin III (10Fn3 ) [121]. Monobody domains have structural homology to IgG. The 94 residues
form a β-sandwich fold with 2 or 3 exposed loops, which are often the randomized region. Unlike
IgG however, monobodies lack a central disulfide bridge, making them much easier to express in
prokaryotic systems.
Anticalins are derived from lipocalins [122]. They are the largest of the common affinity scaffolds,
forming a conical β-barrel fold comprised of 180 amino acids, which is still less than one third the size
of an antibody. As shown in Figure 2.5B, the anticalin binding interface is created by randomizing
the loops and internal residues near the wide end of the barrel. The domain shows a high level of
plasticity, often flexing from its ground-state conformation when binding to its target [116].
Designed ankyrin repeat domains (DARPins, Figure 2.5C) are affinity scaffolds that are made of
five stacked, short coiled-coil domains, usually totaling 166 residues [123]. Libraries are created by
randomizing 6 residues along the same side of each repeat structure. The structures are quite rigid,
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(A) Monobody (PDB ID: 4JE4 [117]) (B) Anticalin (PDB ID: 3BX7 [118])
(C) DARPin (PDB ID: 2BKK [119]) (D) Knottin (PDB ID: 4GUX [120])
Figure 2.5: Other Scaffolds. Scaffold proteins are shown in blue or green. Residues that had been
randomized to create a binding interface are colored pink. Disulfide bonds are colored yellow.
Target molecules are displayed in black. An electron density map, represented by a gray mesh,
shows how well the evolved residues of the affinity ligand fit with the target protein.
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and usually bind their target with a lock-and-key mechanism [116].
Another common structural motif is the knottin. These are the smallest of the scaffolds, usually
around 30 amino acids [124]. Six cysteine residues, forming three disulfide bridges (shown in yellow
in Figure 2.5D), are required so that a protein this small can have a stable tertiary structure. These
interlocking disulfides also make knottin ligands exceptionally stable with regards to boiling, low pH,
and many proteases. Unfortunately, the large number of disulfides make them notoriously difficult
to express and manufacture efficiently.
2.3 Targeting Ligand Conjugation
Bioconjugation is the process of forming a chemical bond between a biological agent, such as a
protein or nucleic acid, and a synthetic agent. This is critical to molecular imaging because the
targeting and imaging aspects of a contrast agent are rarely entirely biological or synthetic. 18FDG
and chimeric fluorescent proteins are notable exceptions. As such, bioconjugations are widely used
in the field of molecular imaging, and the existence of quantitative, efficient conjugate chemistries
are of the utmost importance [1, 125].
2.3.1 Chemical Ligations
A number of chemical methods have been developed to label ligands with cargo, including maleimide,
N-hydroxysuccinimide, carbodiimide, and click chemistries, all of which will be described below
[50, 126, 127, 128]. However, many of these approaches suffer from poor reaction efficiencies and
indiscriminate labeling of nucleophilic residues (e.g. lysines and cysteines) on the targeting ligand.
Random labeling of targeting ligands is problematic because a poorly placed cargo can greatly reduce
a ligand’s affinity for its target. Additionally, each targeting ligand may be labeled with any number
of functional moieties, eliminating their ability to be quantitative or stoichiometric.
Carboxyl-Amine Crosslinkers
Carbodiimides are a class of chemicals that can activate carboxylic acids by readily undergoing
condensation reactions and then serving as excellent leaving groups for amide formation with free
amines. The mechanisms are shown in Figures 2.6A and 2.6B. The carbodiimide group is relatively
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(A) Carbodiimide Heterobifunctional Ligation
(B) Carbodiimide-NHS Heterobifunctional Ligation
(C) Maleimide Ligation
(D) Strain-Assisted Azide-Alkyne Cycloaddition
Figure 2.6: Chemical Ligations
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unstable [129], thus, it is often used in combination with N -Hydroxysuccinimides (NHS) to improve
reaction efficiencies.
Typically, the reactive carboxylate resides on the imaging agent. Carboxylic acids are much more
common on proteins than primary amines [130], so activation of the imaging agent will decrease the
heterogeneity of the conjugation. Pre-activated agent will then be mixed with the targeting ligand,
which will form amide bonds with the imaging agent, producing a targeted contrast agent. Although
this conjugation strategy is popular, it is not efficient. Reaction yields are commonly between 1 and
20% when attaching a targeting ligand to a nanoparticle [129]. It also produces links at random
sites on the protein, which is deleterious to imaging agent efficacy [38].
Thiol-Amine Crosslinkers
Another popular chemistry for heterobifunctional crosslinking is the maleimide-thiol reaction. The
groups undergo an addition reaction in the presence of even a modest base, as shown in Figure 2.6C
[131]. The maleimide is generally only part of a crosslinker, not a part of the imaging agent itself.
The commonly used crosslinker is NHS-maleimide, which acts as a heterobifunctional thiol-amine
crosslinker. Part of the popularity of this linking reaction is due to the fact that while thiol groups
(cysteines) are present in most proteins, they are even less abundant than primary amines [132].
Some proteins, like Annexin A5 (an apoptosis biomarker) have no natural cysteine residues at all,
allowing Fonge et al. to introduce a single cysteine by site-directed mutagenesis [133]. They were
then able to conjugate their cys-Annexin A5 site-specifically and quantitatively to 99Tm−HYNIC.
Thiols can also be added to a protein via treatment with N-succinimidyl S-acetylthioacetate (SATA),
which converts free amines to sulfhydryl groups. Caution must be used while adding free thiol groups,
however, because they can spontaneously form disulfide bonds that lead to unwanted dimerization
and protein aggregation.
The converse, cysteine removal, is also possible. This type of cysteine engineering is often used
in the context of antibody drug conjugates. Antibodies naturally have eight cysteine residues that
form four disulfide bridges. Oddly, antibodies assemble correctly and retain their antigen affinity
with these bonds removed, although they lose some effector functions [134]. Thus, they can be used
as bioconjugation handles, allowing quantitative addition of eight drug molecules [135]. However, a
2-3 fold increase in therapeutic window is achieved by reducing the number of drugs per antibody to
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2-4 [136]. Reducing the number of conjugates has the unfortunate effect of introducing heterogeneity
to the antibody-drug conjugate, which is undesirable from efficacy, manufacturing, and regulatory
standpoints. Because the eight cysteine residues are not required, McDonagh et al. were able to
mutate some of the residues to serine without changing the structure or binding function of an
α-CD30 monoclonal antibody [137]. They were able to create homogeneous, effective antibody-
drugs conjugates by cysteine engineering and maleimide chemistry.
Azide-Alkyne Cycloaddition
A chemistry growing in popularity is the azide-alkyne cycloadditon, which creates a covalent link-
age in the form of a 1,2,3-triazole (shown in Figure 2.6D). The reaction is reliable, high yielding,
biocompatible, and bio-orthogonal. In fact, this reaction is efficient enough to be deemed a “click”
chemistry, which was defined by Sharpless et al. in 2001 [138] to be reactions that are: “modular,
wide in scope, give very high yields, generate only inoffensive byproducts that can be removed by
nonchromatographic methods, stereospecific (but not necessarily enantioselective).” They must also
have the following process characteristics: “simple reaction conditions (ideally, the process should
be insensitive to oxygen and water), readily available starting materials and reagents, the use of no
solvent or a solvent that is benign (such as water) or easily removed, and simple product isolation.”
In the presence of a copper catalyst, several groups have shown cycloaddition yields of greater than
90% in less than 24 hours at standard temperature and pressure [139, 140]. Unfortunately. the
copper catalyst has also shown cytotoxicity, limiting its usefulness [141]. To increase the biocom-
patibility while retaining reaction efficiency, the linear alkyne functional group was replaced by a
cyclooctyne [142]. The cyclic structure creates enormous ring strain and primes the triple bond for
cycloaddition. Not only did this allow the click reaction to proceed without a catalyst, it also accel-
erated the reaction compared to the copper-catalyzed incarnation [142]. The acceleration effect was
further enhanced by electrophilic substitutions at C3 and C8 around the cyclooctyne ring. Two of
these substituted rings, dibenzocyclooctyne (DBCO) and difluorocyclooctyne (DIFO) show triazole
formation rates 60-fold faster than their unsubstituted counterparts [143, 144]. The major drawback
of azide-alkyne cycloadditions in bioconjugation is that neither functional group is found in nature,
so they must be conjugated to a protein by another method, such as NHS-azide or DBCO-maleimide,
prior to the click reaction.
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2.3.2 Enzymatic Ligations
Enzymatic ligation techniques overcome many of the shortcomings attributed to chemical ligations
because they are generally site-specific and stoichiometric [128]. However, many naturally-derived
ligases are limited to natural, or minimally modified, substrates like biotin or lipoic acid [128]. These
additives can then be reacted with the desired cargo. Additionally, the enzymes need to be purified
from the conjugate product, a potential difficulty. Other enzymatic systems, such as SNAP tags,
fuse the enzyme itself to the protein of interest, adding significant and potentially disruptive bulk
to the targeting ligand [126].
Expressed Protein Ligation
Inteins are a class of enzymes that catalyze their own extraction from a mature protein by using
a cysteine or serine residue (the first amino acid within the intein domain) to displace the peptide
bond immediately preceding it, as shown in Figure 2.7. A transesterification then occurs between
the newly formed (thio)ester and a nucleophilic residue immediately following the intein domain.
Finally, a glutamine in the intein cleaves the intein domain from the branched polypeptide and the
ester rearranges to form a peptide bond, leaving an intact protein.
Many intein domains can be split to act in cis, allowing them to ligate together two separate
proteins. An intein particularly adept at this is the intein domain from Nostoc punctiforme DnaE
[145]. It can be split into a 123 a.a. N-terminal domain (IN) and a 36 a.a. C-terminal domain (IC)
that spontaneously associate and restore intein activity. The C-terminal domain is small enough to
be produced by solid-state peptide synthesis, making it amenable to the inclusion of bio-orthogonal
chemistries or non-canonical amino acids. Borra et al. took advantage of this possibility to site-
specifically label a transcription factor in situ [146]. They synthesized an IC peptide containing a
FITC fluorophore C-terminal to the intein region and a dabcyl within the intein, which showed 99%
quenching and improved their signal 30-fold. They transfected the quenched peptide into cell lines
expressing the YY1 transcription factor fused to the IN domain. The split intein reacted in the
cytosol to create a fluorescent YY1 that they tracked to show the effect of active vs. passive nuclear
transport on YY1.
By removing catalytic residues either N-terminal or C-terminal to the intein domain, a crippled
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Figure 2.7: Expressed Protein Ligation. A) Schematic of the intein purification system. The fusion
protein is isolated by affinity chromatography and cleaved off of the column with addition of a
sulfhydryl group. B) The molecular mechanism of intein purification. Four different purification
options are presented. EPL is pathway III, with the cysteine being the N-terminal residue of a
synthetic peptide. Reprinted from [147], Copyright 1997, with permission from Elsevier.
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intein is formed. These can only partially complete their mechanism, leaving a primed thioester that
can be displaced by a different sulfur nucleophile, generally mercaptoethanesulfonic acid (MESNA)
[145]. As detailed in Figure 2.7, Expressed protein ligation (EPL) takes advantage of this by fusing
one end of a crippled intein to a chitin binding domain and the other end to the target protein.
Because the target can be fused to either side of the intein, it can be labeled on either the N or
C terminus. The chimera is expressed in E. coli, bound to a chitin column, and washed to remove
impurities. MESNA is then added overnight to cleave the target off of the intein and column. A
cysteine-containing peptide can then displace the MESNA, labeling the target with whatever else
the peptide contains.
Our group has used EPL extensively to attach affibodies and antibody-linked Protein Z to a
variety of nanoparticles [2, 37, 38, 39]. EPL allows us to attach an alkyne moiety to the C-terminus
of our targeting ligand. This is then covalently bound to particles displaying azide groups via highly
efficient click chemistry. We have also shown that using EPL instead of traditional chemistries
has significant advantages in particle targeting, presumably because the C-terminal label gives the
targeting ligand orientation relative to the particle [2]. For the same reason, Venter et al. used EPL
to produce antigens for a nanoparticle-based vaccine. Maltose-binding protein was expressed and
linked to a peptide containing an aminooxy group, which was subsequently linked to benzaldehyde-
displaying virus-like particle. The aniline-catalyzed ligation produced a particle displaying antigen
in a defined orientation with icosahedral symmetry, which greatly increased the B-cell response over
antigen alone.
Sortase-Tag
Sortase is a transpeptidase found in gram-negative bacteria. It catalyzes the cleavage of the Thr-Gly
peptide bond within its LPXTG recognition motif and the subsequent formation of a new peptide
bond between the now-C-terminal threonine of the motif-containing protein and the primary amine
of a glycine residue (Figure 2.8A). This is done by a reverse-protonated, mono-iso bi bi ping pong
reaction mechanism with a hydrolytic shunt [148], as depicted in Figure 2.8B. At the enzyme’s
optimal pH of 7.8, only a small fraction of the catalytic residues C189 and H120 are correctly
protonated. Therefore, very little of the enzyme is in an active state, about 0.06% [148]. Despite its
low activity, sortase has proven to be one of the most useful enzymes for bioconjugations [149, 150].
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Figure 2.8: Sortase A Mechanism. A) Reaction diagram of the sortase catalytic mechanism. First,
Cys184 cleaves the LPXTG motif between the T and G via tholysis. Then, a peptide beginning with
glycine cleaves the LPXT from the acyl-enzyme intermediate, regenerating the sortase enzyme. B)
Sortase reaction schematic featuring both the transpeptidation and hydrolysis pathways. Adapted
from [148] with permission from John Wiley and Sons.
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The only requirements for sortase tagging, or “sortagging”, seem to be an LPXTG motif and an
N-terminal glycine, although using three to five glycine residues has been shown to improve reaction
efficiency [151]. Calcium is also needed to activate the enzyme. Either can be preceded or followed
by a fully-folded protein or synthetic peptide. As such, sortagging has proven to be a flexible and
broad approach to enzymatically tagging the N- or C- termini of proteins.
Many groups have successfully used the soluble domain of Sortase A (SrtA) from S. aureus in
concert with a fused LPETG motif. That system has been used to label full-length antibodies with
radiohalides for imaging studies [152], an isotopically-labeled, insoluble SH3 domain with a non-
labeled GH1 solubility tag for protein NMR [153], bacterial adhesins to fluorescent microspheres
to study bacterial adhesion to host cells [154], as well as many other applications that have been
previously reviewed [149, 150].
One challenge in sortagging has been that the ligation regenerates an LPXTG motif and produces
a new glycyl-amine, which can lead to the production of the original motif-containing protein and
reduce reaction efficiency. To mitigate this reverse reaction, some have run the ligation in dialysis
tubing to selectively remove the unwanted product [153]. More recently, the Liu group has replaced
the glycyl-amine of the peptide tag with a hydrazine [155]. The modification is still recognized by
the enzyme for ligation but the product is no longer able to serve as a cleavage substrate. Thus,
they produced an irreversible sortagging reaction that led to higher yields and increased purity.
Because the sortase mechanism includes both a cleavage and ligation, the enzyme can be used to
concurrently purify and conjugate a target protein. Chilkoti et al. fused an LPETG motif between
their target protein and an elastin-like-peptide (ELP) [156]. By raising the temperature, they
aggregate the ELP fusions and purify their protein from bulk lystate. They then add an ELP-
tagged sortase, calcium, and a synthetic peptide, which cleaves the ELP tag off of the target protein
while ligating the synthetic peptide to the target. By again inducing ELP aggregation, the ligated
target protein is separated from the unligated target, cleaved ELP tags, and enzyme.
Biotin Ligase
Biotinylation is an attractive method for labeling proteins due to the small size and high specificity
of the tag as well as the femtomolar interaction between biotin and avidin [125]. The E. coli biotin
ligase, BirA, catalyzes the ligation of adenylated biotin to the lysine residue within the 15-amino-
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Figure 2.9: Biotin Analogs. Both ketone 1 (A, [157]) and cis–propargyl biotin (B, [162]) can be
ligated to the biotin acceptor peptide and directly enable bio-orthogonal chemistries.
acid biotin acceptor peptide (BAP) sequence, GLNDIFEAQKIEWHE. BirA is highly specific for
the BAP sequence; overexpressing the enzyme in mammalian cells does not result in biotinylation
of any endogenous proteins [157]. Only one protein is naturally modified by BirA in E. coli cells,
the biotin carboxyl carrier protein (BCCP).
The interaction between biotin and avidin-family proteins is well-characterized and the most
common method of functionalizing a BirA-modified protein. Fluorescently-labeled streptavidin has
been used to image EGFR and AMPA trafficking [157, 158], nanoparticle biodistributions [159, 160],
and even track single neurotrophic factors moving along an axon in real time [161].
While BirA is exquisitely selective for the BAP sequence, it tolerates some promiscuity in the
biotin moiety itself. For example, Chen et al. determined that wild-type BirA will ligate ketone
1 (Figure 2.9A), allowing direct modification of labeled protein with a hydrazine [157]. Slavoff et
al. tested biotin ligases from eight species for activity with a number of biotin analogs [162]. They
found that the enzyme from Pyrococcus horikoshii accepts desthiobiotin azide and cis-propargyl
biotin (which has an alkyne group, Figure 2.9B), allowing them to directly modify proteins for use
in click-chemistry reactions.
Transglutaminase
Microbial transglutaminase (mTG), most often from Streptomyces mobaraensis, catalyzes the trans-
amination reaction of the γ-carbonyl amide of a glutamine with the ε-amine of a lysine or another
primary amine supplied in excess. mTG exhibits broad specificity toward its substrate glutamines,
which is convenient if genetic manipulation of the target protein is impractical. Although there are
no specific sequence requirements for mTG, it generally only recognizes one or two of a protein’s
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surface-exposed glutamine residues. This common belief of limited active glutamines may be due
to publishing bias, however [163]. mTG’s specificity is instead due to local secondary structure (the
Gln must be on a loop) and the properties of nearby residues. Thus, the active glutamines must be
empirically determined for each protein of interest.
A number of approaches have been developed to limit mTG activity to a single site on a target
protein. For instance, producing human IgG1 without glycosylation allows only a single γ-carbonyl
amide to be recognized in the constant region of the heavy chain. Thus, Dennler et al. were able
to produce homogenous antibody-drug conjugates with enzymatically deglycosylated commercial
Trastuzumab (Herceptin) [164]. Mero et al. took advantage of the structural specificity of mTG
by running the enzymatic labeling reaction in PBS with an organic co-solvent, which generally
alters protein structure by disrupting hydrophobic collapse. Adding 30% (v/v) DMSO and 50%
(v/v) ethanol led to site-specific PEGylation of salmon calcitonin and human growth hormone,
respectively, which each have two natural mTG sites [165].
If a target protein has no natural mTG sites, a Q-Tag (PKPQQFM) or K-Tag (MKHKGS)
can be engineered into the protein sequence [166, 167]. For example, Kitaoka et al. attached a
K-tagged alkaline phosphatase to DNA containing glutamine labeled dUTP to produce a sensitive
DNA hybridization probe that could detect as little as 10 fg of target DNA [168].
Aldehyde Tag
Formylglycine-generating enzyme (FGE) can be used to create a unique aldehyde functional group
on a protein. Posttranslationally, FGE oxidizes the cysteine residue within a CxPxR motif to create
a formylglycine (fGly) residue, which can be further functionalized by hydrazone or oxime formation
[169]. Because aldehyde groups are not present in any of the canonical amino acids, the conversion
of a cysteine to formylglycine creates a site-specific, genetically-encoded conjugation handle. Ad-
ditionally, FGE is expressed naturally in the cytoplasm of many prokaryotes and eukaryotes [170]
and can be artificially expressed in secretion pathways [171], making the aldehyde tag accessible to
nearly all expression systems.
Another major advantage of the aldehyde tag is that it is not limited to the N- or C-terminus of the
target protein, but can be present anywhere that is surface accessible. This has proven particularly
useful when engineering monoclonal antibodies to display a specific glycosylation pattern because
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the sugar moiety can be placed in its usual location along the Fc molecule [172]. In a different
study, Drake et al. created a small library of monoclonal antibodies displaying an aldehyde tag in
different locations [173]. After conjugating a drug to the aldehyde, they found that the location not
only affected conjugation efficiency, but also the pharmacodynamics and pharmacokinetics of the
antibody-drug conjugate.
One drawback of the hydrazone and oxime chemistry generally used with the aldehyde tag is
that it is reversible, complicating robust and quantitative protein labeling. To address this issue,
Agarwal et al. created tryptamine derivatives that first react with an aldehyde to create a traditional
oxime and then continued with a Pictet-Spengler reaction that creates a stable carbon-carbon bond
[174]. After being incubated for a week at room temperature, proteins ligated by the Pictet-Spengler
method remained largely conjugated, while those conjugated using oxime chemistry showed nearly
complete hydrolysis.
Sugar Remodeling
IgG carries two well-characterized N-linked glycans. These sugar trees can be trimmed and regrown
post-purification. Because the glycosyltransferases necessary to rebuild the glycan are known to
tolerate chemical modification of their sugar-nucleotide substrates, it is possible to include small
bio-orthogonal functional groups in the remade glycosylation pattern [125]. For example, Li et al.
used a galactosyltransferase (GalT) to remove the outer galactose and sialic acid from a monoclonal
antibody and then religate the galactose residue [175]. They then added recombinant sialyltrans-
ferase (ST6GalI) and azido-modified sialic acid to finish the glycosylation pattern and incorporate
four azide groups per antibody. They then used strain-assisted azide-alkyne click chemistry to add
a variety of chemical functions to the antibody in a site-specific and quantitative manner. While
this technique is powerful and has been used by a number of groups [176, 177, 178], it is limited to
proteins that have well-defined surface glycans.
Fusion Protein Tags
The SNAP tag consists of the active domain of the human DNA repair protein O6-alkylguanine-
DNA alkyltransferase (hAGT) [179]. In the cell, hAGT transfers a methyl group from an O6-
alkylguanine, irreversibly generating a guanine residue and converting the hAGT active site cysteine
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into a methionine. Keppler et al. correctly hypothesized that they could use this mechanism to
permanently ligate other alkyl chains to the hAGT active site. They found that the protein was
incredibly tolerant of O6-benzylguanine (BG) derivatives, allowing them to conjugate biotin and a
number of fluorophores to hAGT. And by genetically fusing hAGT to the N- or C-terminus of a
target protein, they were able to directly and specifically ligate their BG derivatives to the target
protein in any cellular compartment. The technique’s ease of use and broad applicability made
it popular in the scientific literature. Largely used for fluorescence imaging, including advanced
techniques like super-resolution imaging [180] and total internal reflection fluorescence microscopy
[181].
The popularity of the SNAP tag led Gautier et al. to evolve the CLIP tag [182]. Eight mutations
were able to alter the specificity of hAGT from O6-benzylguanine to O6-benzylcytosine (BC), while
maintaining promiscuity in the O6-alkyl chain. In fact, the change in substrate specificity was so
complete that SNAP and CLIP tags can be used in tandem for multichannel labeling of cellular
proteins. An example SNAP/CLIP system is provided by Maurel et al., who used SNAP- and
CLIP-tagged proteins to show membrane protein interactions by independently labeling them with
fluorophores capable of performing time-resolved fluorescence resonance energy transfer [183].
The major drawback of all fusion tags is their ability to alter the functions of the target protein.
This was specifically put to the test by Landgraf et al. by fusing their protein of interest, a Clp
protease to a variety of fusion tags [184]. Prior to the Landgraf study, the Clp family of proteases
had widely been reported to form foci in the E. coli cytoplasm. They hypothesized that after cell
division, an observable (fluorescent) protein should be degraded by Clp faster in the daughter cell
that retained the Clp foci than the daughter cell that needed to synthesize a new one. However, they
saw no difference in degradation rates between daughter cells with untagged ClpX. This led them to
fuse more than 20 visualization tags to ClpX, including the SNAP tag. The result, shown in Figure
2.10, shows the incredible differences in ClpX localization due entirely to their fusion partner. So
while fusion tags can be very powerful tools, the consequences of adding a large fusion domain must
also be kept in mind.
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Figure 2.10: Effects of Fusion Domains. Landgraf et al. fused the protein ClpX to a number of dif-
ferent fusion tags, mostly fluorescent proteins, which caused the proteins to congregate in foci within
the E. coli cell. From the paper: “(a) Schematic of antiparallel fluorescent protein dimer (yellow)
dissociating into monomers (top) and of avidity effects potentially clustering tagged ClpX hexamers
(blue; bottom). For simple monomers, re-association is slow because the molecules diffuse apart;
for tagged oligomers, the complex acts as a scaffold to facilitate re-association. (b) Immunofluores-
cence microscopy with an antibody to ClpX (anti-ClpX) in the wild type (left; magnification of the
boxed region is shown on the right), clpX-Venus strain (middle; Venus fluorescence is shown on the
right) and ∆clpX strain (right). Insets, phase-contrast images. (c) Fluorescence images of bacte-
ria expressing ClpPSNAP tag labeled with tetramethylrhodamine (TMR), compared to wild type
(negative control). Insets, phase-contrast images. (d) Fluorescence images of bacteria expressing
the indicated constructs. Cell outlines (red) are shown for cells with weak cytoplasmic signal. (e,f)
HILO microscopy of gently fixed cells expressing ClpX-mGFPmut3 (e) and ClpP-mGFPmut3 (f).
(g) Phase-contrast (left) and live-cell HILO microscopy fluorescence images (right) of cells expressing
ClpP-mGFPmut3 taken one second apart at time points t1-t4. Scale bars, 1 µm.”
Reprinted by permission from Macmillan Publishers Ltd: Nature Methods [184], copyright 2012.
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2.4 Engineering Ligands and Enzymes
Nature has provided a host of interesting proteins that can be used for both targeting and ligations.
However, native proteins are often unsuitable for man-made systems, as was previously discussed
in Section 2.2. When this happens, it is the province of protein engineers to deliver a custom
protein tailored to the system at hand. The techniques used to develop novel proteins fall into two
broad categories: rational design and directed evolution. As the name implies, proteins created
by the rational design approach are the result of deliberate mutations, fusions, or deletions that
are hypothesized to add or remove specific functionality. In contrast, directed evolution involves
introducing a large number of mutations, in excess of 107, to a coding sequence. The resulting
proteins are expressed in parallel with some link to their coding sequence and then subjected to
rounds of rigorous screening. Only the proteins that meet the conditions of the screen are recovered.
Those sequences then receive additional mutations and are put through another screen; a cycle that
is repeated until a protein that completes its objective with the desired quality is recovered. Both
schools of thought have significant benefits and downfalls, which will be discussed.
2.4.1 Rational Design
The rational design of proteins leverages basic science discoveries in structural biology, systems
biology, and enzymology to create proteins with novel functionalities. Rational design approaches
have the advantage of being hypothesis-driven and testable, making it easy to determine efficacy.
Because so much is known about the systems chosen for rational design, they have a higher likelihood
of success. A heavy dependence on biophysical data is a major downfall of the approach, due to
relative scarcity of well-characterized protein systems and the extensive time and cost required to
obtain that data. Even with those limitations, rational design has been producing useful proteins
for as long as we have been able to read and modify the genetic code.
Chimeric Proteins
Like the mythical beast of ancient Anatolia that had the heads of a lion, goat, and snake, protein
chimeras consist of globular domains from different proteins that have been fused together into a
single polypetide chain. Utilizing molecular cloning techniques or direct DNA synthesis, the engineer
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Figure 2.11: Chimeric Scaffolds Enhance Biosynthetic Pathways. A) Dueber et al. fuzed enzymes
in the mevalonate biosynthetic pathway to protein binding domains and created a scaffold protein
to co-localize the enzymes in specific ratios. B) Mevalonate synthetic flux is altered by changed
the scaffold:enzyme ratios while holding enzyme expression constant. Reprinted by permission from
Macmillan Publishers Ltd: Nature Biotechnology [186], copyright 2009.
is able to create a coding sequence containing the genetic instructions for each desired domain in
series and in frame. By doing this, we can combine the functions of disparate proteins.
Often, these combinations are used to alter the localization, regulation, or binding partners
of a useful enzyme. For example chimeric antigen receptors (CARs) are the fusion of one of the
targeting ligands mentioned in Section 2.2 with the transmembrane and signaling domain of CD3ζ
[185]. When transfected into killer T-cells, CARs redirect the cells’ cytotoxic effect toward a cell
population determined by the targeting ligand. This effect was later enhanced by fusing additional
signaling domains (CD28 and CD134) C-terminal to CD3ζ. This allowed the CAR to simultaneously
activate co-stimulatory pathways that maintain the activated, cytolytic phenotype for longer periods
of time, making the cells much more effective.
Another common use of chimeras is to fuse a binding domain to a protein of interest to direct its
localization inside or outside of the cell. The simplest example of this is the hexahistidine tag; six
histidine residues fused to the N- or C-terminus of a protein imparts high affinity for certain transition
metals. This is used to localize proteins in a cell lysate slurry to added metal-coated beads, purifying
the target protein from the bulk cell solution. This same concept can enable much more complex
interactions. For instance, Dueber et al. fused the enzymes AtoB, HMGS, and HMGR to orthogonal,
transgenic protein-binding domains [186]. They then expressed chimeras of the partner domains
in varying ratios to create scaffold proteins (Figure 2.11). The scaffold significantly increased the
effective concentration of each enzyme in the biosynthetic pathway, allowing them to produce 77-fold
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more product without the additional metabolic burden of overexpressing the enzymes individually.
Due to the innate modular nature of proteins, each globular domain is often fully functional in
the new context of a chimera because globular domains tend to fold independently of one another. To
ensure the independent folding and functionality of each of a chimera’s domains, linker regions can
be included between domains. While linkers are not generally a primary design focus, their selection
can play an important role in protein stability and function [187]. Variations of the glycine-serine
linker, (GGS)n, are the most frequently used linkers due to their flexibility, solubility, and resistance
to proteolysis. On the other end of the spectrum, α-helical linkers, (EAAAK)n, are rigid and can
be used to deter interactions between domains.
Crystal Structures and Computational Analysis
Crystal structures are one of the most important tools in rational design. Using a suite of in silico
tools, such as PyMol [188] and Rosetta [189], the effects of mutations, deletions, and fusions can be
modeled and analyzed before ever reaching the wet lab. Homology modeling allows us to approximate
the tertiary structure of chimeric proteins and predict interactions between domains [190]. Modeled
binding interfaces enabled Han et al. to create a decoy TLR4 receptor specific to the MD2 ligand
[191]. By using a crystal structure of the bound proteins and predicting the change in free energy
resulting from mutations to TLR4, they increased the affinity twenty-fold.
As our understanding of protein structure and function matures, de novo protein design software
is becoming more common and useful. For example, Richter et al. used the Rosetta3 enzyme
modeling suite [192] to design a custom esterase [193]. They used the software to first scan and score
214 potential scaffold enzymes. Next, Rosetta produced a series of mutations to try and optimize
enzyme binding to the transition state of the thiolysis reaction, creating a library of theozymes
(theoretical enzymes). Quantum mechanical calculations were then run on the theozyme mechanisms
to predict reaction rates and cull the library down to 55 candidates, which were cloned and screened
in the wet lab for valid enzymes.
Site-Directed Mutagenesis
Site-directed mutagenesis (SDM) is a simple method that can make profound changes to a protein’s
stability or function. In SDM, a protein engineer makes specific, targeted changes to the DNA
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encoding a protein, resulting in an altered primary structure. The mutations are generally driven
by knowledge of the protein’s crystal structure or the enzyme’s mechanism.
One of the first applications of SDM in protein engineering was to improve protein stability.
A primary source of instability is oxidative stress, especially if the protein has been removed from
its natural environment, which often occurs with industrial enzymes. Subtilisin, a promiscuous
protease found in the Bacillus family, is one such enzyme. It was known that exposure to oxidative
stress led to the conversion of Met222 to methionine sulfoxide and complete inactivation of the
enzyme within minutes [194]. Using SDM, Estell et al. were able to mutate M222 to all 19 other
amino acids and measure their activity and peroxide tolerance [195]. They found that while the
M222A mutation reduced activity by 47%, it also made the enzyme impervious to even 1M H2O2.
The mutated enzyme is also resistant to inactivation by bleach and is now a common ingredient in
laundry detergent [196].
Perhaps the most common modern application of SDM is a loss-of-function mutation. Most
enzyme families have one or two residues that are necessary for their function. These can be
easily identified as they are highly conserved when comparing primary structures. For example,
the C-terminal asparagine is strictly conserved in all intein domains [197]. Mutation of the critical
asparagine residue to alanine results in a branched protein because the intein is unable to complete
its splicing function, resulting in a crippled intein. These partially inactivated inteins form the
basis of the expressed protein ligation technique described in Section 2.3.2 by leaving the N-extein
attached to the protein by a thioester that can be cleaved by an external sulfide group [198].
Less common is a gain-of-function mutation. It is much harder to intuit how altering one or two
amino acids will add a function than how removal of a reserved residue will remove functionality from
a protein. It can be done, however by studying naturally occurring mutations that result in a change
of substrate, product, or binding partner. For example, Reitman et al. mined cancer mutation data
to identify candidates for an enzyme to synthesize (R)-2-hydroxyadipate [199]. They found that a
mutation in the enzyme isocitrate dehydrogenase (IDH) catalyzes a reaction whose product is only
one carbon shorter than (R)-2-hydroxyadipate (Figure 2.12B). The wildtype IDH enzyme is closely
related to homoisocitrate dehydrogenase (HIDH), which serves the same catalytic function as IDH,
but with a metabolite one carbon longer (Figure 2.12C). They correctly hypothesized that making
the analogous mutation to HIDH would lead to the formation of (R)-2-hydroxyadipate, giving the
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(A) Wild-type IDH (B) Mutant IDH (C) Wild-type HIDH (D) Mutant HIDH
Figure 2.12: Gain of Function Mutation. Reitman et al. determined the mutation required to
alter the IDH substrate from (2R,3S)-isocitrate (A) to 2-oxoglutarate (B). They then mapped that
mutation onto the homologous enzyme HIDH, enabling the desired conversion of 2-oxoadipate to
(R)-2-hydroxyadipate (D). Differences in IDH and HIDH substrates are drawn in red. Difference
between the wild-type and mutant substrates are drawn in blue. Adapted with permission from
Macmillan Publishers Ltd: Nature Chemical Biology [199], copyright 2012.
enzyme a new function with only a single mutation.
Recently, SDM has also been gaining traction as a way to introduce unnatural amino acids. Life
has done amazing things with the current twenty canonical amino acids since the standard genetic
code was set at least 2.5 billion years ago [200]. However, the natural amino acids exclude large
portions of the chemistry that can be performed in a lab environment. To bridge this gap, many
research groups have devised ways of incorporating synthetic amino acids with novel functionality
into a cell’s genetic code. The most common way to do this is by suppressing the amber stop codon
(UAG), which accounts for only 7% of E. coli stop codons and is rarely the terminator of critical
genes [201]. By co-transforming cells with orthogonal tRNA and tRNA synthetases, it is possible to
introduce a 21st amino acid into the genetic code. SDM is then used to mutate a natural codon to
TAG, which will be translated by the ribosome into the unnatural amino acid. An example comes
from Hui and Tsourkas, who used amber suppression to replace residues in Protein Z with p-benzoyl-
L-phenylalanine (BPA), a phenylalanie analog containing a benzophenone photocrosslinker [202].
They used SDM to incorporate BPA into 11 unique sites and then measured their ability to form
covalent bonds with different IgGs. These created stable, site-specific IgG-protein Z conjugates that
could never exist using the repertoire of natural amino acids. Researchers have also incorporated
BODIPYFL-lysine, photocaged lysine, and F-para-phenylalanine into proteins to create a FRET
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sensor, activate a signaling pathway with a UV pulse, and study the effects of π interactions on
ligand binding, respectively [203, 204, 205, 206].
2.4.2 Directed Evolution
Directed evolution approaches are useful when there are no known or characterized proteins that
serve a needed function. They require little, if any, biochemical knowledge of the desired outcome. As
a result, many surprising and unpredictable sequences have arisen from evolutionary techniques. For
example, when screening for affibodies with high affinity for Amyloid β, the characteristic biomarker
of Alzheimer’s disease, Grönwall et al. found that their best binder was actually an affibody dimer
linked by a disulfide bond [207]. No one has ever purposely built a bridged affibody homodimer
to bind a single target molecule, so directed evolution provided a solution that had never been
considered.
There are three fundamental aspects of every directed evolution experiment. First, a library
encoding a large number of protein coding sequences quickly creates the genetic diversity that would
occur over eons in a natural setting. Second, a screen that recovers the desired phenotypes provides
an artificial selective pressure that culls the non-functional phenotypes. Finally, a way to link each
sequence in the genetic library to the specific version of the protein it encodes. The most important
of these aspects is the phenotype-genotype link, as that will determine the maximum library size
and available screening methods. The major classes of links are described in detail below.
The major downside of this approach is a large front-end time and capital investment with no
guarantee of success. The largest library may still not contain a functional sequence. The best
sequence may simply not express well in its host organism. The screen may be passable by an
unexpected, undesired phenotype that out-competes the desired phenotype. Still, directed evolution
has been immensely popular and useful.
Cell Surface Display
Cell surface display co-opts the secretory pathways of bacteria and yeast to produce library-encoded
proteins that are anchored to the extracellular surface of the cell membrane. When selecting for
targeting ligands, the cells are incubated with fluorescently labeled target protein and sorted via flu-
orescence activated cell sorting (FACS), which reads the fluorescence signal of each cell individually
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Figure 2.13: Bacterial Surface Display Strategies. A) Proteins and peptides can be cloned into the
loops of OmpA, a well-studied E. coli surface protein. B) Fusions to ice nucleation proteins allow
flexible spacing from the cell surface by including internal repeating domains. C) Autotransporters
express the protein in the periplasm and then actively pull the protein through a channel for it to
refold outside the cell. Adapted from [208], with permission from Elsevier.
and sorts high-signal and low-signal cells into separate collection tubes. The highly fluorescent cells
are subsequently expanded and screened again under more stringent conditions until a suitable bind-
ing partner is found. Although the selection methods for enzyme maturation are less generalizable,
surface display is necessary for precise control of substrate concentrations.
Proteins can be trafficked to the surface of E. coli by a number of methods, shown in Figure 2.13
[208]. In one example, Binder et al. found the autotransporter EspP was the most robust method of
displaying their Anticalin library [209]. They then produced a library of 2× 109 Anticalin variants
with error-prone PCR and sorted for cells that retained fluorescence after one hour of competition
with unlabeled target. The library was able to increase the dissociation half-life of the natural binder
by ten-fold.
Yeast display is generally done with S. cerevisiae by fusing the library protein to Aga2p [210].
During secretion, Aga2p is linked by disulfide bonds to the integral membrane protein Aga1p, which
carries it to the surface. Thus, the displayed protein is transiently in the endoplasmic reticulum
and is subject to ER post-translational modifications like glycosylation and proteolysis. This can
be a disadvantage if displaying an enzyme or cytosolic protein, as glycosylation can disrupt activity
and participate in binding. On the other hand, if the end product will be produced solubly in a
eukaryotic system, yeast display is preferred because it will mimic the end product [211]. Yeast
have been glyco-engineered to reproduce human N-linked glycosylation patterns, making them the
system of choice for selecting and displaying humanized antibodies [212].
Unfortunately, cell surface display systems usually have the lowest library sizes (generally 1×107
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Figure 2.14: Bacteriophage M13. Adaptations of figures from [214] are allowed under the Creative
Commons License v4.0.
to 1×109) [213]. The libraries are limited by the inherent inefficiency of stable genetic transformation.
However, this is balanced by the relevance of the display system to the downstream application [212].
It is much more likely for a targeting ligand evolved in yeast to express robustly in yeast.
Phage Display
Perhaps the most common display technique is phage display, specifically filamentous phage display.
The filamentous bacteriophage M13 (see Figure 2.14) has a simple, circular single-stranded DNA
(ssDNA) genome that encodes only eleven proteins. The life cycle of the phage is well characterized.
It first binds to the F pilus on E. coli. Then it injects its genome and replication enzymes into
the bacterium, which synthesizes the second strand of the genomic plasmid. The eleven genes are
then expressed and assembled in the bacterial periplasm. Newly syntheisized ssDNA genomes are
transported into the assembling phage and extruded from the cell in the pVIII coat protein. Finally,
five copies of pIII are used to cap the phage and it is released into the media. The E. coli cell survives
the infection, albeit with a slower growth rate. For some strains of M13, such as KO7, the genome’s
packaging signal contains mutations that lower its affinity for the coat protein. The phage is thus
capable of preferentially incorporating the ssDNA of a separate plasmid, known as a phagemid,
rather than its genome. When the resulting phage infects a bacterium, the E. coli receives a copy
of the phagemid and will not produce any phage. To create more phage with the phagemid, the
transformed bacteria must be superinfected with M13KO7, which provides the necessary structural
and assembly proteins. If the phagemid encodes one of the phage’s coat proteins, the encoded version
will be randomly incorporated into the daughter phage along with the phagemid that encodes it.
This is the phenotype-genotype link in phage display [215]. Due to the extremely small size of
bacteriophage, libraries of up to 1× 1011 unique sequences can be screened [213].
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Commonly, the protein to be evolved is fused to the N-terminus of the cap protein pIII. pIII
chimeras have been used to evolve many different proteins, but affinity targeting proteins are the
most common. Antibodies [216, 217], scFvs [218], affibodies [108], monobodies [219], and short
peptides [220] have all been evolved by phage display, among many others. Phage have even been
used to select for high-affinity D-peptides by screening against synthesized D-antigens and relying
on the mirror-image hypothesis, which makes an L-peptide binding a D-target equivalent to a D-
peptide binding an L-target [221]. The screen involved in all of these is a binding assay. Briefly,
phage libraries are expressed and purified from E. coli and bound to antigen-coated plates. After a
sufficient amount of time has passed for binding, unbound phage are washed away. Bound phage are
then eluted with acid, protease, or excess antigen. While acid or protease elution can ensure recovery
of all bound phage, eluting with excess antigen can be used to find phage with a particular binding
affinity [222]. The eluted phage infect fresh E. coli cells, which can be grown up for sequencing,
phage production, further cloning, or storage. Phage may also be subjected to a negative screen,
where they are panned against similar antigens, such as different isoforms of the antigen, to remove
non-specific phage.
One of the major advantages of phage display is the robustness of the phage themselves. Bac-
teriophage M13 is heat and acid stable and can only infect E. coli bearing the F plasmid, making
them essentially orthogonal to mammalian systems. Of the major display techniques, phage display
is the only one capable of being screened directly on cultured cells or even in vivo. When screening
against cultured cells, it is imperative to have a good negative screen consisting of cells that differ
from the positive line by only the target antigen. In vivo, the negative screen is the rest of the body
and the target antigen is an unknown molecule on the target tissue [223]. In one example, Arap
et al. injected a phage library into immunodeficient mice bearing a MDA-MB-435 xenograft breast
tumors [224, 225]. They then recovered the phage for amplification and sequencing. The peptides
were tested for affinity and selectivity to determine the best sequence. Finally, they conjugated
the optimal peptide to the chemotherapeutic doxorubicin and administered the targeted drug to
tumor-bearing mice, which showed improved survival over the untargeted drug.
To speed up phage display, Esvelt et al. developed a technique called phage assisted continuous
evolution (PACE) [226]. As shown in Figure 2.15, PACE encodes its library onto an M13 genome
that is missing pIII. Phage infect cells that have been transformed with a plasmid with an error-
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Figure 2.15: Phage Assisted Continuous Evolution. Host cells continuously flow through a lagoon,
where they are infected with selection phage (SP) encoding library members. Functional library
members induce production of pIII from the accessory plasmid (AP) and release progeny capable
of infecting new host cells, whereas non-functional library members do not. Increased mutagenesis
is triggered through induction of the mutagenesis plasmid (MP). Host cells flow out of the lagoon
on average faster than they can replicate, confining the accumulation of mutations to replicating
phage. Reprinted by permission from Macmillan Publishers Ltd: Nature [226], copyright 2011.
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prone polymerase for mutagenesis and a plasmid that codes for an intercellular screen, using the
phage protein pIII as a reporter gene. Because pIII is necessary for phage infection, only phagemids
that code for a passing protein can produce infectious phage. Constructs that cannot pass the screen
are therefore not infective because they lack the necessary cap protein. And because the mutagenic
plasmid is constantly introducing mutations in the phage genome, the library will continue evolving
as the screen is running. Continuous systems such as PACE represent a major advance in directed
evolution, as a few days of PACE can be the equivalent of hundreds of rounds of evolution and
screening. However, PACE is limited to being intercellular screens, which are only applicable to the
evolution of targeting proteins if both the ligand and biomarker can be expressed in E. coli.
Ribosome Display
Ribosome display is a fully in vitro technique. Because it does not require an extremely inefficient
transformation step, it can produce the largest libraries, containing up to 1× 1013 unique sequences
[213]. The key to ribosome display is that the screened sequences must not contain a stop codon.
During protein synthesis, the stop codon recruits release factor proteins that dissociate the ribosomal
subunits from the messenger RNA and nascent peptide chain. By expressing these libraries via in
vitro protein synthesis, the ribosome will stall when it reaches the end of the mRNA because it is
unable to disassemble without a release factor. Thus, the ribosome itself will act as a link between
the coding mRNA and translated protein. The genotype is recovered by simply amplifying the
mRNA with a reverse transcriptase and running a standard PCR.
While ribosome display can screen libraries 100-fold larger than the most diverse phage display
libraries, it is not nearly as robust [227]. Nature treats external RNA as a threat, so enzymes
that degrade RNA, ribonucleases, are everywhere in our environment [228]. And due to the high
specific activity of ribonucleases, a small contamination can destroy an entire sample. In addition,
the genotype-phenotype linkage of a ribosome is not covalent, meaning that inhospitable buffer
conditions such as high/low pH, high temperature, detergents, or organic solvent can disrupt the
ribosome complex and destroy the sample. Thus, ribosome display can only be performed in vitro
in nuclease-free wells with purified antigen.
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Library Generation
None of the above screening techniques can work without a good library of genes for them to screen.
A common way of producing libraries is through random mutagenesis [229]. By amplifying a gene
of interest with Taq polymerase in error prone conditions, which include the presence of MnSO4
and uneven dNTP ratios, it is possible to randomly introduce mutations during the PCR reaction.
The introduction of random mutations mimics natural evolution and generally produces a stable
library. However, stability is traded for lack of diversity, as error-prone PCR only introduces a few
mutations per kilobase. In order to introduce a large number of mutations, like the 13 randomized
amino acids of an affibody, the DNA must be synthesized. Degenerate oligonucleotides allow for
any mixture of nucleic acids at a specific location, making it easy to quickly produce large, targeted
libraries. These libraries of oligonucleotides can be incorporated into the gene in a number of ways,
including PCR, overlap extension, site-directed mutagenesis, and Kunkel mutagenesis [219, 230].
And with the rapid advance of DNA synthesis technologies, entire genes can simply be purchased
with degenerate positions, although this is currently too expensive for routine use.
When designing degenerate oligonucleotides, an important consideration is codon choice [231].
There are 64 codons, but only 20 amino acids, so the NNN codon (N = A, T, C, or G) skews the
library toward the more commonly represented amino acids, like leucine. By instead using NNK (K
= G or T), the codon space is reduced by half, while maintaining the amino acid space. By further
paring down the possible codons, it is possible to design libraries with positions skewed toward
codons more likely to produce a stable result, such as heavily biasing an amino acid toward being
charged or hydrophobic [231, 232, 233, 234, 235].
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Chapter 3
Sortase-Tag Expressed Protein
Ligation
Abstract
Efficient labeling of protein-based targeting ligands with various cargos (drugs, imaging agents,
nanoparticles, etc.) is essential to the fields of molecular imaging and targeted therapeutics. Many
common bioconjugation techniques, however, are inefficient, nonstoichiometric, not site-specific,
and/or incompatible with certain classes of protein scaffolds. Additionally, these techniques can
result in a mixture of conjugated and unconjugated products, which are often difficult to separate. In
this study, a bacterial sortase enzyme was utilized to condense targeting ligand purification and site-
specific conjugation at the C-terminus into a single step. A model was produced to determine optimal
reaction conditions for high conjugate purity and efficient utilization of cargo. As proof-of-principle,
the sortase-tag expressed protein ligation (STEPL) technique was used to generate tumor-specific
affinity ligands with fluorescent labels and/or azide modifications at high purity (>95%) such that it
was not necessary to remove unconjugated impurities. Click chemistry was then used for the highly
efficient and site-specific attachment of the azide-modified targeting ligands onto nanoparticles.
Adapted with permission from [236]. Copyright 2013 American Chemical Society.
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3.1 Introduction
As described in Section 2.3.2, EPL and sortagging have a number of advantages over chemical (and
many enzymatic) bioconjugation strategies. Both are site-specific, stoichiometric, and can attach a
wide array of payloads to the target protein. Despite their advantages, however, the techniques still
fall short of an ideal system for conjugating imaging cargo to a targeting ligand. Ligation of a small
cargo, such as a fluorophore, often has minimal effect on the protein’s physical properties (mass,
charge, hydrophobicity, etc.), making it difficult to separate conjugated products from unligated
reactants in either system. EPL relies heavily on thiol chemistry, so it is incompatible with classes
of targeting ligands that possess disulfide bonds, such as knottins (Section 2.2.4) and antibodies
(Section 2.2.1). In Sortase-mediated transpeptidation, the conjugated product must be purified
from the enzyme as well as the unconjugated proteins.
In this chapter, we set out to create a system that retains all of the advantages of EPL while mak-
ing the technique more efficient, expanding the pool of potential targeting ligands, and simplifying
downstream purification.
3.2 Design Strategy
To mitigate the shortfalls of sortase labeling and expressed protein ligation, we combine the strategies
into a single conjugation and purification technique called Sortase-Tag Expressed Protein Ligation
(known hereafter as STEPL). In a single chimeric protein, we express a targeting ligand in frame
with the sortase recognition motif LPXTG, a (GGS)5 linker, SrtA∆59, and a His6 tag (Figure 3.1).
After binding the chimera to a metal resin, addition of calcium and any protein/peptide with an N-
terminal glycine (and attached cargo, if desirable) activates the sortase domain, ligating the protein
of interest to the peptide while simultaneously cleaving it from the rest of the sortase chimera. Thus
the conjugate is released while the sortase enzyme is retained on the column via the His-tag. By
making purification and conjugation codependent, STEPL remains site-specific and stoichiometric
in nature but does not require any additional steps to remove SrtA from the purified protein sample.
Further, large excesses of peptide are not essential since only correctly ligated product is released
from the affinity column and conditions can be optimized to nearly exhaust any added peptide. The
rationale behind this design is described below:
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Figure 3.1: Sortase-tag expressed protein ligation scheme: Ligands are cloned in series with the amino
acid sequence LPXTG, a (GGS)5 linker, SrtA, and a hexahistidine tag, respectively. The chimeric
protein is expressed and isolated on a nickel column. The addition of calcium and a peptide with an
N-terminal glycine (and optimally three glycines) allows the SrtA enzyme to simultaneously catalyze
ligand release and peptide ligation. This allows any cargo (e.g. a fluorophore, azide, biotin, PEG,
proteins, etc., represented by the star) that is attached to the triglycine peptide to be site-specifically
conjugated to the ligand.
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S. aureus SrtA∆59
Sortase A is uniquely suited to a system that links conjugation to purification because its catalytic
mechanism (described in detail in Section 2.3.2) involves the thiolysis of one peptide bond followed by
the formation of another. Both steps are necessary for transpeptidation, creating a firm link between
substrate cleavage and ligation. By expressing a ligand in cis with a tethered sortase domain, we
can instead link ligand release (cleavage) to ligand bioconjugation (ligation). Additionally, sortase
activity can be modulated by calcium, allowing the chimera to stay intact through expression until
release is desired.
In nature, sortase A is an extracellular protein consisting of an N-terminal transmembrane domain
and a C-terminal soluble domain [237]. By deleting the first 59 amino acids, we are left with only
the soluble catalytic domain that can be used in vitro [149, 150].
LPETG Motif
Although sortase recognizes the ambiguous LPXTG motif (where X is any amino acid), the biocon-
jugation literature quickly converged on X=E as the motif of choice [150]. Thus, LPETG is used as
the sortase recognition motif in this and all subsequent studies.
N-Terminal Ligand
Placing the ligand N-terminal to the sortase motif and catalytic domain is the key differentiator
between STEPL and the Mao sortase expression system [238]. In the previous system, the protein
of interest was expressed at the C-terminus of the chimera so that only the thiolyis step is required
for release and a single N-terminal glycine is left as an expression scar. By reversing the order of
domains in STEPL, the initial thiolysis of the T−G bond keeps the protein of interest attached to
the catalytic domain (and therefore the solid substrate) via an acyl-enzyme intermediate. Only when
a glycine-initiated peptide is used to reform a T−G peptide bond is the protein of interest actually
released from the enzyme. This mechanism requires the protein of interest to have a C-terminal
conjugation to be recovered from the column. STEPL has a larger expression scar (LPET), but this
is irrelevant since a larger C-terminal conjugate is the desired outcome.
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Figure 3.2: STEPL Flexible Linker Design. A) Crystal structure of Sa-SrtA active domain showing
24.5Å between the N-Terminus of the domain and Cα of the LPETG ligand.
(GGS)5 Linker
Five GGS repeats were chosen for this fusion construct because the crystal structure (shown in Figure
3.2) reports a length of 24.5Å between the N-terminus of the sortase domain and its active site [239],
corresponding to the length of approximately three GGS repeats (8.8Å each). Thus a (GGS)5 linker
was expected to provide sufficient spatial flexibility for the sortase domain to recognize and bind the
LPETG motif.
His6 Affinity Tag
The hexahistidine tag for metal ion affinity chromatography enjoys widespread use in biology because
it is a small, soluble tag which binds tightly to inexpensive nickel or cobalt resins. Thus, His6 was
chosen for STEPL due to its ubiquity and simplicity. Notably, STEPL avoids one of the major
drawbacks of the His6 tag, generally “sticky” proteins; because the column is never eluted with
imidazole, the impurities remain bound to the column.
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Figure 3.3: Western Blot of EGFP released from an affinity column under various conditions. An
EGFP · STEPL fusion protein was expressed and washed on an affinity column. The column was
then treated with various concentrations of triglycine and Ca2+. Released GFP was detected by
western blot.
Triglycine Peptide
Only one N-terminal glycine is necessary for sortase-mediated ligation. However, beginning the
peptide with three glycine residues allows the sortase to accommodate the peptide more easily and
results in greater efficiency [150]. Thus, all STEPL peptides described will begin with GGG.
3.3 Determination of Calcium Dependence
A valuable feature of the STEPL system is that it allows for the site-specific labeling of recombinantly
expressed proteins without requiring any steps in addition to what is normally required for protein
purification. Under optimal conditions, all of the recombinant protein that is released from the
affinity column would be labeled with the desired cargo as a result of the SrtA-mediated ligation
reaction. To evaluate the efficiency of this ligation reaction and to assess the extent of any non-
specific cleavage of the LPXTG motif, in the absence of ligation, a model system was designed with
EGFP as the “ligand” (EGFP · STEPL). This allowed for quantitative monitoring of protein release
from the affinity column in the presence and absence of triglycine and calcium. Notably, peptides
with two or more glycines are typically preferred for SrtA-mediated ligations since they exhibit
significantly improved binding and catalysis [238].
Initial studies with the EGFP-STEPL system, in the presence and absence of Ca2+ (5mM) and
triglycine ([GGG], 25µM or 100 µM), revealed that release of the GFP from the affinity column
increased with triglycine concentration (Figure 3.3). However, it was also observed that Ca2+ alone
could lead to some non-specific release of GFP, albeit at lower levels than when triglycine was also
present. In the absence of Ca2+, no GFP was released from the affinity column, with or without
triglycine. These results suggested that it was important to identify an optimal Ca2+ concentration
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Figure 3.4: Effect of calcium on the efficiency of protein ligation. An EGFP · STEPL fusion protein
was expressed and washed on an affinity column. The column was then treated with various con-
centrations of Ca2+, in the presence of triglycine, at 37◦C for 4hrs. These experiments provided a
measure of the total amount of ligated and unligated product ([EGFP]Total) released from the affinity
column for each Ca2+ concentration. The amount of unligated product ([EGFP]unligated) was deter-
mined by performing analogous experiments in the absence of triglycine. The percent protein con-
jugated ([EGFP]ligated) was then calculated as ([EGFP]Total− [EGFP]unligated)/([EGFP]Total) ∗ 100.
that would maximize the ratio of ligated (i.e. GFP-triglycine conjugates) to unligated recombinant
protein. Therefore, GFP-STEPL was performed in the presence of a fixed concentration of triglycine
(25µM) and increasing concentrations of Ca2+ (0 to 5 mM). These experiments provided a measure
of the total amount of ligated and unligated product released from the affinity column for each
Ca2+ concentration. The amount of unligated product was determined by performing analogous
experiments in the absence of triglycine. The maximum percent of ligated product occurred at
Ca2+ concentrations below 100µM (Figure 3.4). Therefore, a Ca2+ concentration of 100µM was
used for all subsequent experiments.
3.4 Modeling and Optimization of the STEPL Reaction
In order to further optimize the GFP-STEPL procedure, a systematic study on the effect of triglycine
concentration, reaction temperature, and reaction time on the amount of recombinant protein re-
leased from the affinity column was conducted (Figure 3.5). As expected, the rate of protein release
increased with triglycine concentration and reaction temperature. All experimental data was fit with
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Figure 3.5: Modeled and actual EGFP release from an affinity column as a function of temperature,
triglycine concentration, and time. An EGFP · STEPL fusion protein was expressed and washed on
an affinity column. The column was then treated with 0mM (asterisk), 25µM (star), 100µM (dia-
mond), 200µM (square), or 5mM (circle) triglycine and 100µM Ca2+. EGFP release was monitored
as a function of time. Protein release experiments were conducted at 37◦C(top), 25◦C(middle), and
6◦C(bottom). All data was fit using a kinetic model of EGFP cleavage that takes into account both
triglycine-dependent and triglycine-independent pathways. Modeled GFP release (lines) has been
superimposed onto the recorded data (symbols).
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a kinetic model of the reaction, detailed below in Reaction C3.1.
EGFP + SrtA←−
k1
EGFP · SrtA +GGG−−−−→
k2
EGFP ·GGG+ SrtA (C3.1)
This model assumes that transpeptidation is the rate-limiting step of the glycine-dependent pathway
and therefore collapses reversible peptide binding and transpeptidation into a single second-order
rate constant. To include temperature dependence, the model also assumes that the rate constants
can be modeled by the Arrhenius equation. Thus, the model’s parameters are the preexponential
constants and activation energies of the two pathways (Table 3.1). As shown in Figure 3.5, the
model provides an acceptable fit to the observed data.
The kinetic model was used to predict the effect of various reaction conditions on three outcomes:
(i) the percentage of released protein that is ligated to the peptide, (ii) the percentage of peptide
consumed in the reaction, and (iii) the yield of ligated protein (i.e. the amount of ligated protein
normalized by the total amount of protein initially bound to the affinity column) (Figure 3.6). The
value for each of the desired outcomes was determined for reaction times of 2, 4, 6, and 24 h, with
100µM CaCl2, initial triglycine peptide concentrations of 1 to 1000 µM, reaction temperatures of
4, 25, or 37◦C, and assuming 100µM initial protein concentration on the affinity column. It was
determined that the purity of the ligated protein was independent of reaction time, as it is simply
a ratio of the two rate constants. As a result, adding excess peptide could be used to drive the
ligation reaction and overwhelm the basal cleavage rate. Overall, if a highly pure ligated product is
desirable, >95% purity can be achieved by simply using 2-fold or greater molar excess of triglycine-
containing peptide compared with the concentration of total column-bound protein (at 37◦C, Figure
3.6C). This is significantly lower than the 10-fold excess of peptide typically required for efficient
intein-based EPL [2].
If it is more desirable to exhaust all of the triglycine peptide than achieve high purity of the
ligated product, perhaps because the peptide is functionalized with a cargo that is cost-prohibitive,
Table 3.1: Model Parameters. The kinetics model determined Arrhenius pre-exponential constants
and activation energies for the glycine-free (k1) and glycine-dependent pathways (k2).
Pathway Pre-exponential Constant (A) Activation Energy (∆G‡) Rate Constant at 37◦C
Glycine-free 4.0568× 102s−1 3.8463× 104J/mol 0.0419s−1
Glycine-dependent 2.9246× 1010s−1M−1 5.4958× 104J/mol 5.0352× 103s−1M−1
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Figure 3.6: Model predictions of STEPL ligation efficiency, triglycine peptide utilization, and the
percent yield of expressed GFP that is recovered from the affinity column. The kinetic model of
GFP cleavage from the STEPL system was evaluated with initial conditions of 100µM Ca2+, 100µM
EGFP · SrtA, and 1µM to 1mM triglycine at 4◦C, 25◦C, and 37◦C for 0 to 24hrs. The percentage
of GFP that has been ligated to triglycine (time independent) and the percentage of triglycine
peptide consumed during a 6 hr incubation was determined for reaction temperatures of (A) 4◦C,
(B) 25◦C, and (C) 37◦C. Dotted lines at 90% and 95% are included for reference. The percentage of
ligated GFP recovered after a 2, 4, 6, and 24 hour incubation was determined as a function of excess
triglycine (relative to the total amount of EGFP · SrtA) for reaction temperatures of (D) 4◦C, (E)
25◦C, and (F) 37◦C.
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Table 3.2: Synthetic Peptides
Peptide Molecular Weight (Da) λex/λem
P3.1 NH2-Gly-Gly-Gly-Lys(HiLyteFluor 750)-NH2 1,327 754/778
P 3.2 NH2-Gly-Gly-Gly-Lys(5-FAM)-Gly-Gly-Ser-Lys(N3)-NH2 1,030 492/518
Figure 3.7: Her2/neu affibody expression and ligation. An SDS-PAGE gel was run with (1) marker,
(2) raw lysate of bacterially expressed STEPL-Her2 affibody, and (3) Her2 affibody purified using a
2-fold excess of HiLyte 750-labeled triglycine peptide, 100µM Ca2+ at 37◦C for 6hr. Black signal is
from SimplyBlue SafeStain protein stain. Red signal is HiLyte 750 peptide fluorescence.
then >90% peptide consumption can be achieved by adopting reaction conditions whereby the
recombinantly expressed protein is in 4-fold or greater molar excess over the peptide (at 37◦C,
Figure 3.6C). However, this comes at the cost of reduced purity of the ligated product and will likely
require additional purification to remove unligated targeting ligands.
Higher reaction temperatures can be used to speed up the reaction and improve peptide utiliza-
tion, particularly at lower triglycine peptide concentrations, but purity of the ligated product is only
marginally improved. When yield is considered, the STEPL system clearly favors higher tempera-
tures regardless of whether high purity of the ligated protein or high peptide utilization is desirable.
(Figure 3.6D-F). Of course, some proteins may be unstable at high temperatures, requiring longer
reactions to be performed at room temperature or in a cold room.
3.5 Fluorophore Ligation
To demonstrate the utility of STEPL as a general methodology for the site-specific labeling of
tumor targeting ligands with imaging agents, the coding sequence for a Her2/neu-targeting affibody
(ZHer2) was cloned into the STEPL vector. The affibody was expressed and conjugated to a triglycine
peptide containing the near-infrared dye HiLyte Fluor 750 (Table 3.2, P 3.1) using conditions that
were expected to result in >95% purity of the fluorescent labeled affibody, based on the kinetic
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Figure 3.8: Functional evaluation of the Her2 affibody-HiLyteFluor 750 conjugate. (A) Her2/neu
positive and negative cells were incubated with Her2/neu-targeted affibodies that were conjugated
to HiLyteFluor 750 (red) using the STEPL system. Cells were also stained with Hoechst 33342
(nuclear stain, blue). (B) In-cell western quantification of HiLyteFluor 750 fluorescence.
model established above (2-fold excess peptide, 100µM Ca2+, 37◦C, 6hr). Efficient ligation between
the affibody and the fluorescently-labeled peptide was confirmed by SDS-PAGE (Figure 3.7). The
major band in the 700nm channel (protein stain) co-localized with the single fluorescent band in the
800nm channel (HiLyte Fluor 750), following removal of excess free peptide by dialysis. Only a very
faint signal stemming from the unligated protein was observed in the 700 nm channel, at a slightly
lower molecular weight than the ligated product. To confirm that the affibody remained functional
following the ligation reaction, it was incubated with T6-17 and NIH/3T3 cells in vitro, which are
positive and negative for the Her2/neu receptor, respectively (Figure 3.8). As expected, the affibody
labeled the T6-17 cells exclusively, with no observable labeling of the NIH/3T3 cells. Further,
the addition of excess unlabeled affibody (i.e. cleaved with triglycine) competitively inhibited the
binding of the fluorescently labeled affibody to T6-17 cells, suggesting that binding was specific for
the Her2/neu receptor. Quantification using an in-cell western assay (Figure 3.8B) corroborated the
fluorescence microscopy findings. Similar results were obtained by applying the epidermal growth
factor receptor (EGFR)-targeted affibody, ZEGFR, to EGFR-positive and negative cells (Figure 3.9).
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Figure 3.9: Functional evaluation of the EGFR affibody-FAM conjugate. EGFR positive and neg-
ative cells were incubated with Her2/neu-targeted affibodies that were conjugated to FAM (green)
using the STEPL system. Cells were also stained with Hoechst 33342 (nuclear stain, blue).
3.6 Azide Ligation and Nanoparticle Synthesis
In addition to imaging agents, STEPL can also be used to conjugate various other functional moieties
including bio-orthogonal reactive groups (e.g. azide) onto the C-terminus of targeting ligands. The
site-specific introduction of azides onto recombinant proteins provides a very favorable approach
for the efficient coupling of targeting ligands to nanoparticles using click chemistry. In particular,
this approach allows tight control over both ligand orientation and density on the nanoparticle
surface. We have previously shown that both of these factors can have a dramatic impact on
nanoparticle avidity [38]. As proof-of-principle, the Her2/neu affibody was conjugated to a synthetic
peptide containing a green fluorophore (5-FAM) as well as an azide group (Table 3.2, P 3.2). This
conjugate was then reacted with superparamagnetic iron oxide (SPIO) nanoparticles functionalized
with azadibenzocyclooctyne (ADIBO). ADIBO is a dibenzocyclooctyne derivative capable of copper-
free click reactions with azides. The resulting ZHer2-SPIO conjugates were incubated with T6-17
and NIH/3T3 cells. Cell labeling was then assessed by acquiring T2 relaxation times and T
∗
2 -
weighted images of cell lysates (Figure 3.10). The Her2-positive cells exhibited a marked decrease
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Figure 3.10: Functional evaluation of the Her2 affibody-SPIO conjugates. Her2/neu-positive and
Her2/neu-negative cells were incubated with Her2-SPIO conjugates in the presence and absence of
excess free affibody. Free affibody served as a competitive inhibitor to confirm specific binding of the
Her2/neu receptor. Relaxivity measurements and T ∗2 -weighted MR images of each cell suspension
were acquired.
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in T ∗2 -relaxation times, consistent with the presence of SPIO, in comparison to Her2-negative cells.
An observable negative contrast was also observed upon MR imaging of the Her2-positive cells.
Competitive inhibition, using an excess of unlabeled ZHer2, led to a loss in MR contrast, indicative
of receptor-specific binding. Therefore, these results provide clear evidence that STEPL can be
combined with click chemistry for the site-specific attachment of targeting ligands onto nanoparticles.
3.7 Discussion
STEPL offers a number of features that make it a very favorable approach for bioconjugation reac-
tions. First and foremost, STEPL combines release of recombinant proteins from the affinity column
and bioconjugation into a single step. This greatly simplifies the entire bioconjugation procedure
since no subsequent labeling and purification steps are required, saving time, money, and complexity.
Second, STEPL allows for the site-specific conjugation of cargo. Site-specific functionalization has
been shown to be beneficial in a number of applications including the preparation of protein-drug
conjugates, which often exhibit higher efficacy than randomly labeled targeting ligands [240]. It has
also been shown that the site-specific attachment of targeting ligands to nanoparticles can improve
nanoparticle avidity [162]. Third, STEPL conjugates the peptide to ligand in a stoichiometric man-
ner. This is particularly important when labeling targeting ligands with imaging agents, since it
allows for precise quantitative imaging. Fourth, the conditions used to release protein from the affin-
ity column can be manipulated to ensure that essentially all of the recovered protein is conjugated
with the desired cargo. This eliminates the often difficult process of purifying conjugated products
from unconjugated proteins. Since in many applications a large protein is labeled with low molecular
weight drugs or imaging agents, the conjugated and unconjugated forms of the protein can differ
by as little as a few hundred to a few thousand Da, potentially without any significant change to
hydrophobicity or charge. Fifth, construction of the STEPL system as a single expressible protein
removes the additional step of removing sortase from the conjugated product, a common feature of
current sortase conjugation systems [150, 156, 241]. Additionally, in systems where unconjugated
ligand is easily separable, the reaction conditions could be altered to ensure that expensive synthetic
peptides can be exhausted in the ligation reaction. Thus, STEPL is a single-chain, self-cleavable
system where high-cost components can be fully utilized; traits highly desirable in industrial protein
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production as they reduce overall cost and time [242].
The one identified shortcoming of Sortase A is that it exhibits some cleavage even in the absence
of glycine. Previous studies have addressed this problem by making a destabilizing mutation to Trp-
194. However, we hypothesized that reducing the calcium concentration would have a similar effect
with finer control. This was found to be true, as sub-millimolar calcium concentrations provided a
sharp, dose dependent drop in background cleavage. There is also potential for background cleavage
during expression due to cytosolic calcium in the bacterium. However, the calcium level inside E.
coli is estimated to be between 0.1 - 1µM [243], so while there is likely some loss, it should be
minimal and could always be discouraged by the aforementioned mutation.
To further optimize and understand the cleavage reaction, a kinetic model was established and
its parameters (time, temperature, and initial triglycine concentration) were systematically varied.
To simplify the model, the reversible binding of peptide to the enzyme and product conversion were
condensed into one second-order rate constant. This is justifiable because the applicable peptide
concentrations do not appear to saturate the binding curve and the determined rate constants are
well below the diffusion limit [244, 245], implying that product conversion is rate limiting.
The model reveals a fundamental conflict between conjugate purity and peptide utilization. The
glycine-independent pathway can be easily overwhelmed by adding a large excess of peptide to drive
the glycine-dependent pathway. On the other hand, the peptide can be fully utilized by making
it the limiting reactant. Therefore, if product purity is required and downstream purification of
unreacted ligand would be difficult, it is optimal to use excess peptide. If peptide utilization is the
primary concern, the optimal conditions are 37◦C with a 1:4 ratio of synthetic peptide to STEPL
protein, although it is important to note that in this latter case additional purification is needed
to purify conjugated product from unconjugated proteins. Systems where the peptide enables the
conjugate to be immobilized onto a surface or particle are ideal candidates for peptide exhaustion.
In this study, STEPL was used to functionalize affibodies with chemical groups useful for molec-
ular imaging. A near-IR fluorophore was utilized to optically differentiate between cells expressing
and lacking the proto-oncogene Her2/neu. The NIR-dyed affibody was used to quantify Her2/neu
expression differences between the T6-17 and NIH/3T3 cells, which demonstrates STEPL’s utility
for in-cell western techniques. Additionally, STEPL was used to conjugate a bio-orthogonal reactive
group (an azide) to the Her2/neu affibody. The azide readily reacted to a strained alkyne on the
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surface of superparamagnetic iron oxide nanoparticles. Due to the site-specific nature of STEPL,
the affibody was linked in a specific orientation, which greatly increases the particle’s efficacy in dis-
tinguishing between cells expressing and lacking Her2/neu. STEPL has the potential to conjugate
many other moieties to its target protein, such as biotin, poly(ethylene-glycol), antibiotics, metal
chelates, and photocrosslinkers, all of which have been proven compatible with the sortase enzyme
[150].
3.8 Conclusions
STEPL has proven to be a flexible and efficient system for molecular imaging and targeted therapeu-
tic applications. This study validated and optimized the system for ligand purity and peptide-cargo
utilization. STEPL was then used to visualize and quantify Her2/neu and EGFR expression in vitro.
Moreover, because it has the ability to link virtually any protein expressible in bacteria with any
cargo that can be attached to a triglycine peptide, STEPL has potential applications in many fields.
3.9 Materials & Methods
Cloning
Sa-SrtA∆59 [238] was amplified from pGMBCS-SrtA (Addgene plasmid 21931 [153]) with an N-
terminal (GGS)5 sequence and C-terminal H6 sequence. To facilitate blue/white screening, the Lac
operon was amplified from pUC19 (Invitrogen) in an antisense orientation with a C-terminal sequence
coding for the restriction site XhoI, the sortase recognition sequence LPETG, and the (GGS)5 linker.
Overlap-extension PCR was used to join the Lac operon product to the Sa-SrtA59 product. The
full sequence was then cloned into pRSET-A (Invitrogen) via the NdeI and MluI restriction sites,
creating the STEPL vector, pSTEPL (see Plasmid Map 3.1). Sequences were verified by restriction
analysis and sequencing. The EGFP sequence, ZHer2 sequence [113], and ZEGFR sequence [114] were
amplified with 5’ NdeI and 3’ SalI sites and cloned into pSTEPL via its NdeI and XhoI sites (Plasmid
Maps 3.2, 3.3, and 3.4, respectively). White colonies were picked and verified by restriction analysis
and sequencing.
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Plasmid Map 3.1: pSTEPL
Feature Location
T7 Promoter 20-39
LacZ 384-106
LacZα 222-154
LacO 424-402
Plac -10 434-429
Plac -35 458-453
CAP Binding Site 490-478
Sortase Motif 497-511
(GGS)5 Linker 512-556
Sa-SrtA∆59 557-997
His6 998-1015
T7 Terminator 1044-1173
f1 Origin 1244-1699
bla Promoter 1731-1835
AmpR 1830-2690
pUC Origin 3508-2835
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Plasmid Map 3.2: pSTEPL/EGFP
Feature Location
T7 Promoter 20-39
Chimeric ORF 100-1344
EGFP 100-816
Sortase Motif 823-837
(GGS)5 Linker 838-882
Sa-SrtA∆59 883-1323
His6 1324-1341
T7 Terminator 1370-1499
f1 Origin 1570-2025
bla Promoter 2057-2161
AmpR 2156-3016
pUC Origin 3843-3161
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Plasmid Map 3.3: pSTEPL/Her2Affb
Feature Location
T7 Promoter 20-39
Chimeric ORF 100-816
Her2 Affibody 100-288
Sortase Motif 295-309
(GGS)5 Linker 310-354
Sa-SrtA∆59 355-795
His6 796-813
T7 Terminator 842-971
f1 Origin 1042-1497
bla Promoter 1529-1633
AmpR 1628-2488
pUC Origin 3306-2633
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Plasmid Map 3.4: pSTEPL/EGFRAffb
Feature Location
T7 Promoter 20-39
Chimeric ORF 100-804
EGFR Affibody 100-276
Sortase Motif 283-297
(GGS)5 Linker 298-342
Sa-SrtA∆59 343-783
His6 784-801
T7 Terminator 830-959
f1 Origin 1030-1485
bla Promoter 1517-1621
AmpR 1616-2476
pUC Origin 3294-2621
Section 3.9: Materials & Methods 70
Protein Expression, Cleavage, & Bioconjugation
Constructs were transformed into the BL12-derived Rosetta2 BL21(DE3) line (EMD Millipore).
50mL starter cultures were grown overnight in LB-Ampicillin. These were added to 450mL of LB
and grown to an OD600 of 0.8-1 before induction with 0.5mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG). Cultures were allowed to express for 24hrs at 25◦C. Cells were then harvested by centrifu-
gation (6000g, 15min) and resuspended in 10mL of lysis buffer (50mM NaH2PO4, 300mM NaCl,
1mg/mL Lysozyme, 1 EDTA-free cOmplete Mini protease inhibitor tablet (Roche), pH 7.5). Lysates
were incubated at room temperature for 30min under gentle agitation before freezing overnight at
-80◦C. Samples were then thawed and incubated for 30min with DNAse I (Roche) under gentle
agitation. Lysates were then sonicated and separated by centrifugation (10,000 rpm, 30min).
For optimization experiments, 8mL of clarified lysate for each condition was incubated for 1 hr
with 0.6mL Talon resin (Clontech, equilibrated in lysis buffer). The lysate and beads were then added
to a column and beads were washed with 6mL STEPL buffer (20mM Tris-base, 50mM NaCl, pH
7.5). Washed beads were resuspended in a total of 1.2mL of STEPL buffer containing the indicated
amounts of CaCl2 and triglycine (Sigma-Aldrich) and aliquoted into three 1.5mL microcentrifuge
tubes. Samples were shaken at 1,000 rpm, the indicated temperature, and protected from light. At
each timepoint, samples were spun down at 3,000 rpm for 5min. Absorbance spectra were taken
of the supernatants from 400-600nm using a Cary 100 Bio UV-Visible Spectrophotometer (Varian)
and the sample was returned to shaking. At the end of the timecourse, beads were washed three
times with 1mL STEPL buffer and incubated for 30 min in 100mM EDTA. Stripped beads were
spun down as before and the absorbance spectra were taken of the supernatants from 400 600nm.
For bioconjugation experiments, 8mL of clarified lysate was incubated for 1hr with 0.5mL Talon
resin (equilibrated in lysis buffer). The lysate and beads were added to a column and beads were
washed with 5mL STEPL buffer. 400µL of STEPL buffer containing 150µM synthetic peptide (Table
3.2) or 5mM triglycine (for labeled and unlabeled preparations, respectively) and 100µM CaCl2 was
flowed over the beads until it replaced the wash buffer. Columns were protected from light and
reacted for 6hrs at 37◦C. 1mL of STEPL buffer was added to the column and the flowthrough
collected. To remove unreacted peptide, flowthrough was dialyzed three times against 4L of STEPL
buffer at 4◦C while protected from light (Slide-A-Lyzer2 cassettes, 3.5K cutoff, Thermo Scientific).
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EGFP Release Analysis & Model Design
Absorbance spectra obtained from optimization samples were baseline corrected and the EGFP
concentration was determined using the Beer-Lambert law (ε(EGFP, 488nm) = 55, 000M−1cm−1,
[246]). EGFP concentrations were fit to the sum of equations (3.4) and (3.5) in the following system
of ODEs using non-linear least squares:
d [EGFP · SrtA]
dt
= −k1 [EGFP · SrtA]− k2 [EGFP · SrtA] [GGG] (3.1)
d [SrtA]
dt
= k1 [EGFP · SrtA] + k2 [EGFP · SrtA] [GGG] (3.2)
d [GGG]
dt
= −k2 [EGFP · SrtA] (3.3)
d [EGFP]
dt
= k1 [EGFP · SrtA] (3.4)
d [EGFP ·GGG]
dt
= k2 [EGFP · SrtA] [GGG] (3.5)
k1 = A1Te
−∆G‡1/RT (3.6)
k2 = A2Te
−∆G‡2/RT (3.7)
where the model fits for A1, A2,∆G
‡
1, and ∆G
‡
2. Temperatures are on the Kelvin scale. Initial
EGFP · SrtA concentration was determined by adding the concentration of EGFP in the final time-
point to the concentration of EGFP from the stripped beads. Initial triglycine concentration and
temperature were varied experimentally. Initial conditions for [SrtA], [EGFP], and [EGFP ·GGG]
were zero. Model predictions were produced with the following initial conditions: 100µM Ca2+,
100µM EGFP · SrtA, 1µM - 1µM triglycine, 4◦ - 37◦C.
Cell Culture
NIH/3T3 and T6-17 cells (i.e. NIH/3T3 cells engineered to stably express Her2/neu; kindly provided
by Dr. Mark Greene, University of Pennsylvania) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin at 37◦C
and 5% CO2. H1666 cells expressing pLKO.shCTRL and pLKO.shEGFR [247] (kindly provided by
Dr. Matthew Lazzara, University of Pennsylvania) were maintained in RPMI supplemented with
10% fetal bovine serum, 1% penicillin/streptomycin at 37◦C and 5% CO2.
Section 3.9: Materials & Methods 72
Fluorescence Analysis of Cell Targeting
NIH/3T3 and T6-17 cells were incubated with 1µM Her2/neu affibody conjugated to HiLyte Fluor
750 for 4 hours in full media with and without a 10-fold excess of unlabeled ZHer2. Cells were washed
3 times with affibody-free media before being imaged in serum-free DMEM. Imaging was performed
with an Olympus IX81 inverted fluorescent microscope with a back-illuminated EMCCD camera
(Andor) and a SOLA excitation source (Lumencor). Images of HiLyte Fluor 750 were acquired
using the filter set (HQ710/75, HQ810/90, Q750LP) (Chroma). A LUC PLAN FLN 40X objective
(NA 0.6) was used for all imaging studies. ImageJ was used to merge the fluorescent images and
equalize levels. After optical imaging, the plate was scanned by an Odyssey Imaging System (Li-
Cor). User-defined regions of interest were drawn within each well and fluorescence within the
800-channel was quantified to determine relative Her2/neu expression.
Relaxation Measurements of Cell Targeting and MR Imaging
Azodibenzocyclooctyne (ADIBO)-functionalized superparamagnetic iron oxide (SPIO) nanoparticles
were synthesized as previously described [38]. Azide-modified ZHer2 was conjugated to ADIBO-SPIO
nanoparticles by combining 5mg Fe/mL SPIO nanoparticles with 30µM affibody. Reactions were
mixed overnight at room temperature and affibody-SPIO conjugates were purified on PD-10 columns
(GE Healthcare).
T6-17 and NIH/3T3 cells were incubated with 125µg Fe/mL of Her2/neu-targeted SPIO for 45
minutes in full media with and without a 100-fold excess of unlabeled ZHer2 in triplicate. Cells were
transferred to 1.5mL microcentrifuge tubes and washed with 500µL PBS three times before being
resuspended in 300µL RIPA Lysis Buffer (Millipore). T2 measurements were taken using a benchtop
relaxometer (Bruker mq60). Following relaxation measurements, cell lysates were combined and
100µL was transferred to wells of a 364-well plate. Images of the cells were taken on a 9.4-T magnet
interfaced to a Varian INOVA console using a 70 mm inner diameter volume coil for radiofrequency
transmission and reception. T ∗2 -weighted gradient echo (GRE) MR images were collected using
parameters as follows: repetition time (TR) = 200 ms, echo time (TE) = 5 ms, flip angle = 20◦,
slice thickness = 0.5 mm, number of acquisitions = 8.
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Chapter 4
Making Bispecific Ligands with
STEPL
Abstract
Bispecific targeting ligands have proven to be useful in a number of applications, such as targeted
immunotherapies, molecular imaging, and delivery across the blood-brain barrier. However, the
generation of such agents can be difficult. In this study, we use the Sortase-Tag Expressed Protein
Ligation system to produce eight monomeric and dimeric targeting ligands from only two optimized
expression cassettes for the affibodies ZHer2 and ZEGFR. The ligands are then assayed to determine
their apparent affinity for Her2/neu-positive, EGFR-positive, and Her2/neu/EGFR double-positive
cell lines. This data is used to predict the ligand concentration that will maximize contrast between
the single- and double-positive cell lines, which is supported by fluorescence microscopy.
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4.1 Introduction
As described in Section 2.1.4, bispecific targeting ligands have proven useful in increasing the speci-
ficity of an imaging agent, recruiting killer T-cells to a tumor, and transporting agents across the
blood-brain barrier, among other applications. The Sortase-Tag Expressed Ligation (STEPL) system
is particularly adept at creating bispecific ligands due to the inherent modularity and site specificity
of its active enzyme, S. aureus Sortase A, a calcium-dependent bacterial transpeptidase that cleaves
the threonine-glycine peptide bond in its recognition motif, LPXTG, and subsequently ligates any
other protein that begins with a glycine residue to restore a threonine-glycine bond [237]. The ability
of sortase to link any two proteins, so long as one contains LPXTG and the other an N-terminal
glycine, makes sortagging an incredibly powerful and versatile bioconjugation strategy. By making
one of the reactant proteins synthetically, non-canonical amino acids can be included that can give
the protein bio-orthogonal chemical reactivities, fluorescence, lipid anchors, PEG chains, and an-
tibiotics, among many other functionalizations [149]. Notably, synthetic peptides are not limited to
just a single modification, so they can be added in controlled combinations and stoichiometries.
STEPL further improves on traditional sortase-mediated conjugations by expressing the target
protein, sortase recognition motif, a flexible linker, the sortase active domain, and a hexahistidine
tag as a single fusion protein. This chimeric design allows the active enzyme to be immobilized onto
a metal resin along with any unconjugated ligand, eliminating the need for inefficient downstream
purifications. The addition of calcium and a synthetic peptide activates the sortase domain and re-
sults in the simultaneous cleavage of the target protein off of the column and C-terminal conjugation
of the synthetic peptide, resulting in >95% of the collected protein being ligated to the synthetic
peptide [236]. In addition to being efficient, STEPL is also modular. Once a ligand has been cloned
into the pSTEPL vector and its expression has been optimized, it can be ligated to any number
of synthetic peptides. This makes it easy to incorporate different functionalities onto a targeting
ligand, such as the bio-orthogonal crosslinking groups necessary for the production of bispecifics.
When crosslinking two biomolecules, the strain-assisted azide-alkyne cycloaddition reaction has
emerged as a robust strategy [248]. In addition to being a “click” reaction, which designates it as
efficient, biocompatible, and modular [138], the reaction is also bio-orthogonal, which limits potential
unwanted products. The azide and dibenzocyclooctyne (DBCO) groups can be incorporated into
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Figure 4.1: Bispecific Ligand Generation using STEPL. Arrays of hetero- and homodimers are
easily generated in the STEPL system. First, the targeting ligands must be cloned into pSTEPL
and expressed. Second, targeting ligands are cleaved off of separate columns using peptides that
contain bio-orthogonal chemistries, such as the azide-alkyne click groups. These peptides may
contain multiple lengths and categories of spacer regions. Finally, dimers are created by simply
mixing monomers with compatible reactive groups. Although this figure depicts the ligands and
peptides used in this study, they may be substituted for any of the wide range of ligands and
peptides compatible with the STEPL system with the same effect.
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Table 4.1: Synthetic Peptides
Peptide Molecular Weight (Da) λex/λem
P3.2 NH2-Gly-Gly-Gly-Lys(5-FAM)-Gly-Gly-Ser-Lys(N3)-NH2 1,030 492/518
P 4.1 NH2-Gly-Gly-Gly-Lys(TAMRA)-Gly-Gly-Ser-Cys-NH2 1,034 541/568
P 4.2 NH2-Gly-Gly-Gly-Lys(TAMRA)-Gly-Gly-Ser-Cys(DBCO-maleimide)-NH2 1,462 541/568
P 4.3 NH2-Gly-Gly-Gly-Lys(TAMRA)-Gly-Gly-Ser-Cys(DBCO-(PEG)4-maleimide)-NH2 1,709 541/568
synthetic peptides, making the reaction compatible with the STEPL system as well. By purifying
one ligand with a peptide containing an azide and one with a peptide containing DBCO, the ligands
can be crosslinked by simply incubating them together in Tris buffer, generating dimeric ligands
of controlled specificity and stoichiometry. The modularity inherent to the STEPL system allows
for easy alteration of the chemical crosslinking strategy as well as the length of the spacer region
between the constituent ligands, making STEPL exquisitely well-suited to the generation of bispecific
targeting ligands.
In this study, we produced an array of homodimeric and heterodimeric affibodies with two differ-
ent spacer regions using the STEPL system (Figure 4.1). The affibodies are then used to compare
the effects of dimerization and spacing on targeting specificity and relative affinity.
4.2 Affibody Dimerization
One of the major advantages of the STEPL system is that it is easy to produce the same protein with
a number of different modifications. Taking advantage of this capability, we expressed the ZHer2-
and ZEGFR-STEPL constructs cloned in Chapter 3, cleaving each with Peptides P 3.2, P 4.2, and
P 4.3 (Table 4.1), which contain functional groups compatible with the strain-assisted azide-alkyne
cycloaddition click chemistry.
The modified affibodies were then incubated with each other in various combinations to create a
variety of hetero- and homodimers (Table 4.2). Affibody dimerization was verified by SDS-PAGE.
As shown in Figure 4.2, purified dimers have a higher apparent molecular weight (approximately
20 kDa) than the monomers (6.6 kDa). It was expected that the dimers would exhibit an apparent
molecular weight of roughly twice the monomers, around 13 kDa. However, the bulky dibenzocy-
clooctyne and poly(ethylene-glycol) groups added by the peptide likely inhibit motility through the
poly(acrylamide) gel, giving it a higher apparent molecular weight.
In all, we were able to create eight unique affibody constructs while only optimizing two protein
Section 4.2: Affibody Dimerization 77
Table 4.2: Affibody Click Reactions. Homo- and heterodimeric affibodies were created by incubating
one azide-conjugated affibody with one DIBO-conjugated affibody. Created dimers are indicated
with a X. Construct names are in parentheses.
ZHer2 ·DIBO ZHer2 · (PEG)4 ·DIBO ZEGFR ·DIBO ZEGFR · (PEG)4 ·DIBO None
ZHer2 ·N3 X(HH) X(H4H) X(HE) X(H4E) X(H)
ZEGFR ·N3 X(EE) X(E4E) X(E)
Figure 4.2: Affibody Dimerization. Affibody monomers and dimers were analyzed by SDS-PAGE and
imaged by UV fluorescence. Dimers have an apparent molecular weight of nearly 20kD, indicating
successful click reactions.
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expression protocols. We easily incorporated two different linker lengths, which could potentially
alter binding properties. It was also possible to include fluorophores on each of the peptides, which
enabled us to quantify the samples to ensure equimolar click reactions and to use both monomers
and dimers in downstream imaging and flow cytometry applications. The site-specific and stoichio-
metric bioconjugation of multiple chemical functionalities would be much more complicated in other
chemical and enzymatic bioconjugation systems.
This study gave only a small example of the combinatorial possibilities of creating bispecific
ligands with STEPL. There are many biomarkers that already have affinity ligands compatible with
the STEPL system (See Section 2.1.3). Expressing just five of these ligands via STEPL enables
quick access to ten unique bispecific molecules, five homodimers, and five monomers per linkage. A
panel of ten would give 45 bispecific ligands, in addition to the ten monomers and ten homodimers.
As the number of potential biomarkers increases, the modularity of STEPL becomes more and more
powerful, quickly entering the realm of medium to high-throughput screens.
STEPL’s modular approach to creating bispecific proteins would also benefit systems where one
of the affinity ligands is always the same. For example, the generation of BiTE agents could be made
much more efficient by scaling production of the α-CD3 ligand. Partner ligands could then simply
be expressed in STEPL, cleaved with a compatible peptide, and reacted with stock α-CD3 ligand.
Many other groups have recognized the utility in a modular approach to creating bispecific tar-
geting ligands and published their own techniques to accomplish this [249, 250, 251, 252]. However,
using STEPL to generate modularity has distinct advantages over these previous technologies. Un-
like modular systems relying on IgG heavy and light chain interactions, STEPL is not limited to
any one class of proteins. Ligand classes could even be mixed and matched using STEPL. It would
work just as well linking a nanobody to an scFv as it would dimerizing two affibodies. Also, since
the linker is being introduced by conjugation, the system is symmetric, as opposed cloned systems
where asymmetry is coded into the protein, such as knob-in-hole bispecific antibodies. There is no
need to clone different constructs for the ligand to receive an azide or alkyne functionalization. That
is decided post-expression, during purification. Finally, spacer regions have been shown to have a
large effect on bispecific functionality [253]. The inclusion of a spacer region in the peptide rather
than the cloning sequence allows that to be changed and optimized as easily as the linking chemistry.
One previously reported method for bispecific generation also uses sortase A and azide-alkyne
click chemistry [252]. Wagner et al. also took advantage of the incredible flexibility of the sortase
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Figure 4.3: T6-17/Affibody Binding Curves. Mean fluorescence intensity as determined by flow
cytometry was fit to a ligand binding model. Modeled fractional saturation (lines) were superimposed
onto the measured mean intensities (circles) for affibodies that showed affinity for the T6-17 cell line
in the measured range. Monospecific ZEGFR ligands showed no binding to T6-17 cells.
enzyme to create a modular system. Although this is very similar to what is described in this
study, STEPL still retains all of the advantages over traditional sortagging that we have previously
described [236]. Specifically, linking protein purification to sortase activity leads to purer samples,
less peptide waste, and simpler downstream processing.
4.3 Determination of Apparent Affibody KDs
To quantify the differences between the six dimeric and two monomeric affibodies that were gener-
ated, the ligands were applied to the Her2/neu+ cell line T6-17, the EGFR+ cell line KB, and the
Her2/neu+/EGFR+ cell line SK-BR-3. 5 × 104 cells were incubated with affibody concentrations
ranging from 100 nM to 100 fM before being assayed for cell binding by flow cytometry. The mean
fluorescence intensity fluorescence intensity for each sample was then fit to a ligand-binding curve
to determine the apparent dissociation constant (KD) for each affibody-cell line pair. These curves
are detailed in Figures 4.3, 4.4, and 4.5. As expected, the ZEGFR homodimers and monomer showed
no affinity for the EGFR-negative T6-17 cells, while ZHer2 homodimers and monomer showed no
affinity for the Her2/neu-negative KB cell line. All of the affibodies bound to the double-positive
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Figure 4.4: SK-BR-3/Affibody Binding Curves. Mean fluorescence intensity as determined by flow
cytometry was fit to a ligand binding model. Modeled fractional saturation (lines) were superimposed
onto the measured mean intensities (circles) for affibodies that showed affinity for the SK-BR-3 cell
line in the measured range, which was all eight.
Figure 4.5: KB/Affibody Binding Curves. Mean fluorescence intensity as determined by flow cy-
tometry was fit to a ligand binding model. Modeled fractional saturation (lines) were superimposed
onto the measured mean intensities (circles) for affibodies that showed affinity for the KB cell line
in the measured range. Monospecific ZHer2 ligands showed no binding to KB cells.
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Table 4.3: Ligand Binding Parameters. Values and 95% confidence intervals are listed for the ligand
KDs and receptor copy numbers per cell as determined by the mathematical model.
Ligand KDs (nM) T6-17 SK-BR-3 KB
H 10.45 ± 0.31 4.89 ± 0.94
E 21.08 ± 43.21 10.18 ± 0.72
HH 3.12 ± 1.41 1.60 ± 0.14
H4H 5.11 ± 0.37 2.21 ± 0.76
HE 21.07 ± 1.84 4.82 ± 0.57 17.59 ± 5.63
H4E 19.41 ± 1.19 4.34 ± 0.43 17.83 ± 1.76
EE 40.15 ± 73.91 41.92 ± 61.21
E4E 25.03 ± 8.92 7.29 ± 0.70
Receptor Copy Number
Her2/neu 7,223,620 ± 69,665 3,081,328 ± 2,304,491 4,994 ± 81,526
EGFR 0 ± 2,958 316,433 ± 359,378 1,806,512 ± 290,473
SK-BR-3 cells to some extent. The ZHer2-derived affibody constructs showed tighter binding than
did the ZEGFR-derived constructs, consistent with previous measurements of the monomeric affibod-
ies’ affinities [112]. Values of the fitted parameters are listed in Table 4.3. The model did a good job
fitting the ZHer2-containing ligands, it did less well at determining the parameters involving EGFR.
This is most likely due to a combination of EGFR being expressed in lower amounts than Her2/neu
and ZEGFR having a lower molecular affinity for its target than ZHer2.
The ligand binding experiments clearly illustrate the utility in being able to quickly screen dimers
with different linker properties. For the ZHer2 homodimers, the (PEG)4-containing linker reduces
affinity of the ligand by around 50% for both the T6-17 and SK-BR-3 cell lines. The opposite is
true for the ZEGFR homodimers, where the addition of the (PEG)4 group doubles the affinity as
compared to the E4E protein. And the (PEG)4 group makes no difference for the heterodimers.
These conflicting results are not easily predicted, so it is important to be able to easily and modularly
incorporate different linker regions so that the best design can be determined empirically.
4.4 Increased Fluorescence Specificity
An enhancement index was determined for each of the affibodies to quantify its selectivity for the
double-positive cell line. The enhancement index for a given ligand was defined as the ratio of
apparent dissociation constants for that ligand with the double-positive line to the ligand with a
single-positive cell line multiplied by the ratio of the available receptors on the double-positive line to
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Figure 4.6: Affibody Enhancement Indices. Ratios of the apparent dissociation constants and 95%
confidence intervals for each affibody between the double-positive SK-BR-3 cell line and the single-
positive T6-17 and KB lines. Positive values indicate stronger binding to the double-positive line.
the available receptors on the single-positive line. Positive enhancement indices indicate a selective
advantage for the double-positive cells and negative values mean tighter binding to the single-positive
line. The calculated values, presented in Figure 4.6, showed that monomers and homodimers are
more selective for the single-positive lines or are statistically indifferent. This is likely because of
the higher receptor expression on the T6-17 and KB cell lines. The heterodimers, however, showed
selectivity for the SK-BR-3 double-positive cell line. Selectivity for SK-BR-3 cells over KB cells is
higher than selectivity for T6-17 cells, probably driven by the higher affinity of the ZHer2 component.
Before obtaining images of the cells, the optimal ligand concentrations to enhance selectivity were
determined by subtracting the fractional saturation curve of a ligand against the signal-positive cell
lines from the fractional saturation curve of the ligand against double-positive cell lines. Shown in
Figure 4.7, the concentrations that show the maximum difference vary between affibodies, but are
generally near 1 × 10−8 molar. Thus, all of the cell lines were incubated with 10 nM ligand and
the images in Figures 4.8, 4.9, and 4.10 were obtained. In agreement with the flow cytometry data,
both monomers labeled the single-positive lines more than the double-positive line. Homodimers
did not obviously distinguish between single- or double-positive lines, with the exception of the E4E
construct that clearly selected for the KB cells, as the enhancement index predicted. However, the
bispecific ligands were able to specifically label the SK-BR-3 double-positive cells to a greater extent
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Figure 4.7: Differential Ligand Binding. The difference was calculated between fractional saturation
curves between the single- and double-positive cell lines. Maximum values denote the optimal ligand
concentration to select for one cell line over the other.
T6-17 SK-BR-3 KB
Her2+ Her2/EGFR+ EGFR+
H
E
Figure 4.8: Bispecific Fluorescence Imaging: Monomers. Fluorescence images of cell lines treated
with monomeric affibodies. ZHer2 labels both Her2/neu positive cell lines, while ZEGFR labels both
EGFR positive cell lines.
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T6-17 SK-BR-3 KB
Her2+ Her2/EGFR+ EGFR+
HH
H4H
EE
E4E
Figure 4.9: Bispecific Fluorescence Imaging: Homodimers. Fluorescence images of cell lines treated
with homodimeric affibodies. ZHer2 dimers label both Her2/neu positive cell lines, while ZEGFR
dimers label both EGFR positive cell lines.
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T6-17 SK-BR-3 KB
Her2+ Her2/EGFR+ EGFR+
HE
H4E
Figure 4.10: Bispecific Fluorescence Imaging: Heterodimers. Fluorescence images of cell lines treated
with heterodimeric affibodies. In both cases, the bispecific affibody labels the double-positive line
to a greater extent than the single-positive lines.
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than the T6-17 Her2/neu-positive cell and the KB EGFR-positive cells. These images validate the
hypothesis that the bispecific ligands will provide enhanced selectivity for a cell line presenting both
ligands. There may also be a synergistic effect to drive this selectivity despite a lower receptor count
on the SK-BR-3 cells.
4.5 Conclusions
STEPL is a facile and modular system for generating bispecific targeting ligands. Using four peptides
and two affibody-STEPL chimeras, a panel of eight homo- and heterodimeric affibodies were created
in a matter of days. The affinities of these ligands were determined by flow cytometry and used
to calculate the optimal ligand concentration to specifically label a double-positive cell line. This
simple example demonstrates how the inherent flexibility of the STEPL system to conjugate a wide
array of targeting ligands to any synthetic peptide with an N-terminal glycine allows this one system
to create ligand dimers with differing specificities, spacers, and multiple chemical functionalities.
4.6 Materials & Methods
Peptide Labeling
Peptide P 4.1 (synthesized by Anaspec, Inc., 6 mg/mL in dimethylformamide (DMF)) was incu-
bated with a 2-fold excess of tris(2-carboxyethyl)phosphine (TCEP) (Sigma, 0.5M) and a 4-fold
excess of either dibenzocyclooctyne−maleimide (DIBO-maleimide, Sigma, 5 mg/mL in DMF) or
dibenzocyclooctyne−(PEG)4−maleimide (Sigma, 5 mg/mL in DMF) for 4 hours at room temper-
ature. 10 volumes of methyl tert-butyl ether (Sigma) was then added to precipitate the peptide,
which was pelleted and resuspended in 0.1M Tris Buffer, pH 8 (Mediatech). DIBO-linked peptide
was purified by reverse-phase high performance liquid chromatography (RP-HPLC) (Agilent) and
resuspended in STEPL buffer (20mM Tris-base, 50mM NaCl, pH 7.5).
Protein Expression, Cleavage, & Bioconjugation
ZHer2 and ZEGFR sequences were cloned into the pSTEPL vector (see Section 3.9). 25mL starter
cultures were grown overnight in LB-Ampicillin. These were added to 225mL of LB and grown
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to an OD600 of 0.8-1 before induction with 0.5mM Isopropyl β-D-1-thiogalactopyranoside (IPTG).
Cultures were allowed to express for 24hrs at 25◦C. Cells were then harvested by centrifugation (3000
RPM, 15min) and resuspended in 10mL of lysis buffer (50mM NaH2PO4, 300mM NaCl, 1mg/mL
Lysozyme, 1 EDTA-free cOmplete Mini protease inhibitor tablet (Roche), pH 7.5). Lysates were
incubated at room temperature for 30min under gentle agitation before freezing overnight at -80◦C.
Samples were then thawed and incubated for 30min with DNAse I (Roche) under gentle agitation.
Lysates were then sonicated and separated by centrifugation (16,000g, 30min).
8mL of clarified lysates was incubated for 1hr with 0.5mL Talon resin (equilibrated in lysis buffer,
Clontech). The lysate and beads were added to a column (BioRad) and resin was washed with 5mL
STEPL buffer. 600µL of STEPL buffer containing 200µM synthetic peptide and 100µM CaCl2 was
flowed over the beads until it replaced the wash buffer. Columns were protected from light and
reacted for 6hrs at 37◦C. 1mL of STEPL buffer was added to the column and the flowthrough
collected. Conjugated affibody was purified from excess peptide by RP-HPLC and resuspended in
0.1M Tris-HCl, pH 8.
Dimerization
For the dimerization reactions, equimolar azide-conjugated and DIBO-conjugated affibody were
incubated together for 24 hours. Reactions were then purified by RP-HPLC and resuspended in
0.1M Tris-HCl, pH 8. Dimerization was confirmed by SDS-PAGE (4-12% Gel, Life Technologies).
After PAGE, fluorescent bands were imaged by UV transillumination. Then proteins were visualized
by incubating the gel with SimplyBlue SafeStain (Life Technologies) for 1 hour, followed with an
overnight wash in deionized water.
Cell Culture
KB (ATCC) and T6-17 cell lines (NIH/3T3 (ATCC) cells engineered to stably express Her2/neu;
kindly provided by Dr. Mark Greene, University of Pennsylvania) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin at 37◦C and 5% CO2. SK-BR-3 cells (ATCC) were maintained in McCoy’s medium
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37◦C and 5% CO2.
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Flow Cytometry
Cells were lifted off their plates with enzyme-free dissociation buffer (PBS base, Millipore) and
concentrated to 5 × 105/mL. Serial dilutions of affibody (100 nM - 100 fM, 10-fold dilutions) were
incubated with 5 × 104 cells in full media for 30 min at 37◦C while shaking to maintain reaction
homogeneity. Cells were then held on ice until samples were analyzed on a BD LSR II flow cytometer
(5,000 counts/sample, 532 nm laser, 575/26 nm filter).
Computational Analysis
The mean fluorescence intensities (MFIs) for each cell line/affibody pair were simultaneously fit to
determine that affibody’s apparent dissociation constant (KD,app) and receptor copy number (NR)
for each cell line using Equation 4.1 in MATLAB. Because the affinities were weaker than expected
for all of the ligands, the data could not be fit to the standard ligand binding model of [L]/(KD+[L]),
which requires multiple fully saturated points to fit a reliable dissociation constant. Therefore, data
was fit to a more complicated model that does not rely on the excess ligand assumption:
MFI = F0 + (Fmax − F0) ∗
[A] + [Ri] +KD,app −
√
([A] + [Ri] +KD,app)
2 − 4 [A] [Ri]
2 [RT]
(4.1)
[R] =
NR ∗NC
NA ∗ V
(4.2)
where Fmax and F0 scale the fractional saturation curve to the fluorescence data, [A] is the affibody
concentration, [Ri] is the concentration of surface receptor that binds to the affibody being fit
(Her2/neu, EGFR, or both), [RT] is the sum of Her2/neu and EGFR ligand concentrations, NC
is the number of cells per well, NA is Avogadro’s number, and V is the volume of media in the
well. Parameter confidence intervals were also determined by MATLAB. For plotting, all curves
were normalized such that the predicted values spanned the range of [0,1].
The enhancement index (EI) was calculated by dividing the single-positive dissociation constant
by the double-positive dissociation constant for each affibody (ER, Equation 4.3) and submitting it
to the transformation in Equation 4.4, which ensures the magnitude of EI is greater than 1 while
Section 4.6: Materials & Methods 89
changing the sign if the ligand is more selective for the single-positive cells.
ER =
KD,app,T6−17 or KB
KD,app,SK−BR−3
∗ NR,SK−BR−3
NR,T6−17 or KB
(4.3)
EI = exp (|lnER|) ∗ lnER
|lnER|
(4.4)
The optimal concentration of bispecific affibodies was then determined by subtracting the mod-
eled fractional saturation curve for T6-17 or KB cells from the curve for SK-BR-3 cells for each of
the affibodies.
Fluorescence Imaging
All cell lines were incubated with the optimal concentration of each bispecific affibody for 1 hour in
full media. Cells were washed 3 times with affibody-free media before being imaged in serum-free
DMEM. Imaging was performed with an Olympus IX81 inverted fluorescent microscope with a back-
illuminated EMCCD camera (Andor) and a SOLA excitation source (Lumencor). Images of 5-FAM
and TAMRA fluorescence were acquired using the filter sets (HQ545/30, HQ620/60, Q570lp) and
(HQ710/75, HQ810/90, Q750LP) (Chroma) after focusing with white light. A LUC PLAN FLN
40X objective (NA 0.6) was used for all imaging studies. All images were exposed for 2 seconds and
are displayed with the same linear contrast curve.
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Chapter 5
Enhancing STEPL Yield through
Directed Evolution
Abstract
Sortase-tag expressed protein ligation (STEPL), a robust and flexible system for protein expression
and bioconjugation, is plagued by a reduction in protein yield due to unwanted sortase activity dur-
ing protein expression. This study set out to evolve the STEPL system to reduce in situ cleavage by
decreasing the calcium sensitivity of the sortase enzyme or by changing the trigger ion to manganese,
a less-abundant, biocompatible, and industry-friendly divalent cation. Bacterial, yeast, and bacte-
riophage evolution systems were explored to produce an assay for sortase activity that contained a
genotype-phenotype linkage. Phage display libraries were produced by randomizing the amino acids
in the two loops known to bind the native calcium ion with directed, optimized degenerate codons.
A number of screens and screening strategies were employed. However, none of the screens were
able to produce a viable candidate for an improved STEPL system.
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5.1 Introduction
In Chapter 3, it was described in detail how well the STEPL system works once the chimeric protein
is in a controlled buffer setting. However, it was only briefly mentioned that STEPL can be unstable
when in culture media during expression, due to inherent calcium in the media. In fact, the initial
expression studies show that much of the STEPL protein is cleaved before ever reaching the column
(Figure 5.1). While this early cleavage does not effect the final product’s purity, it does greatly
reduce the overall yield.
We postulated that the early cleavage was due to calcium ions present in the growth media and
within the cells themselves [243]. This problem could be fixed in one of three ways. First, calcium
could be eliminated from the growth media by using M63 minimal media produced in reverse-
osmosis water [254]. However, protein expression is difficult in minimal media, requiring a number
of potential additives to finally produce a “witch’s brew” STEPL expression media. This route could
potentially work in E. coli, which do not require calcium to grow, but it restricts STEPL’s use in
eukaryotes and even other prokaryotes. A second strategy would be to alter sortase such that it
needs an additional small molecule to be activated. Finally, the sortase catalytic domain could be
evolved to alter its relationship with calcium in one of the following ways:
Eliminate Calcium Ion Sensitivity By eliminating the need for calcium entirely, we would also
abolish the calcium-driven background cleavage. Instead, sortase activity would be triggered
solely by the presence of a triglycine peptide. Thus, no cleavage would occur until the peptide
was added to the column. This would greatly increase purity as well.
Weaken Calcium Binding If it were harder for sortase to bind calcium, more would be needed
to trigger cleavage. Raising the necessary calcium concentration to well above what would be
present in a cell would also avoid cleavage until it is desired on the column.
Alter the Trigger Ion While calcium is generally present at high concentration in biological sys-
tems, many other divalent cations are not. By altering sortase to bind one of those instead of
calcium, it would be likely to avoid unwanted cleavage due to a trace element’s presence.
The evolution option is the most promising because it is the smallest change to the STEPL system
that could yield the desired outcome.
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Figure 5.1: Early Cleavage Expression Fractions. A large amount of cleavage product can be seen
in the lysate lanes (i.e. EGFP and Sa-SrtA∆59-His6), indicating that most of the STEPL chimera
is cleaved during expression and therefore cannot be conjugated or recovered.
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In this chapter, we will evaluate the feasibility of making these alterations by exploring the
evolution systems and library designs that could be used to reduce the unwanted background cleavage
during STEPL expression.
5.2 Selection of Evolution System
The first consideration when evaluating a directed evolution system is the choice of genotype-
phenotype linkage, a number of which are described in Section 2.4.2. Background cleavage is occur-
ring within the cell, so a living display technology is ideal because it will most closely replicate those
conditions. In addition, a cellular screen will also select for constructs with better expression profiles.
This is normally a downfall of display screens, but because STEPL is an expression system, it is a
desirable trait in this case. Therefore, E. coli, yeast, and phage display systems were considered as
potential screens.
5.2.1 E. coli Display
E. coli display seemed like the best option to evolve the STEPL system for many reasons. Sortase
naturally occurs on the surface of gram-positive bacterial cells, so it is likely that STEPL should
work extracellularly as well. In addition, STEPL has already been thoroughly proven in a bacterial
system. Also, the entire problem of background cleavage during expression was defined in the context
of E. coli. It may not exist or have a different cause in other systems. For all these reasons, E. coli
display was chosen as the first evolution system to be evaluated.
The screening strategy for an E. coli display system is depicted in Figure 5.2. In the proposed
system, E. coli is transformed with a membrane-anchored STEPL system that has a fluorescent
ligand. The cells are grown to a high density, pelleted, and resuspended in a negative screen buffer.
The negative buffer contains a calcium level deemed to be tolerable and no triglycine. Sequences
with background cleavage, such as wild-type, will cleave while incubating in this buffer and lose their
fluorescent ligand. The cells are then sorted by fluorescence-activated cell sorting (FACS), which
is able to sort individual cells into different tubes based on the cell’s fluorescent signal. Cells with
high signal will pass the negative screen and be regrown to density. These cells are pelleted and
resuspended in a positive reaction buffer, which contains the desired metal ion and Gly3. Mutants
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(A) Molecular Mechanism (B) Screen Design
Figure 5.2: Bacterial Display Scheme. A) STEPL can be adapted for bacterial display by using a
fluorescent ligand and a C-terminal membrane anchor. This will give a high fluorescent signal if the
construct has not cleaved and a low signal if it has cleaved. B) A library of Sa-SrtA∆59 mutants
is cloned into the surface display system and expressed in E. coli Mutants are then exposed to a
negative screen and sorted by FACS. Highly fluorescent cells will pass the screen, be amplified, and
be incubated in the desired reaction conditions. FACS sorting for non-fluorescent cells will provide
the desired genotypes.
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that were unable to cleave in the previous buffer but can cleave in the positive buffer now lose their
fluorescent ligand. After incubation, these cells are also sorted by FACS, but this time, the cells
with low signal will be chosen. Surviving clones are randomly chosen for sequencing and biochemical
analysis.
There are a few strategies for trafficking proteins to the outer membrane of E. coli (see Figure
2.13), but only one that allows the C-terminal anchor needed for STEPL, the autotransporter.
Autotransporters are a class of structural proteins in gram-negative bacteria that are expressed in
the periplasm. The C-terminal domain is a transmembrane pore that actively translocates the N-
terminal domain out of the periplasm into extracellular space. Due to the inherent modularity of
autotransporters and their ability to translocate large globular domains across the outer membrane,
they are the display strategy of choice for enzymatic screens [208]. Therefore, pSED/sfGFP (Plasmid
5.1) was created by cloning in frame an N-terminal periplasmic signal sequence, super-folder GFP
(sfGFP), the sortase motif LPETG, (GGS)5, Sa-SrtA∆59, and the autotransporter EspP. Super-
folder GFP was used because EGFP is known to export poorly from E. coli and sfGFP was designed
to survive the E. coli secretion pathways [255]. The autotransporter EspP was chosen because it
performed well in other studies [208, 209].
To validate pSED/sfGFP, the construct was expressed in E. coli overnight. Cells were then
pelleted and resuspended into STEPL buffer, where the cleavage reaction could be monitored. Since
sortase concentration was a critical parameter while initially characterizing the STEPL system, 1
mL aliquots of the cells were pelleted and resuspened in 0.1 to 1 mL of STEPL buffer to create
different resuspension densities and therefore different sortase concentrations. As shown in Table
5.1, even after incubating the reactions at 37◦C overnight with high concentrations of CaCl2 and
Gly3 (5 mM each), no sfGFP cleavage was observed.
Because sortase is known to work extracellularly, it was hypothesized that the STEPL construct
was trapped in the bacterial cytoplasm or periplasm. To test this, cells expressing pSED/sfGFP
were labeled and assayed for surface exposed GFP. Figure 5.3 shows that the cells expressing the
surface displayed pSED/sfGFP were able to be stained by α-GFP antibodies as well as Co-NTA resin
bound to EGFP. The cytosolically expressed pSTEPL/EGFP could not be stained by the antibody.
Thus, the pSED construct must be correctly trafficked to the bacterial surface.
Sortase activity could also be impaired if the enzyme is physically too close to the autotransporter
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Figure 5.3: GFP Surface Expression. E. coli expressing pSED/sfGFP were stained with an
α-GFP antibody, indicating surface expression of sfGFP. Cells expressing the internal construct
pSTEPL/EGFP as well as Co-NTA beads with and without bound EGFP were used as staining
controls.
Figure 5.4: Bacterial Display Cleavage. All three generations of pSED constructs were assayed for
EGFP release into the supernatant. None show enough cleavage to be used in a directed evolution
system.
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to refold or find its LPXTG motif. If this is the case, adding a linker between the autotransporter and
sortase should allow the enzyme to regain activity. With that in mind, pSED2/sfGFP (Plasmid 5.2)
and pSED2.5/sfGFP (Plasmid 5.3) were cloned to insert (GGS)5 and ECFP between Sa-SrtA∆59
and EspP. The new clones were expressed in E. coli, resuspended in STEPL buffer with and without
5mm CaCl2 and Gly3, and allowed to react for six hours at 37
◦C. Unfortunately, neither provided
a working STEPL display system, as shown in Figure 5.4. Thus, spacing from the bacterial surface
was not likely to be the issue.
If sortase is active in the extracellular context naturally, being expressed on the surface, and
sufficiently spaced from cell but is still inactive in the display context, it may not be refolding
properly after transport through the EspP pore complex. A potential fix for this problem is to use
another autotransporter. Therefore, pSED3/sfGFP (Plasmid 5.4) was cloned by replacing EspP with
EstA, the second best performing system as per Binder et al. [209]. This construct was also expressed
in E. coli, resuspended in STEPL buffer with and without 5mm CaCl2 and Gly3, and allowed to
react for six hours at 37◦C. It still showed no activity (Figure 5.4). Thus, it was presumed that the
STEPL system was incompatible with E. coli display.
5.2.2 Yeast Display
The second system that was considered was yeast display. The yeast display screen is conceptually
identical to the bacterial display screen. The major difference is that the STEPL chimera would
be trafficked to the yeast secretory pathway co-translationally, rather than the post-translational
translocation through the E. coli autotransporter. This is much easier on the enzyme, as evidenced
by the prior use of sortase within eukaryotic secretory pathways [256, 257]. However, Dr. Colin
Greineder, a collaborator working to adapt STEPL to yeast systems, discovered that Sa-SrtA∆59 is
heavily glycosylated in the secretory pathways of both P. pastoris (Figure 5.5) and S. cerevisiae (data
not shown). These glycogens have the potential to influence the evolution process by interacting
with the sortase in ways that would not occur within the cell. Therefore, yeast display was likely
not a viable evolutionary technique in this case.
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Figure 5.5: Sortase Glycosylation in Yeast. STEPL constructs were produced in P. pastoris ex-
pression vectors and targeted to the cytosol or the secretory pathway. Cultures were grown of each
and analyzed via Western blot. When expressed intercellularly, the STEPL construct runs at the
expected molecular weight of 46 kDa. The secreted STEPL construct runs much higher as a result
of N-linked glycosylation. Figure courtesy of Dr. Colin Greineder.
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5.2.3 Phage Display
Phage display is another viable option for evolving the STEPL system to acquire altered divalent
cation sensitivity. Like bacterial display, the constructs would be expressed in the proven E. coli
system. But Bacteriophage M13 is assembled in the periplasm, so the enzyme would only need to
survive one translocation in phage display. This is expected to help mediate the problems that were
associated with E. coli display.
Figure 5.6 shows a schematic of the phage display screen for STEPL. First, a library of Sa-
SrtA∆59 mutants fused to pIII is transformed into E. coli. Those cells are then amplified and
infected with CM13 helper phage to induce phage production. STEPL-pIII fusions are randomly
incorporated into phage as they are assembled and secreted. The phage are isolated and resuspended
into the negative screening buffer. The STEPL “ligand” mediates phage attachment to an antigen
coated plate. After incubating the phage in the negative buffer, the wells are washed to remove any
phage that cleave during expression or the negative screen. The wells are then filled with positive
screening buffer and allowed to incubate again. Supernatant containing phage that cleaved under
the desired conditions is used to infect fresh E. coli cells, which are then amplified for additional
screening and/or plated onto agar plates for clonal sequencing and analysis.
Two different phagemids were constructed to perform the above screen. Both encoded a fu-
sion protein with the PelB periplasmic signal sequence, a ligand, LPETG sortase recognition motif,
(GGS)5 linker, Sa-SrtA∆59, a flexible linker, and the C-terminal portion of M13 pIII. As the “lig-
and”, the plasmid pComb3XM/SBP (Plasmid 5.6) contained the sequence for the streptavidin bind-
ing peptide (SBP) [258] and the other, pComb3XM/Avi (Plasmid 5.7), contained the sequence for
the biotin acceptor peptide, also known as the Avi-Tag [157]. Both mediate specific binding to strep-
tavidin (SAv), although with very different strengths. SBP has nanomolar affinity for SAv, whereas
a biotinylated Avi-Tag has femtomolar affinity, approximately a million times tighter [213, 258]. The
Avi-Tag construct is obviously preferred, but both were moved forward in parallel. To validate the
assay, both phagemids were mutated to eliminate sortase activity by changing the active cysteine,
C180, to an alanine residue.
All four constructs were transformed into E. coli cells, which were then infected with CM13
helper phage to induce phage production. The Avi-Tag phage were assembled in an E. coli strain
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Figure 5.6: Phage Display Screening Cycle. Phagemid libraries were electroporated into E. coli,
which produced modified phage displaying the modified pIII and a streptavidin-binding ligand.
Phage were then bound to wells coated in streptavidin and incubated in the negative buffer. Phage
with sortase mutants that cleaved during expression (yellow, orange, red) or during the negative
screen (purple) were washed away. Next, the remaining phage were incubated in positive buffer.
Phage that cleaved during the positive screen (blue, green) were collected, leaving phage that could
not cleave (brown, pink) bound to the plate. That supernatant then infected E. coli cells that
could be amplified for another round of phage display or plated for further analysis.
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Figure 5.7: Phage Display Validation Assay. SBP and Avi-Tag containing STEPL-pIII phage were
incubated in STEPL blocking buffer with and without calcium and triglycine. All phage were also
added to unblocked wells as a positive control and inactivated C180A phage were added to blocked
wells without streptavidin as a negative control. Stock CM13 phage bound to unblocked wells was
a positive control for expression. Avi-Tag constructs did not bind the plate. SBP constructs bound
if the sortase enzyme had been inactivated.
that overexpresses biotin ligase so that the STEPL-pIII fusion would contain a biotin conjugation.
Isolated phage were split into two pools and incubated in STEPL blocking buffer (STEPL buffer
with 2% w/v powdered, biotin-free milk) or STEPL blocking buffer supplemented with 100 µM
CaCl2 and 200 µM Gly3. After four hours, the phage were applied to blocked wells that had
been coated with SAv. As a positive control, phage in STEPL buffer without milk were added to
unblocked wells, where they could freely adsorb to the surface. Blocked wells with no streptavidin
provided negative controls. After washing the wells vigorously, phage remaining in the wells were
quantified by phage ELISA. As shown in Figure 5.7, the Avi-Tag phage did not bind to any blocked
wells, indicating a lack of biotin conjugation. The PelB signal sequence translocates proteins to
the periplasm post-translationally, however this may occur too quickly for biotin ligase to label the
Avi-Tag in the cytoplasm. The SBP phage showed robust binding when inactivated, but binding
was significantly reduced in the active constructs both with and without calcium and triglycine.
Most likely, this is due to the high levels of calcium in the powdered milk, nearly 4 mM in 2% milk
[259]. This does not allow for fine control of calcium concentrations, so a number of other blocking
buffers were analyzed to determine the best option (Figure 5.8). Milk performed significantly better
than the other options. Since the purpose of the screen is to make STEPL insensitive to high levels
of calcium, the calcium in the powdered milk is acceptable and was used in all subsequent assays.
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Figure 5.8: Blocking Buffers. Wild-type and C180A SBP-STEPL phage were incubated in various
blocking buffers before being bound to streptavidin coated plates, washed, and assayed for binding.
Biotin-free 2% milk showed less non-specific binding than any other buffer.
Table 5.2: Trace Elements Approved for Bolus Injection. Metal ions in this table are approved for
bolus inection by the FDA. Maximum bolus injection doses are calculated for a 80kg patient with a
5 L blood volume.
Ion Blood Concentration [260] Bolus Concentration Citation
Cr(III) 7 µM 100 µM [261]
Cu(III) 16 µM 30 mM [262]
Mn(II) 14 nM 19 mM [263]
Zn(II) 16 µM 78 mM [264]
Thus, pComb3XM/SBP can be screened for STEPL activity and served as the wild-type con-
struct for phage display.
5.3 Selection of Metal Ion
One of the evolution options identified in Section 5.1 was changing STEPL’s calcium sensitivity
to a different metal ion. The ion must be a biocompatible trace element, which greatly reduces
the potential field of elements. Those elements were further narrowed to chemicals approved for
bolus injection by the U.S. Food and Drug Administration because they will be safe if any of the
metal contaminates a STEPL-derived imaging agent and will enable future applications that involve
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(A) NNK Library Structure (B) Optimized Library Structure
Figure 5.9: Sortase Calcium Binding Loop. Crystal structures of the Sa-SrtA∆59 calcium binding
loop are color coded to show the hydropathy index of each randomized amino acid in the NNK (A)
and optimized (B) libraries. Pink NNK codons are slightly hydrophilic. Blue VRK codons are very
hydrophilic. Gray codons are hydrophobic.
Table 5.3: Degenrate Codons
Codon Hydropathy Index Possible Amino Acids Number of Codons
NNK -0.22 20 ACDEFGHIKLMNPQRSTVWY* 32
VRK -3.02 9 DEGHKNQRS 12
NTR 3.75 4 ILMV 8
STEPL as a cleaving agent in vivo (see Chapter 6). Those metals are described in Table 5.2. Of
those metals, chromium was eliminated due to the low bolus dose. Copper was eliminated due to
toxicity [141]. Zinc, while having the largest maximum dose, is heavily regulated and eliminated due
to potential downstream manufacturing issues. Manganese had a reasonable bolus concentration,
the lowest basal concentration in the blood, and is compatible with mass production. Therefore,
Mn2+ was chosen to replace calcium as the STEPL trigger ion.
5.4 Library Design
Structural biology revealed that Sa-SrtA∆59 binds its calcium ion through five specific amino acids
in the β3/β4 and β6/β7 loops [265]. Therefore, the phage display libraries used in this study focus
on the twenty amino acids that make up those loops, as shown in Figure 5.9. If all 20 positions
were to be randomized with standard NNK codons, which code for all possible amino acids, the
codon and amino acid spaces would be astronomical, 1.2 × 1024 and 1.4 × 1021, respectively. The
vast majority of these libraries will be non-functional because they will not code for valid loops,
greatly decreasing the probability of finding the desired protein sequence. By optimizing the codons
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(A) Codon Hydropathy
(B) Codon Diversity
Figure 5.10: Degenerate Codon Properties. (A) Average codon hydropathy index is plotted for each
randomized position for both libraries. The optimized library attempts to mirror wild-type residues.
(B) Codon and amino acid diversity at each position are plotted for both libraries. As desired, the
optimized library has significantly reduced diversities.
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in the library, overall amino acid and codon spaces can be reduced and the library skewed toward
sequences that are more likely to encode functional sortase clones. Figures 5.9 and 5.10 compare the
properties of an optimized library. The optimized library was designed by picking degenerate codons
that encode for amino acids with similar overall properties to the wild-type residues (Figure 5.10A).
Most of the residues, 16 of 20, should be hydrophilic, polar amino acids because most of the loops
are surface exposed and oxygen or nitrogen atoms would be needed to coordinate with calcium or
manganese ions. These residues are encoded by VRK, whose possible amino acids are enumerated in
Table 5.3. Two residues in the wild-type sequence are hydrophobic. Labeled in gray in Figure 5.9B,
these reach into the core of the protein and hold the β3/β4 loop close to the protein. Because these
are most likely necessary for a stable structure, those two positions were encoded by NTR, which
will translate to a hydrophobic residue. The final two positions are serines in the wild-type enzyme,
which are only slightly hydrophilic. It is unclear how these interact with their neighboring residues
and the overall structure, so they were encoded by NNK, whose average hydropathy also mimics
that of serine. As shown in Figure 5.10B, the optimized library’s diversity was much lower than the
NNK library, reducing the codon and amino acid spaces to 5.8 × 1017 and 2.0 × 1015, respectively.
These are still larger than the most diverse phage display libraries (approximately 1× 1011), but a
much higher percentage of the potential library could be translated to phage.
Before a screen could be performed, it was necessary to define a robust method of library creation.
The first successful Sa-SrtA∆59 libraries were created by synthesizing degenerate oligonucleotides
and using them to amplify the internal portion of Sa-SrtA∆59 between the β3/β4 and β6/β7 loops.
Those were then woven together with the C-terminal portion of Sa-SrtA∆59 by PCR, and inserted
into the rest of pComb3XM/SBP via restriction-ligation reactions (see Section 5.7 for more detail).
Sequencing data from a pool of the resulting plasmids showed that this method produced libraries
heavily biased toward the wild-type sequence (Figure 5.11, top and middle chromatograms). This
most likely occurred because oligonucleotides that resemble the wild-type sequence will bind better
to the region and therefore act as better primers in the amplification reaction. To avoid this,
a new strategy was developed whereby the entire region of Sa-SrtA∆59 between the β3/β4 and
β6/β7 loop libraries was constructed from synthetic oligonucleotides. This strategy is depicted in
Figure 5.12. Briefly, a series of overlapping oligonucleotides were designed that included the entire
region between and including the two libraries. The oligos served as primers for one another in an
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Figure 5.11: Library Quality by Generation Method. Base calls and the chromatagram for the
β6/β7 loop of the wild-type Sa-SrtA∆59 sequence (top) and libraries generated by amplifying a Sa-
SrtA∆59 section off of the plasmid with degenerate oligonucleotides (middle) or by weaving together
synthetic oligonucleotides (bottom). The amplification sequence shows a heavy bias toward the wild-
type sequence, especially for the G/C bases. The woven library shows no such bias. Randomized
bases are annotated and should be VRK VRK VRK VRK (V=A/C/G, R=A/G, K=G/T).
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Figure 5.13: Recovered Sequences from Library X4Gβ.
isothermal weaving reaction, which filled in the missing bases and ligated the strands together. The
most important aspect of this is that no oligonucleotides bound to the randomized regions of the
degenerate oligonucleotides. The complement strand was thus created by a DNA polymerase that
has no bias toward any sequence, wild-type or other. This library generation method allowed for a
truly random library, as shown by the bottom chromatogram in Figure 5.11.
5.5 Screening Results
5.5.1 Phage Library X4Gβ
The first library to be screened was created by isothermal weaving and also combined with the rest
of the pComb3XM/SBP vector by isothermal assembly, creating a library of 5.4×106 unique phage.
Although this was a small library, it was large enough to screen. Resulting phage were subjected to
a negative screen of 2 hours in 4 mM Ca2+ and a positive screen of 4mM Ca2+ and 200 µM Gly3 for
either 1 hour at 37◦C or 30 minutes at room temperature. After 5 rounds of screening (successive,
with no mutagenesis in between rounds), 24 colonies from each group were sent to sequencing. Of
those 48 colonies, 5 sequences were recovered, shown in Figure 5.13. These five sequences were cloned
into pSTEPL/EGFP (Plasmid 3.2) and assayed for observable cleavage. The results are tabulated
in Table 5.4. All of the clones either did not cleave under any conditions or cleaved no matter the
condition. Note that colony M, which contained a stop codon in the library sequences, was not
assayed.
Section 5.5: Screening Results 110
T
ab
le
5.
4
:
P
h
ag
e
D
is
p
la
y
P
re
li
m
in
ar
y
D
at
a.
S
eq
u
en
ce
s
re
co
v
er
ed
fr
o
m
p
h
a
g
e
d
is
p
la
y
w
er
e
cl
o
n
ed
in
to
th
e
p
S
R
T
A
/
E
G
F
P
v
ec
to
r.
T
h
e
re
su
lt
in
g
p
ro
te
in
s
w
er
e
ex
p
re
ss
ed
,
b
o
u
n
d
to
co
b
a
lt
re
si
n
,
a
n
d
th
ei
r
ex
p
re
ss
io
n
w
a
s
m
ea
su
re
d
q
u
a
li
ta
ti
v
el
y
fo
r
p
re
li
m
in
a
ry
st
u
d
ie
s.
E
G
F
P
fl
u
o
re
sc
en
ce
w
a
s
es
ti
m
a
te
d
b
y
U
V
tr
a
n
si
ll
u
m
in
a
ti
o
n
to
b
e
n
o
n
fl
u
o
re
sc
en
t
(—
),
sl
ig
h
tl
y
fl
u
o
re
sc
en
t
(+
),
fl
u
o
re
sc
en
t
(+
+
),
o
r
h
ig
h
ly
fl
u
o
re
sc
en
t
(+
+
+
)
a
s
co
m
p
a
re
d
to
th
e
w
il
d
-t
y
p
e
co
n
tr
o
l.
F
lu
o
re
sc
en
ce
w
a
s
o
b
se
rv
ed
fo
r
th
e
co
lu
m
n
fl
ow
th
ro
u
g
h
s,
re
si
n
b
ef
o
re
cl
ea
va
g
e,
a
n
d
a
ft
er
4
h
o
u
rs
(2
4
h
o
u
rs
)
a
t
th
e
sa
m
p
le
’s
p
o
si
ti
v
e
sc
re
en
te
m
p
er
a
tu
re
u
n
d
er
th
e
fo
ll
ow
in
g
cl
ea
va
g
e
co
n
d
it
io
n
s:
N
eg
(0
m
M
C
a
C
l 2
,
0
m
M
G
ly
3
,
0
m
M
M
n
C
l 2
),
B
a
se
(1
0
0
µ
M
C
a
C
l 2
,
1
0
0
µ
M
G
ly
3
,
0
m
M
M
n
C
l 2
),
↑C
a
(5
m
M
C
a
C
l 2
,
1
0
0
µ
M
G
ly
3
,
0
m
M
M
n
C
l 2
),
↑C
a
,
M
n
(5
m
M
C
a
C
l 2
,
1
0
0
µ
M
G
ly
3
,
5
m
M
M
n
C
l 2
),
↑C
a
,
-G
ly
(5
m
M
C
a
C
l 2
,
0
m
M
G
ly
3
,
0
m
M
M
n
C
l 2
),
C
a
,
↑M
n
(5
m
M
C
a
C
l 2
,
2
0
0
µ
M
G
ly
3
,
8
0
m
M
M
n
C
l 2
).
C
lo
n
es
th
a
t
w
er
e
su
b
je
ct
ed
to
a
d
d
it
io
n
a
l
m
u
ta
g
en
es
is
a
n
d
sc
re
en
in
g
a
re
b
o
ld
ed
.
N
eg
at
iv
e
S
cr
ee
n
C
o
n
d
it
io
n
s
P
os
it
iv
e
S
cr
ee
n
C
on
d
it
io
n
s
E
G
F
P
C
le
av
ag
e
C
on
d
it
io
n
s
L
ib
ra
ry
C
o
lo
n
y
[C
a
C
l 2
]
(µ
M
)
[M
n
C
l 2
]
(µ
M
)
[G
ly
3
]
(µ
M
)
T
em
p
(◦
C
)
H
ou
rs
[C
aC
l 2
]
(µ
M
)
[M
n
C
l 2
]
(µ
M
)
[G
ly
3
]
(µ
M
)
T
em
p
(◦
C
)
H
ou
rs
F
lo
w
th
ro
u
gh
B
ea
d
s
N
eg
B
as
e
↑C
a
↑C
a,
M
n
↑C
a,
-G
ly
C
a,
↑M
n
X
4G
β
W
T
—
+
+
—
+
+
R
T
5
.1
4,
00
0
0
0
37
2
4,
00
0
0
20
0
R
T
0.
5
—
+
—
—
R
T
5
.1
5
4,
00
0
0
0
37
2
4,
00
0
0
20
0
R
T
0.
5
—
+
—
—
37
5.
K
4,
00
0
0
0
37
2
4,
00
0
0
20
0
37
1
—
+
+
+
37
5.
T
4,
00
0
0
0
37
2
4,
00
0
0
20
0
37
1
—
+
—
—
X
4
W
N
L
ε
W
T
—
+
+
—
+
+
+
+
+
+
+
G
M
4.
B
4,
00
0
0
0
37
2
4,
00
0
5,
00
0
20
0
37
4
+
+
+
—
G
M
4.
E
4,
00
0
0
0
37
2
4,
00
0
5,
00
0
20
0
37
4
+
+
+
—
G
M
5.
S
4,
00
0
0
0
37
2
4,
00
0
5,
00
0
20
0
37
4
—
+
+
+
—
(—
)
—
(—
)
—
(—
)
—
(—
)
G
M
5.
T
4,
00
0
0
0
37
2
4,
00
0
5,
00
0
20
0
37
4
+
+
+
—
G
M
5.
D
D
4,
00
0
0
0
37
2
4,
00
0
5,
00
0
20
0
37
4
—
+
—
(—
)
—
(—
)
—
(—
)
—
(—
)
G
4.
11
4,
00
0
0
0
37
2
4,
00
0
0
20
0
37
4
+
+
+
+
—
(—
)
—
(—
)
—
(—
)
—
(—
)
G
5.
18
4,
00
0
0
0
37
2
4,
00
0
0
20
0
37
4
+
+
+
—
(—
)
—
(—
)
—
(—
)
—
(—
)
G
5
.2
2
4,
00
0
0
0
37
2
4,
00
0
0
20
0
37
4
+
+
+
+
+
—
(—
)
—
(—
)
—
(+
+
+
)
—
(+
+
+
)
G
5.
24
4,
00
0
0
0
37
2
4,
00
0
0
20
0
37
4
+
—
G
5.
30
4,
00
0
0
0
37
2
4,
00
0
0
20
0
37
4
+
+
+
+
+
—
(—
)
—
(—
)
—
(—
)
—
(—
)
X
H
4W
S
L
α
W
T
—
+
+
—
+
+
+
+
+
+
G
5.
G
1
4,
00
0
0
0
37
2
4,
00
0
0
20
0
R
T
1
—
+
+
—
(—
)
—
(—
)
—
(—
)
G
5.
H
1
4,
00
0
0
0
37
2
4,
00
0
0
20
0
R
T
1
—
+
+
+
—
(—
)
—
(—
)
—
(—
)
G
5.
E
2
4,
00
0
0
0
37
2
4,
00
0
0
20
0
R
T
1
+
+
+
+
—
(—
)
—
(—
)
—
(—
)
G
5.
G
3
4,
00
0
0
0
37
2
4,
00
0
0
20
0
R
T
1
+
+
+
—
G
M
5.
B
5
4,
00
0
0
0
37
2
4,
00
0
5,
00
0
20
0
R
T
1
—
+
—
(—
)
—
(—
)
—
(—
)
G
4
a.
A
7
4,
00
0
0
20
0
37
2
10
,0
00
0
20
0
R
T
1
+
+
—
(—
)
—
(—
)
—
(—
)
G
4
a.
C
7
4,
00
0
0
20
0
37
2
10
,0
00
0
20
0
R
T
1
—
+
—
(—
)
—
(—
)
—
(—
)
G
4
a.
G
7
4,
00
0
0
20
0
37
2
10
,0
00
0
20
0
R
T
1
—
+
+
—
(—
)
—
(—
)
—
(—
)
G
4
a.
A
9
4,
00
0
0
20
0
37
2
10
,0
00
0
20
0
R
T
1
+
+
+
—
G
4
a.
D
9
4,
00
0
0
20
0
37
2
10
,0
00
0
20
0
R
T
1
—
+
+
—
(—
)
—
(—
)
—
(—
)
G
M
4
a.
C
10
4,
00
0
0
20
0
37
2
4,
00
0
5,
00
0
20
0
R
T
1
—
+
+
+
—
(—
)
—
(—
)
—
(—
)
G
M
4
a.
D
10
4,
00
0
0
20
0
37
2
4,
00
0
5,
00
0
20
0
R
T
1
+
+
—
(—
)
—
(—
)
—
(—
)
G
M
4
a.
A
11
4,
00
0
0
20
0
37
2
4,
00
0
5,
00
0
20
0
R
T
1
+
+
+
+
—
(—
)
—
(—
)
—
(—
)
G
M
4
a.
B
1
1
4,
00
0
0
20
0
37
2
4,
00
0
5,
00
0
20
0
R
T
1
—
+
+
+
—
(—
)
—
(—
)
—
(—
)
G
M
4
a.
G
11
4,
00
0
0
20
0
37
2
4,
00
0
5,
00
0
20
0
R
T
1
—
+
+
+
—
(—
)
—
(—
)
—
(—
)
G
M
4
a.
E
12
4,
00
0
0
20
0
37
2
4,
00
0
5,
00
0
20
0
R
T
1
+
+
+
—
(—
)
—
(—
)
—
(—
)
X
4
W
E
A
L
β
W
T
—
+
+
—
+
+
+
+
B
.F
3
4,
00
0
0
20
0
R
T
1.
5
4,
00
0
80
,0
00
20
0
R
T
0.
5
—
+
+
+
—
(—
)
—
(—
)
—
(—
)
X
5A
L
α
W
T
—
+
+
—
+
+
+
+
F
.C
1
1
4,
00
0
0
20
0
R
T
1.
5
4,
00
0
80
,0
00
20
0
R
T
1.
5
—
+
+
+
—
(—
)
—
(—
)
—
(—
)
Section 5.5: Screening Results 111
Figure 5.14: Recovered Sequences from Library X4WNLε.
The vast majority of the clones submitted to sequencing in this and the previous library did
not contain a coding sequence for Sa-SrtA∆59. The plasmids contained a deletion between the
(GGS)5 linker in STEPL and the flexible linker at the N-terminus of pIII. These sequences are
highly similar and GC rich, so this was likely due to a recombination event, which is possible during
isothermal assembly. Therefore, the remaining libraries were placed into the pComb3XM/SBP vector
by ligation.
5.5.2 Phage Library X4WNLε
With no success in the initial trial of tuning sortase’s calcium sensitivity, the next library was also
screened for manganese-triggered activity. This library of 4.0× 106 unique phage was also split into
two screens. All went through a 2 hour negative screen in 4 mM Ca2+ and positive screens for 4
hours at 37◦C with either 4mM Ca2+ and 200 µM Gly3 or 4mM Ca
2+, 200 µM Gly3, and 10 mM
MnCl2. 16 colonies in each group were sequenced after both rounds 4 and 5, resulting in 26 unique
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potential sequences (Figure 5.14). Of these, 5 sequences from each screen were chosen to be cloned
into pSTEPL/EGFP and assayed. Table 5.4 again shows that none of the sequences performed as
expected within 4 hours.
One clone that was screened for reduced calcium sensitivity, however, did show cleavage only
under high-calcium conditions at 24 hours, G5.22. That clone was therefore subjected to random
mutagenesis along the entire length of the Sa-SrtA∆59 sequence to create a phage library of 2.5×106
unique clones. Those were screened for activity at room temperature in 1 hour. After 5 rounds, 16
clones were sent to sequencing. None contained DNA that could be sequenced. It might not have
been possible to increase the activity of G5.22, so it was no longer pursued.
A common feature of the clones resulting from the calcium screens is a cysteine at position 109.
That implies that it plays an important role in how these phage are passing the screen. Since the
bacterial cytoplasm (where the assayed proteins are produced) is a reducing environment, but the
periplasm (where the phage are produced) is oxidizing, the pSTEPL/EGFP mutants containing the
conserved cysteine may not be able to make a critical disulfide. They were therefore expressed in
a special E. coli strain that has an oxidizing cytoplasm. Unfortunately, all colonies again showed
negative results (data not shown), so a reduced thiol was not the problem.
5.5.3 Phage Library XH4WSLα
After having no duplicate sequences in Library X4WNLε, the screens were made harder to pass,
with the hope that this would further narrow the field and allow a consensus sequence to emerge.
A library of 6.0× 107 clones was screened under four different conditions:
1. A negative screen of 4mM Ca2+ for 2 hours at 37◦C followed by a positive screen of 4mM
Ca2+ and 200 µM Gly3 for 1 hour at room temperature.
2. A negative screen of 4mM Ca2+ for 2 hours at 37◦C followed by a positive screen of 4mM
Ca2+, 5mM MnCl2, and 200 µM Gly3 for 1 hour at room temperature.
3. A negative screen of 4mM Ca2+ and 200 µM Gly3 for 2 hours at 37
◦C followed by a positive
screen of 10mM Ca2+ and 200 µM Gly3 for 1 hour at room temperature.
4. A negative screen of 4mM Ca2+ and 200 µM Gly3 for 2 hours at 37
◦C followed by a positive
screen of 4mM Ca2+, 5mM MnCl2, and 200 µM Gly3 for 1 hour at room temperature.
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Figure 5.15: Recovered Sequences from Library XH4WSLα.
Table 5.5: Sortase Activity after Acid Shock. pSTEPL/EGFP proteins were expressed, bound to
cobalt resin, and their ability to release EGFP into the supernatant was measured qualitatively by
UV transillumination to be nonfluorescent (—), slightly fluorescent (+), fluorescent (++), or highly
fluorescent (+++) after 4 hours at 37◦C.
Acid Conditons Cleavage Conditions
pH Time 0 µM CaCl2, 0 µM Gly3 100 µM CaCl2, 200 µM Gly3
4 10 min — +++
7 N/A — +++
After 5 rounds of screening conditions 1 and 2, and 4 rounds of screening conditions 3 and 4, 24
clones of each were sent to sequencing. 17 viable sequences were returned (Figure 5.15). Again these
sequences had no duplicates or consensus. Still, all 17 were cloned into pSTEPL/EGFP and assayed
for activity in the positive and negative buffers. None showed conditional activity (Table 5.4).
5.5.4 Phage Library X4WEALβ
To try and improve the display results, a new screening method was employed, as shown in Figure
5.16. It was hypothesized that the SBP-streptavidin interaction was not strong enough to hold for the
long negative and positive incubations in the coated wells, so the new screen was designed to minimize
the time that phage spent bound to the plate. Briefly, libraries are transformed into E. coli, which
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Figure 5.16: Altered Phage Display Screening Cycle. Phagemid libraries were electroporated into
E. coli, which produced modified phage displaying the modified pIII and a streptavidin-binding
ligand. Phage were then incubated in the negative buffer before being bound to wells coated in
streptavidin. Phage with sortase mutants that cleaved during expression (yellow, orange, red) or
during the negative screen (purple) could not bind and were washed away. Next, the remaining
phage acid eluted off of the plate before being incubated in positive buffer. These phage were then
applied to a different streptavidin-coated well. Phage that cleaved during the positive screen (blue,
green) were collected, leaving phage that could not cleave (brown, pink) bound to the plate. That
supernatant then infected E. coli cells that could be amplified for another round of phage display
or plated for further analysis.
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are induced to produce phage that randomly include the mutant STEPL-pIII chimeras as well as the
encoding plasmid. The phage are incubated in the negative selection buffer in a polypropylene tube.
With 30 minutes remaining in the incubation, the phage are transferred to a streptavidin coated
plate and allowed to bind. Then, unbound phage are washed away with vigorous pipetting, which
removes any mutants that cleave during expression or in the negative screening buffer. Uncleaved
phage that remain bound to the plate are eluted in pH 4 acetate buffer for 10 minutes. These
phage are then neutralized with sodium hydroxide and incubated in positive screening buffer in
another polypropylene tube. Again, phage are transferred to a streptavidin-coated well with 30
minutes remaining in the positive incubation. Supernatant, which contains STEPL mutants that
were inactive during expression and the negative screen but gained activity during the positive screen,
is collected and used to infect fresh bacterial cells. The bacteria are then used to produce phage for
another screen or grown on plates for sequencing and analysis. STEPL’s ability to maintain activity
after the acid elution was determined by assaying wild-type pSRTA/EGFP for EGFP cleavage after
a 10 minute pH 4 acid shock (Table 5.5).
In addition, it was theorized that the optimized β3/β4 and β6/β7 loop library may have been too
optimal, resulting in almost entirely functional proteins because loops are very tolerant of mutations
between similar amino acids. Therefore, another layer of diversity was added by running error-
prone PCR reactions on top of the randomized loops. The inclusion of random mutations should
allow for even harsher screening conditions because residues that more directly affect the enzymatic
mechanism could be altered.
A library of 1.0× 107 mutants was screened under four conditions:
1. A negative screen of 4mM Ca2+ for 1.5 hours at room temperature followed by a positive
screen of 4mM Ca2+ and 200 µM Gly3 for 4 hours at room temperature.
2. A negative screen of 4mM Ca2+ for 1.5 hours at room temperature followed by a positive
screen of 4mM Ca2+ and 200 µM Gly3 for 30 minutes at room temperature.
3. A negative screen of 4mM Ca2+ and 200 µM Gly3 for 1.5 hours at room temperature followed
by a positive screen of 4mM Ca2+, 80mM MnCl2, and 200 µM Gly3 for 4 hours at room
temperature.
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Figure 5.17: Recovered Sequences from Library X4WEALβ.
4. A negative screen of 4mM Ca2+ and 200 µM Gly3 for 1.5 hours at room temperature followed
by a positive screen of 4mM Ca2+, 80mM MnCl2, and 200 µM Gly3 for 30 minutes at room
temperature.
The manganese screens had a much larger concentration of MnCl2 to try and pull out sequences
with even a low affinity for manganese, which could then be increased in subsequent libraries.
After five days, 16 clones from each condition were sent for sequencing. No viable sequences
resulted from conditions 1 or 2, but 9 identical sequences resulted from conditions 3 and 4 (Figure
5.17). However, Table 5.4 again shows that the sequence had no activity in cells with oxidizing or
reducing cytoplasms.
5.5.5 Phage Library X5ALα/X4WSLβ
Finally, a pooled library of Sa-SrtA∆59 with only random mutagenesis and Sa-SrtA∆59 with only
the optimized loop library was screened under the following conditons:
1. A negative screen of 4mM Ca2+ for 1.5 hours at room temperature followed by a positive
screen of 4mM Ca2+ and 200 µM Gly3 for 4 hours at room temperature.
2. A negative screen of 4mM Ca2+ and 200 µM Gly3 for 1.5 hours at room temperature followed
by a positive screen of 4mM Ca2+, 80mM MnCl2, and 200 µM Gly3 for 4 hours at room
temperature.
Beginning with 3.7×106 sequences, 16 clones from each condition were sequenced. One good sequence
was returned, from the manganese screen, containing a single point mutation, Q64R (Figure 5.18).
The clone showed no activity (Table 5.4).
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Figure 5.18: Recovered Sequences from Library X5ALα/X4WSLβ.
5.6 Conclusions
Unfortunately, this study was unable to produce STEPL mutants with a lower calcium sensitivity
or a manganese sensitivity. Bacterial display was not a viable strategy because the sortase enzyme
could not survive translocations across both E. coli membranes. Yeast display was not attempted
due to heavy glycosylation of the sortase in the endoplasmic reticulum. Phage display produced a
construct with an active sortase and an assay that physically held or released the phage based on
enzymatic activity. However, despite the use of both randomly generated and specifically optimized
libraries under a number of different screening conditions, no clones were obtained that were also
functional in the original STEPL assay.
5.7 Materials & Methods
Bacterial Display
Cloning
To construct pSED/sfGFP (see Plasmid Map 5.1), the coding sequence for EspP and the OmpA
signal were obtained from the NCBI nucleotide database (accession no. FJ875095) and synthesized
by IDT. sfGFP was amplified off of the instructional plasmid pGlo (Bio-Rad). The sequences for
LPETG, (GGS)5, and Sa-SrtA∆59 were amplified together off of pSTEPL. These three amplicons
were then woven together via PCR and cloned into pRSET-A via restriction-ligation. pSED2/sfGFP
(Plasmid Map 5.2) and pSED2/sfGFP (Plasmid Map 5.3) were cloned by first inserting an EagI
restriction site between the coding sequences for Sa-SrtA∆59 and EspP in pSED/sfGFP. Oligos
containing (GGS)5 and appropriate overhangs were ligated into pSED/sfGFP that had been digested
with EagI to create pSED2/sfGFP. pSED2.5/sfGFP was then constructed by amplifying ECFP off
of pECFP and cloning it into the same restriction site. pSED3/sfGFP was created by ordering the
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entire expression cassette from IDT and cloning it into pRSET-A. The EstA sequence was obtained
from the NCBI nucleotide database (accession no. AF005091.1). Insert directionality and all final
vectors were verified by sequencing.
Cleavage Assay
First, single colonies or stabs of glycerol stocks were grown for 24-hours in 10 mL of ZYP-5052
(Ameresco) supplemented with 100 µg/mL Amp. 1 mL aliquots were pelleted at 6,000g for 5
minutes and then resuspended in the appropriate amount of STEPL buffer with or without 5 mM
CaCl2 and 5 mM Gly3 (Sigma). Cultures were then shook at 37
◦C overnight. For the first six hours,
cells were pelleted and observed with UV light once per hour.
Immunohistochemistry
Both pSED/sfGFP and pSTEPL/EGFP expression cells were grown for 24-hours in 10 mL of ZYP-
5052 (Ameresco) supplemented with 100 µg/mL Amp. For half of the pSTEPL/EGFP stock, the
chimeric protein was purified and bound to Talon resin (Clontech) as previously described (Section
3.9). Cells and beads were pelleted at 8,600g for 3 minutes and washed three times with 1 mL ice-cold
STEPL buffer. Samples were then resuspeneded in 1 mL ice-cold STEPL buffer with Rabbitα-GFP
(GE) antibody and shook for 2 hours at 4◦C. After another three washes, samples were resuspended
in 1 mL ice-cold STEPL buffer with α-Rabbit secondary antibody conjugated to a 700nm fluorophore
(LiCor) and shook for 1 hour at 4◦C. Samples were again washed 3 times and then resuspended in
100 µL ice-cold STEPL buffer. These were then transferred to a 96-well plate that was imaged and
quantified by the LiCor Odyssey fluorescence scanner.
Phage Display
Phagemid Cloning
All of the phagemids were derived from pComb3X (generously gifted by Dr. Donald Siegel). Before
any other cloning, the amber stop codon in pComb3X’s linker region was deleted by site-directed
mutagenesis (Quikchange II Kit, Agilent Genomics), creating the vector pComb3XM (see Plasmid
Map 5.5). The mutation was validated by sequencing.
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Plasmid Map 5.1: pSED/sfGFP
Feature Location
T7 Promoter 20-39
Chimeric ORF 100-2382
OmpA Signal 103-165
sfGFP 172-888
Sortase Motif 895-909
(GGS)5 Linker 910-954
Sa-SrtA∆59 955-1395
EspP β Domain 1396-2301
T7 Terminator 2330-2495
f1 Origin 2530-2985
bla Promoter 3017-3121
AmpR 3116-3976
pUC Origin 4794-4121
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Plasmid Map 5.2: pSED2/sfGFP
Feature Location
T7 Promoter 20-39
Chimeric ORF 100-2382
OmpA Signal 103-165
sfGFP 172-888
Sortase Motif 895-909
(GGS)5 Linker 910-954
Sa-SrtA∆59 955-1395
(GGS)5 Linker 1426-1470
EspP β Domain 1477-2382
T7 Terminator 2411-2540
f1 Origin 2611-3066
bla Promoter 3098-3202
AmpR 3197-4057
pUC Origin 4875-4202
Section 5.7: Materials & Methods 121
Plasmid Map 5.3: pSED2.5/sfGFP
Feature Location
T7 Promoter 20-39
Chimeric ORF 100-2382
OmpA Signal 103-165
sfGFP 172-888
Sortase Motif 895-909
(GGS)5 Linker 910-954
Sa-SrtA∆59 955-1395
ECFP 1426-2151
EspP β Domain 2158-3063
T7 Terminator 3092-3221
f1 Origin 3292-3747
bla Promoter 3779-3883
AmpR 3878-4738
pUC Origin 5556-4883
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Plasmid Map 5.4: pSED3/sfGFP
Feature Location
T7 Promoter 20-39
Chimeric ORF 100-2415
OmpA Signal 103-165
sfGFP 172-888
Sortase Motif 895-909
(GGS)5 Linker 910-954
Sa-SrtA∆59 955-1395
EstA β Domain 1426-2415
T7 Terminator 2447-2576
f1 Origin 2647-3102
bla Promoter 3134-3121
AmpR 3116-3976
pUC Origin 4794-4121
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Plasmid Map 5.5: pComb3XM
Feature Location
Lac Promoter 145-172
LacO 179-201
OmpA Signal Sequence 222-284
M13 pIII-C 494-1027
F1 Ori 1501-1195
AmpR 1848-2507
ColE1 Ori 2605-3287
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The streptavidin binding peptide (SBP) sequence (MDEKTTGWRGGHVVEGLAGELEQL-
RARLEHHPQGQREP) and the Avi-Tag sequence (GLNDIFEAQKIEWHE) were codon-optimized
and synthesized by IDT. The j5 program was used to design PCR primers to amplify the pComb3XM
backbone and sortase A active site with the linker and LPETG motif from pSTEPL [266]. The lin-
ear PCR fragments were combined through isothermal assembly [267] to create pComb3XM/SBP-
STEPL and pComb3XM/Avi-STEPL (see Plasmid Maps 5.6 and 5.7). Gibson reactions were
transformed into Top10 competent cells (Life Technologies). Resultant vectors were validated by
sequencing. Site-directed mutagenesis (Quikchange II Kit, Agilent Genomics) was used to intro-
duce the inactivating C180A mutation into both vectors, creating pComb3XM/SBP-C180A and
pComb3XM/Avi-C180A (Plasmid Maps not shown). Resultant vectors were validated by Sanger
sequencing.
To create a phagemid that linked the STEPL system to pIII via a helical linker, the α-helical linker
sequence (GSG(EAAAK)4GSG) plus 20bp upstream/22bp downstream overlaps was synthesized by
IDT as a series of single-stranded oligonucleotides. The pComb3XM/SBP vector was amplified to
create a linear product that excluded the native glycine-serine linker but included the upstream
and downstream overlaps. The PCR product was then digested with DpnI (New England Biolabs),
purified on a 0.7% low-melt agarose gel (Lonza), and re-amplified by PCR with the PhireII-Hotstart
Enzyme (Thermo Fisher). 1 pmol of backbone was then combined with 10 µM of each oligo and
2X Gibson Assembly Master Mix (New England Biolabs) and incubated at 50◦C for 1 hour before
being transformed into Top10 cells (Life Technologies). Resultant vectors (see Plasmid Map 5.8)
were validated by sequencing.
Helper Phage Preparation
Overnight cultures of XL1-Blue cells (Agilent) were grown in SB Media (Gentrox) containing 10
µg/mL tetracycline. The following day, 10 µL of the culture was added to 10 mL of SB Media with
tetracycline and shook at 37◦C for 1 hour. Then 10 µL of CM13 helper phage stock (Antibody
Design Labs) was added to the culture and allowed to infect at room temperature for 15 minutes
before being shook for an additional 2 hours at 37◦C. The culture was then added to 500 mL of
SB Media containing 70 µg/mL kanamycin before being shook overnight at 37◦C. The next day,
the culture was split into 50 mL aliquots and bacterial cells were removed by pelleting at 3,000g
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Plasmid Map 5.6: pComb3XM/SBP-STEPL
Feature Location
Lac Promoter 145-172
LacO 179-201
Chimeric ORF 222-1496
OmpA Signal Sequence 222-284
Streptavidin Binding Peptide 285-398
Sortase Motif 399-413
(GGS)5 Linker 414-458
Sa-SrtA∆59 459-899
β3/β4 Loop 594-629
β6/β7 Loop 789-800
C184 Catalytic Residue 831-833
M13 pIII-C 963-1496
F1 Ori 1970-1664
AmpR 2317-2976
ColE1 Ori 3074-3756
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Plasmid Map 5.7: pComb3XM/Avi-STEPL
Feature Location
Lac Promoter 145-172
LacO 179-201
Chimeric ORF 222-1496
OmpA Signal Sequence 222-284
Avi-Tag R⃝ 285-329
Sortase Motif 330-344
(GGS)5 Linker 345-389
Sa-SrtA∆59 390-830
β3/β4 Loop 525-560
β6/β7 Loop 720-731
C184 Catalytic Residue 762-764
M13 pIII-C 894-1427
F1 Ori 1901-1595
AmpR 2248-2907
ColE1 Ori 3005-3687
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Plasmid Map 5.8: pComb3XH/SBP-STEPL
Feature Location
Lac Promoter 145-172
LacO 179-201
Chimeric ORF 222-1496
OmpA Signal Sequence 222-284
Streptavidin Binding Peptide 285-398
Sortase Motif 399-413
(GGS)5 Linker 414-458
Sa-SrtA∆59 459-899
β3/β4 Loop 594-629
β6/β7 Loop 789-800
C184 Catalytic Residue 831-833
α-helical Linker 963-1040
M13 pIII-C 1041-1493
F1 Ori 1967-1661
AmpR 2314-2973
ColE1 Ori 3071-3753
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for 15 minutes. Supernatants were then incubated at 70◦C for 20 miuntes before being centrifuged
again at 3,000g for 15 minutes. Supernatants were transferred to new tubes and stored at 4◦C until
needed.
Preparation of Streptavidin plates
10 µg of purified streptavidin (Fisher, diluted to 4 mg/mL in PBS, pH 5) was added to 96-well,
clear, flat bottom, half area, high bind plates (Corning). Plates were sealed and incubated for 2
hours at 37◦C. The PBS solution was removed and wells were then blocked by filling them with
STEPL buffer with 2% w/v biotin-free powdered milk (LabScientific) and incubating for at least 1
hour at 37◦C or room temperature.
Phage Assay Validation
First, the vectors pComb3XM/SBP-STEPL, pComb3XM/Avi-STEPL, pComb3XM/SBP-C180A,
and pComb3XM/Avi-C180A were transformed into Biotin XCell
TM
F’ electrocompetent cells (Lu-
cigen). Transformed colonies were used to inoculate 10 mL overnight cultures in SB Media (50
µg/mL carbenicillin, 10 µg/mL tetracycline) at 37◦C. The next day, the cultures were expanded to
50 mL of SB Media (50 µg/mL carbenicillin, 10 µg/mL tetracycline) and grown to an OD600 of 1
by shaking at 37◦C. At that point 2 mL of helper phage were added to each culture, and allowed
to infect stationary at room temperature for 15 minutes. Cultures were then expanded to 200 mL
of SB Media (50 µg/mL carbenicillin, 10 µg/mL tetracycline) and shook for an additional 2 hours
at 37◦C. Finally, kanamycin was added to a concentration of 70 µg/mL and cultures were shook
overnight at 25◦C.
The following day, bacterial cells were removed from the overnight cultures by pelleting at 3,000g
for 15 minutes. Sodium chloride (Fisher, 3% w/v) and poly(ethylene glycol) (Sigma, MW 8000, 4%
w/v) were dissolved into the supernatants by shaking vigorously at 37◦C for 5 minutes before being
incubated on ice for 30 minutes. Phage were then pelleted by centrifugation at 15,000g for 15
minutes. Pellets were resuspended in 2 mL of STEPL Buffer with 2% w/v bovine serium albumin
by gentle rocking for 30 minutes at room temperature. Impurities were removed by centrifugation
at 10,000g for 5 minutes at 4◦C. Supernatants were finally passed through a steile filter to obtain
purified phage.
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Table 5.6: Phage Library Nomenclature. In order to keep track of the libraries that were created, a com-
mon nomenclature was employed. All libraries follow the scheme [Vector(s)][Generation][Cloning][Attempt].
The vector, generation, and cloning portions are described in the table. The attempt portion is a sequential
Greek letter used to separate libraries created with the same cloning plan.
Vectors Library Generation Cloning Techniques
Symbol Vector Symbol Technique Symbol Technique
H pComb3XH 1 Kunkel Mutagenesis A AgeI/NcoI Digest
X pComb3XM 2 Site-Directed Mutagenesis E Error-prone PCR Amplifcation
3 Degenerate Oligo PCR G Gibson Assembly
4 Gibson Oligo Weaving H HindIII Digest
5 Error-Prone PCR L Ligation
M MluI Digest
N HindIII/NcoI Digest
S HindIII/NcoI Digest, Short primers
W PCR Weaving
Phage were then added in a 4:1 ratio to STEPL Buffer containing 10% w/v biotin-free powdered
milk (LabScientific, final 2% w/v) and incubated at room temperature for 1 hour. Triglycine (Sigma)
and CaCl2 (Sigma) were added with final concentrations of 5 mM and 100 µM, respectively, in half
of the sample and phage were allowed to cleave for 1 hour at 37◦C. Phage were then added to a
streptavidin-coated plate (see above) and incubated for 4 hours at 37◦C. Then, wells were washed
six times with TBS + 0.05% Tween-20 by vigorously pipetting and incubating with wash buffer for
4 minutes before shaking out the solution. Anti-M13 antibody conjugated to horseradish peroxidase
(Abcam) was diluted to working concentrations in STEPL buffer with 2% w/v biotin-free powdered
milk and incubated in the wells for 1 hour at 37◦C. Wells were again washed six times with TBS
+ 0.05% Tween-20 by vigorously pipetting and incubating with wash buffer for 4 minutes before
shaking out the solution. TMB substrate solution (Pierce) was added to the wells and allowed to
react for 30 minutes before measuring the absorbance at 370 nm on a Tecan Infinate 200 Plate
Reader. Positive controls were produced by incubating phage in unblocked wells. A control for
streptavidin binding was produced by incubating C180A samples in blocked wells that had not been
coated in streptavidin. All samples were run in triplicate.
Phage Library Cloning
Phage Libraries were cloned in a number of different ways. The component techniques are summa-
rized in Table 5.6 and described below.
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Library Generation: Method 1 – Kunkel Mutagenesis
First, pComb3XM/SBP-STEPL was electroporated into electrocompetent XL1-Blue cells (Agilent
Genomics, 2500 V, 25 µF, 200 Ω, 2 mm cuvette). 6 colonies were picked in the morning and used
to inoculate 200 mL of 2xYT Media with 100 µg/mL carbenicillin and 12.5 µg/mL tetracycline.
The culture was shook at 37◦C until it reached an OD600 of 0.5. 5 mL of helper phage (see above)
was added to the culture and it was allowed to infect for 15 minutes at room temperature before
being shook for an additional hour at 37◦C. Cells were then pelleted by centrifugation at 3,000g
for 15 min and resuspended in 200 mL of fresh 2xYT Media with 100 µg/mL carbenicillin, 12.5
µg/mL tetracycline, and 0.25 µg/mL uridine. The culture was then shook for 24 hours at 25◦C. The
following day, bacterial cells were removed from the overnight cultures by pelleting at 3,000g for 15
minutes. Sodium chloride (Fisher, 1.5M) and poly(ethylene glycol) (Sigma, MW 8000, 24% w/v)
were added to the supernatant and the phage were allowed to precipitate at room temperature for
15 minutes. Phage were then pelleted by centrifugation at 15,000g for 10 minutes at 15◦C. Tubes
were inverted for 10 minutes to drain excess supernatant before phage were resuspended in 6 mL
of PBS. Uracil-doped-single-stranded DNA (ssDNA) was then obtained with a QiaPrep R⃝ Spin M13
Kit (Qiagen).
4.4 pmol of 5’-phosphorylated mutagenic oligonucleotides (IDT) were annealed to 8 µg of ssDNA
in buffer TM (50 M Tris−HCl, 10 mM MgCl2, pH 7.5) by heating to 90◦C for 2 minutes and then
decreasing the temperature by 1◦Cminute until it reached 25◦C. The DNA was then supplemented
with ATP (0.8 mM final concentration, New England Biolabs), DTT (5 mM final concentration,
Fisher), dNTP mix (0.8 mM final concentration, each, Fisher), T4 ligase (20,000 units, New England
Biolabs), and T7 polymerase (30 units, New England Biolabs). The reaction was run for 3 hours at
20◦C followed by 20 minutes at 75◦C to inactivate the enzymes. The QiaQuik PCR Cleanup Kit
(Qiagen) was used to recover double-stranded DNA, which was then electroporated into 200 µL of
electrocompetent XL1-Blue cells (Agilent Genomics, 2500 V, 25 µF, 200 Ω, 2 mm cuvette).
Library Generation: Method 2 – Site-Directed Mutagenesis
Methylated pComb3XM/SBP-STEPL was obtained via the QIAquick Spin miniprep Kit (Qiagen)
from overnight cultures of transformed Top10 cells. 10 PCR reactions were run, each consisting
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of 1X Phire Green Reaction Buffer (Thermo Fisher), 200 µM dNTPs, 2% v/v DMSO, 100 ng of
pComb3XM/SBP-STEPL, 0.5 µM of each forward strand mutagenic oligonucleotide, and 1 unit
Phire Hot Start II polymerase (Thermo Fisher). After 50 cycles of PCR, according to the product
protocol, 20 units of the restriction enzyme DpnI (New Englnad Biolabs) was added to each reaction
and incubated at 37◦C for 2 hours to degrade the template DNA. Reactions were then concentrated
and purified using the QIAquick PCR Cleanup Kit. DNA was then electroporated into 200 µL of
electrocompetent XL1-Blue cells (Agilent Genomics, 2500 V, 25 µF, 200 Ω, 2 mm cuvette).
Library Generation: Method 3 – Degenerate Oligonucleotide PCR
The central portion of Sa-SrtA∆59 was amplified from 50 ng of pComb3XM/SBP-STEPL using
the sense-strand mutagenic oligonucleotides for the β3/β4 loop and the antisense-strand mutagenic
oligonucleotide for the β6/β7 loop. After 50 cycles of PCR, according to the Phire Hot Start II
polymerase protocol, product was purified from the template by agarose gel electrophoresis. The
gel band was then cut out and purified with a QIAquick Gel Extraction Kit (Qiagen).
Library Generation: Method 4 – Gibson Oligonucleotide Assembly
A series of overlapping oligonucleotides were designed with melting temperatures near 50◦C (see
Figure 5.12), which were produced by IDT. Oligos were diluted to 10 µM and mixed together. The
mixture was heated to 95◦C for 5 minutes and then cooled 1◦C/minute until reaching 25◦C. 1 µL
of the annealed oligos was then mixed with 9 µL of deionized water and 10 µL of Gibson Assembly
Master Mix (New England Biolabs). The reaction was held at 60◦C for 1 hour. After, the entire
Gibson reaction was used as template DNA in a PCR reaction, using the primers Weave Lib Fwd
and Weave Lib Rev (see Figure 5.19). After 50 cycles of PCR, according to the Phire Hot Start II
polymerase protocol, product was purified from the template by agarose gel electrophoresis. The
gel band was then cut out and purified with a QIAquick Gel Extraction Kit (Qiagen).
Library Generation: Method 5 – Error-Prone PCR
Random mutations were added to the wild-type Sa-SrtA∆59 sequence by amplifying the entire se-
quence with an error-prone polymerase (Clontech Diversify Kit). 50 ng of pComb3XM/SBP-STEPL
was amplified by the TITANIUM Taq Polymerase using the Weave N Fwd and Weave C Rev Short
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primers (see Figure 5.19) with the addition of 640 µM MnSO4 to further reduce the Taq fidelity
to 3.5 mutations/kb (roughly 2 mutations per Sa-SrtA∆59 sequence). The PCR product was then
diluted 1:1000 and used as the template in a second round of error-prone PCR, with the same con-
ditions (roughly 4 mutations per Sa-SrtA∆59 sequence). All of the second round product was used
in a high-fidelity PCR reaction (Phire Polymerase, Thermo Fisher) to amplify the library to the
necessary quantities.
Cloning Technique E
For libraries with an E in the cloning strategy, the entire Sa-SrtA∆59 gene was assembled by other
methods (generally PCR weaving). The Sa-SrtA∆59 fragment was then amplified by error-prone
PCR in the same way as Library Generation Method 5 above.
Cloning Technique G
For libraries with a G in the cloning strategy, backbone vectors and libraries were amplified by
PCR. Products were then subjected to DpnI digestion and agarose gel purification, which removed
all template DNA. Purified fragments were again amplified by PCR to obtain at least 1 µg of
backbone DNA. Backbone and library amplicons were combined in a 1:3 ratio and added to 2X
Gibson Assembly Master Mix (New England Biolabs, 20 µL total reaction per 1 pmol of backbone
DNA) and incubated at 50◦C for 1-4 hours.
Phage Library Screening
Phage Screening: Libraries X4Gβ, X4WNLε, and XH4WSLα
6 µg of each library DNA was electroporated into 800 µL of electrocompetent XL1-Blue cells (Agilent
Genomics, 2500 V, 25 µF, 200 Ω, 2 mm cuvette). Transformants were diluted into 5 mL of SOC
Media (Corning) and allowed to recover by shaking for 1 hour at 37◦C. Then, 8 mL of pre-warmed SB
Media was added to the cells along with carbenicillin (20 µg/mL final concentration) and tetracycline
(10 µg/mL final concentration) and shook for an hour at 37◦C. Carbenicillin was then added to raise
the concentration to 50 µg/mL and the cells were shook for another hour at 37◦C. Next, 2 mL of
CM13 helper phage (see above for preparation) was added and cells were incubated stationary at
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room temperature for 15 minutes. Infected cultures were added to 185 mL of pre-warmed SB Media
(50 µg/mL carbenicillin, 10 µg/mL tetracycline) and shook at 37◦C for 2 hours. Finally, kanamycin
was added to a final concentration of 70 µg/mL and cultures were shook overnight at 37◦C.
For each day of screening, phage were harvested as described above (Phage Assay Validation).
Phage were added to STEPL Buffer containing 10% w/v biotin-free powdered milk (LabScientific)
and appropriate solutes to produce the negative screening conditions described in Section 5.5. Phage
were then added to a streptavidin-coated plate (see above) and incubated for the amount of time
indicated in Section 5.5 at 37◦C. Then, wells were washed six times with TBS + 0.05% Tween-20
by vigorously pipetting and incubating for 4 minutes before shaking out the wash buffer. STEPL
Buffer containing 2% w/v biotin-free powdered milk and appropriate solutes to produce the positive
screening conditions described in Section 5.5 was then added to the wells, which were then incubated
as described in Section 5.5. Supernatants were gently transferred to 2 mL of XL1-Blue cells (OD600 =
1) and allowed to infect for 15 minutes at room temperature. 2 µL of infected culture was used for
titering.
6 mL of pre-warmed SB Media was added to the infected cells along with carbenicillin (20 µg/mL
final concentration) and tetracycline (10 µg/mL final concentration) and shook for an hour at 37◦C.
Carbenicillin was then added to raise the concentration to 50 µg/mL and the cells were shook
for another hour at 37◦C. Next, 1 mL of CM13 helper phage was added and cells were incubated
stationary at room temperature for 15 minutes. Infected cultures were added to 91 mL of pre-
warmed SB Media (50 µg/mL carbenicillin, 10 µg/mL tetracycline) and shook at 37◦C for 2 hours.
Kanamycin was added to a concentration of 70 µg/mL and cultures were shook overnight at 37◦C.
Phage Screening: Libraries G5.22-5ALα, X4WEALβ, X5ALα, and X4WSLβ
3 µg of each library DNA was electroporated into 300 µL of electrocompetent XL1-Blue cells (Agilent
Genomics, 2500 V, 25 µF, 200 Ω, 2 mm cuvette). Transformants were diluted into 5 mL of SOC
Media (Corning) and allowed to recover by shaking for 1 hour at 37◦C. Then, 8 mL of pre-warmed
SB Media (Gentrox) was added to the cells along with carbenicillin (20 µg/mL final concentration)
and tetracycline (10 µg/mL final concentration) and shook for an hour at 37◦C. Carbenicillin was
then added to raise the concentration to 50 µg/mL and the cells were shook for another hour at
37◦C. Next, 2 mL of CM13 helper phage (see above for preparation) was added and cells were
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incubated stationary at room temperature for 15 minutes. Infected cultures were added to 185 mL
of pre-warmed SB Media (50 µg/mL carbenicillin, 10 µg/mL tetracycline) and shook at 37◦C for
2 hours. Finally, kanamycin was added to a concentration of 70 µg/mL and cultures were shook
overnight at 37◦C.
For each day of screening, phage were harvested as described above. Phage were added to STEPL
Buffer containing 10% w/v biotin-free powdered milk (LabScientific) and appropriate solutes to pro-
duce the negative screening conditions described in Section 5.5 and incubated at room temperature
for 1 hour. Phage were then added to a streptavidin-coated plate (see above) and incubated for
30 minutes at room temperature. Then, wells were washed six times with TBS + 0.05% Tween-20
by vigorously pipetting and immediately shaking out the wash buffer. Remaining phage were then
eluted with acetate buffer (pH 4) for 10 minutes. Eluate was transferred to a microcentrifuge tube
containing 3.5% v/v 0.5 M sodium hydroxide. 5X STEPL Buffer containing 10% w/v biotin-free
powdered milk and appropriate solutes to produce the positive screening conditions described in
Section 5.5 was then added to the neutralized phage, which were then incubated at room temper-
ature for the amount of time conditions described in Section 5.5. With 30 minutes remaining in
the incubation time, phage were added to a streptavidin-coated plate (see above) and incubated at
room temperature. Supernatants were gently transferred to 2 mL of XL1-Blue cells (OD600 = 1)
and allowed to infect for 15 minutes at room temperature. 2 µL of infected culture was used for
titering. Finally, phage were amplified as described above.
Cloning of Library Results into pSTEPL/EGFP
The library regions of interesting clones and the pSTEPL/EGFP backbone were amplified by
PCR and agarose gel purified. Products were then re-amplified to obtain at least 1 pmol of
pSTEPL/EGFP backbone and 3 pmol library per reaction. The fragments were incubated in 1X Gib-
son Assembly Master Mix (New England Biolabs) for 1 hour at 50◦C. 1:3 dilutions of the isothermal
assembly reactions were then transformed into One-Shot Top10 cells (Life Technologies). Plasmids
were verified by sequencing before being transformed into Rosetta2 BL21 DE3 cells (EMD Millipore)
or the disulfide-forming SHuffle T7 Express cells (New England Biolabs).
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Preliminary Clone Characterization
25mL starter cultures were grown overnight in LB-Ampicillin. These were added to 225mL of LB
and grown to an OD600 of 0.8-1 before induction with 0.5mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG). Cultures were allowed to express for 24hrs at 25◦C. Cells were then harvested by centrifuga-
tion (6000 RPM, 15min) and resuspended in 10mL of lysis buffer (50mM NaH2PO4, 300mM NaCl,
1mg/mL Lysozyme, 1 EDTA-free cOmplete Mini protease inhibitor tablet (Roche), pH 7.5). Lysates
were incubated at room temperature for 30min under gentle agitation before freezing overnight at
-80◦C. Samples were then thawed and incubated for 30min with DNAse I (Roche) under gentle ag-
itation. Lysates were then sonicated and separated by centrifugation (10,000 rpm, 30min). 8mL of
clarified lysate was incubated for 1 hr with 0.5mL Talon resin (Clontech, equilibrated in lysis buffer).
The lysate and beads were then added to a column and beads were washed with 5mL STEPL buffer.
Washed beads were resuspended in a total of 1mL of STEPL buffer containing the indicated amounts
of CaCl2, triglycine, and MnCl2 (Sigma-Aldrich) and aliquoted into 1.5mL microcentrifuge tubes.
Samples were shaken at 1,000 rpm, the indicated temperature, and protected from light. At each
timepoint, samples were spun down at 3,000 rpm for 5min. GFP fluorescence was then observed
with a UV transilluminator.
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Chapter 6
Overall Conclusions and
Future Directions
6.1 Thesis Discussion
6.1.1 Design and Optimization of Sortase-Tag Expressed Protein Ligation
The ability to attach a payload to a targeting ligand is a fundamental requirement in the field of
molecular imaging. While this is simple to do if both the ligand and payload are small molecules,
the problem becomes much more complex when either is a protein. Many chemical approaches to
bioconjugation have been developed. However, these techniques are often not efficient, stoichiomet-
ric, or site specific. They may also exclude large numbers of potential ligands, such as those with
disulfide bonds. Enzymatic bioconjugation techniques ameliorate some of these issues, but are also
limited by constraining useable payloads to structures chemically similar to their natural substrates,
requiring large fusions that alter the properties of the targeting ligand, or necessitating difficult
downstream purifications. Keeping all of these considerations in mind, we set out to create a novel
bioconjugation technology that combines the small size and flexibility of chemical techniques with
the efficiency and specificity of enzymatic approaches.
We were able to do this by utilizing the transpeptidation activity of S. aureus Sortase A. In
the presence of Ca2+, the enzyme recognizes the pentapeptide sequence LPXTG and then catalyzes
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the replacement of the glycine residue with any other polypeptide that has an N-terminal glycine.
Nearly any molecule, biological or synthetic, can flank the LPXTG peptide or follow the N-terminal
glycine of the second molecule, yielding an efficient, site-specific transformation unprecedented in
its flexibility. Our novel technique, Sortase-Tag Expressed Protein Ligation (STEPL), harnessed the
power of the sortase enzyme by expressing its active domain as part of a larger chimeric protein.
The STEPL chimera consisted of, from N- to C-terminus, the protein to be conjugated, the sortase
recognition motif LPETG, a flexible linker sequence, the sortase active domain, and a hexahistidine
tag. The construct was then expressed in the E. coli cytoplasm and purified by metal affinity
chromatography. However, rather than eluting the chimeric protein off of the metal resin, the bound
beads were incubated with CaCl2 and a short, synthetic peptide. This activated the sortase domain,
cleaving the target protein off of the column via conjugation of the peptide. In theory, linking
protein cleavage to bioconjugation should result in complete bioconjugation of all target protein
that is released from the beads, eliminating the need for large excesses of synthetic peptide and
greatly simplifying downstream workups.
In practice, the system works in much the same way. The major difference is due to a peptide-
independent hydrolytic shunt in the sortase mechanism. To quantify the effect of this side reaction,
a simple test system was constructed using the reporter protein EGFP as the target protein to
be conjugated and triglycine as the synthetic peptide. We were able to monitor STEPL activity
under a number of initial conditions by measuring the EGFP concentration in the supernatant,
which would only occur if the enzyme actively cleaved the protein off of the beads. First, we used
this assay to determine the optimal CaCl2 concentration. While the hydrolytic shunt is active
in the absence of peptide, calcium is necessary even for this side reaction. By titering CaCl2 in
the presence and absence of 25 µM triglycine, we calculated a ratio of ligated to unligated free
EGFP as a function of calcium concentration. In less than 100 µM CaCl2, the system reported a
high percentage of conjugated product. This ratio quickly dropped off at higher concentrations, so
100 µM was determined to be the optimal calcium concentration for the STEPL system.
After that, we used the EGFP-STEPL reporter construct to analyze the effects of reaction time,
reaction temperature, and peptide concentration. These parameters are not independent of one
another, so a mass-action kinetics model was developed that used the Arrhenius definition of a rate
constant to capture temperature-dependence. The model was fit to wet-lab quantification of EGFP
Section 6.1: Thesis Discussion 139
release under varying conditions to determine the pre-exponential constants and activation energies
of both the glycine-dependent and glycine-independent pathways of the sortase mechanism. The
calculated parameters had reasonable magnitudes and model-predicted EGFP release fit the data
well. The model was finally used to predict the yield of conjugated protein, the percentage of re-
leased protein that would be conjugated, and the percentage of peptide consumed by the STEPL
reaction. Conjugation percentage was heavily dependent on initial peptide concentration and weakly
temperature dependent, with more peptide and higher temperatures leading to more pure results.
A ratio of initial peptide to initial chimera that gave >95% conjugated protein could be found for
all temperatures and times greater than 30 minutes. For a 6 hour reaction, only a two-fold excess of
peptide was needed for 95% purity at 37◦C. Peptide utilization was heavily dependent on both tem-
perature and initial peptide concentrations. The peptide dependence was the inverse of conjugation
purity, with peptide utilization increasing with decreasing initial peptide concentrations. Although
peptide utilization of >90% were possible, this only occurred within 6 hours at 37◦C. Finally, overall
yield increased with temperature and peptide concentration. Thus, 37◦C was determined to be the
optimal temperature for all outcomes. Interestingly, peptide utilization and conjugate purity were
found to be competing interests. Therefore, STEPL reactions can be optimized for peptide utiliza-
tion if downstream applications facilitate easy separation of conjugated and unconjugated protein,
such as subsequent surface functionalization, or for high purity if further purifications would be
difficult, for instance if the protein will be used directly for imaging or therapy.
This novel system for protein purification and bioconjugation offers many advantages over other
chemical and enzymatic ligation technologies by combining their advantages and avoiding their
shortcomings. Like chemical crosslinkers, but unlike most enzymes, STEPL can conjugate a broad
selection of bio-orthogonal functionality to a protein while adding minimal bulk. However, being an
enzymatic reaction, it is more efficient, site-specific, and quantitative, unlike most chemical conju-
gations. Because STEPL consists of a single chimeric protein, it eliminates the need for subsequent
purification of the sortase enzyme from the ligation products. What makes STEPL truly unique in
the field of bioconjugation, however, is that it links protein purification to bioconjugation. In doing
this, it can produce a high-purity, quantitatively labeled product or utilize most of an expensive
reagent. Both approaches reduce the time, cost, and complexity of bioconjugation, making it a
significant advance in the field with applications throughout academia and industry. STEPL has
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the potential to aid in the production of protein-drug conjugates, PEGylated biologics, biophysical
probes, and of course molecular imaging agents, among many other applications.
6.1.2 Applications of the STEPL System
Though promising, the STEPL system is only useful if it eases or enables the production of useful
conjugated proteins. With that in mind, we tested STEPL’s ability to create ligands for interesting
downstream applications. For this thesis, STEPL was used to express the affibodies ZHer2 and
ZEGFR, small proteins that bind tightly and specifically to the extracellular domains of the Her2/neu
and EGFR receptors, respectively. Affibodies were chosen because they express easily in the E. coli
cytoplasm and are very stable after purification, allowing us to focus on the contributions of the
STEPL system without adding complications derived from the targeting ligand itself.
Fluorescence Imaging
STEPL’s first use was the generation of targeted fluorescence contrast agents. The ZHer2 affibody
was cloned into pSTEPL and expressed in bacterial cells. A synthetic peptide containing the near-IR
fluorophore HiLyteFluor750 was used to cleave the affibody off of the column. After simple dialysis
of the column eluate into Tris-buffered saline to remove excess peptide, the sample was analyzed
by SDS-PAGE, which showed a single, fluorescent band that corresponded to the size of ZHer2. No
unconjugated affibody could be visualized on the gel, indicating that STEPL did indeed produce a
high-purity protein conjugate as predicted by the model. The conjugated affibody was then applied
to Her2/neu positive and negative cell lines. Fluorescence imaging revealed that the fluorescent
ZHer2 successful labeled only the Her2/neu positive cells, which could also be greatly reduced by
competitive inhibition with unlabeled ZHer2. In addition to microscopy, affibody labeling of the
Her2/neu positive cell line was quantified with a fluorescence scanner, essentially creating an in-cell
western reagent. These results were then duplicated by cleaving an ZEGFR-STEPL construct with
a synthetic peptide containing a different fluorophore, 5-FAM, a fluorescein derivative. Again, the
reagent specifically labeled an EGFR-positive cell line, as determined by florescence microscopy.
Thus, STEPL quickly and efficiently produced a fluorescence contrast agent with all of the expected
properties and a simpler downstream purification. The only workup step, dialysis to remove excess
labeling reagent, would be necessary in any system.
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Nanoparticle Synthesis
The ZHer2-STPEL chimera was also cleaved with a peptide containing a lysine residue that was
modified to have an azide functional group, which is capable of participating in the azide-alkyne
cycloaddition click reaction. While the label used for fluorescence imaging could be incorporated
anywhere that does not interfere with binding, the C-terminal location of the azide functionalization
has been proven to significantly improve the final performance of a targeted nanoparticle [2]. The
ZHer2-azide conjugate was then reacted with superparamagnetic iron oxide (SPIO) nanoparticles that
displayed a strained cyclooctyne derivative, which efficiently formed covalent bonds with the azide
moiety on the affibody. The resulting targeted SPIO particle was able to decrease the T ∗2 relaxivity
of Her2/neu positive cells, while inducing no change in the relaxivities of Her2/neu negative cells
or those in subjected to competitive inhibition. These changes in T ∗2 were echoed in MR images,
which showed significant darkening of the Her2/neu positive cell lines. STEPL was able to quickly
and efficiently create a targeted nanoparticle with all of its expected properties intact.
Modular Generation of Bispecific Ligands
The ZHer2 and ZEGFR chimeras were each cleaved with three different peptides: one containing a
fluorophore and a DBCO, one containing a fluorophore and a DBCO separated from the peptide
by a flexible (PEG)4 linker, and the azide peptide described above. DBCO-conjugated affibod-
ies were then incubated with azide-conjugated affibodies to create a set of six dimeric affibodies
ZHer2-ZHer2, ZHer2-(PEG)4-ZHer2, ZHer2-ZEGFR, ZHer2-(PEG)4-ZEGFR, ZEGFR-ZEGFR, and ZEGFR-
(PEG)4-ZEGFR. Dimerization was confirmed by SDS-PAGE. Affibody titers were then incubated
with a Her2/neu-positive cell line, an EGFR-positive cell line, and a double-positive cell line. By
measuring the mean fluorescence intensity of each binding reaction, we were able to calculate ap-
parent dissociation constants for each of the affibody-cell line pairs and compare the effects of
homodimerization against heterodimerization and using a long spacer against a short spacer. The
calculated dissociation constants were then used to determine the concentration of heterodimers
that will most enhance selection for the double-positive cell line, 10 nM. That concentration of each
affibody was finally incubated with cells to obtain fluorescence images that supported our hypothesis
that the bispecific ligand would show enhanced specificity for the double-positive cell line.
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This was a simple illustration of what promises to be a much more powerful technology. Using
STEPL and click chemistry as a method for generating modular bispecifics expands the field from
specific IgG heavy-light chain interactions to any two ligands that can be expressed in bacterial cells.
The inherent flexibility in STEPL would allow for the mixing of different classes of targeting ligands
and easy assaying of different spacer moieties.
6.1.3 Directed Evolution of the STEPL System
The STEPL system has proven to be very useful, but it could always be better. One of STEPL’s
shortcomings was that there was always a reduction of protein yield due to calcium-induced cleavage
within the expression cell. To remedy this, we proposed evolving the sortase enzyme to either require
much higher calcium concentrations for activity or to require a different divalent metal ion entirely.
We then attempted bacterial and phage display screens that would enable directed evolution of the
sortase active domain in the STEPL context.
An E. coli display system was designed that used an autotransporter protein to facilitate trans-
port of super-folder GFP (sfGFP), the LPETG recognition motif, a flexible linker, and the sortase
active domain across the outer membrane and hold the chimera on the cell surface. This seemed to
be the most promising option because sortase is naturally on the surface of gram-positive bacteria
and the construct would be expressed in E. coli, where all the previous STEPL work had already
been done. However, the system had no detectable sortase activity even in saturating levels of
triglycine and calcium. Immunohistochemistry assays showed that sfGFP had indeed been exported
to the surface of the cell, so the system was altered by introducing a second flexible linker to in-
crease the distance between the cell surface and STEPL domains. This had no effect. Neither did
separating the STEPL domains from the surface by including a fully functional ECFP domain or
using a different autotransporter. Most likely, the sortase active domain did not re-fold correctly
after being denatured during transport to the cell surface.
A yeast display system was briefly considered. However, data showed that the sortase domain
was heavily glycosylated in the yeast endoplasmic reticulum. This could potentially have large and
unknown effects on the evolutionary process, so yeast display was not pursued.
A phage display system was designed that linked the STEPL domains to the phage surface by
the coat protein pIII. The STEPL “ligand” bound the structure to streptavidin either by directly
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including the streptavidin binding peptide (SBP) or the biotin acceptor peptide, which is biotiny-
lated in vivo. An active sortase domain would cleave off the ligand and release the phage from
a streptavidin-coated plate, an easy physical separation that is much less subjective than sorting
cells based on fluorescence. When assayed for activity, only the SBP-bearing phage bound to the
plate. The phage displaying the biotin acceptor peptide probably did not spend enough time in
the cytosolic compartment to be biotinylated, so that construct was discarded. The SBP-STEPL
phage, however, showed robust activity in the phage system. Due to high levels of calcium in the
milk-based blocking buffer, the only phage that did not cleave were those with the C180A mutation
that eliminates sortase activity. Phage were assayed in a number of other blocking buffers, but none
prevented non-specific binding as well as the 2% milk. Because all of the screening buffers would
have contained high calcium concentrations in order to weaken its binding affinity for sortase, the
biotin-free 2% milk was chosen as the blocking buffer. Thus, a phage display screening assay was
validated and it was chosen as the method of directed evolution for the STEPL system.
Now that a screen had been established, a library to screen could be designed. The β3/β4 and
β6/β7 loops constitute the calcium binding pocket in sortase, so mutations were focused on the
twenty residues that make up those two loops. The potential library size of randomizing all twenty
positions to all twenty amino acids was astronomically large, so an optimized library was designed.
In this library, the available amino acids for each position would mimic the hydrophobicity of the
wild-type residue. This design would ensure that the β3/β4 loop was still anchored to the core of
the protein by two hydrophobic residues. It would also provide an abundance of residues capable of
coordinating a metal ion. By restricting the codons of 18 of the 20 positions, the potential library
size was reduced by a factor of 106, yielding a library that is still too large to sample most of
the sequences but is enriched for sequences more likely to work. While cloning the library, it was
observed that the standard method of using degenerate oligonucleotides as PCR primers resulted in
biasing the library toward the wild-type sequence, especially for the GC bases. To avoid this effect,
libraries were instead produced as a system of overlapping oligonucleotides that were combined by
isothermal assembly. Thus, complimentary library regions were created by a polymerase without
any bias toward the wild-type bases.
With a screen and a library, evolution could begin. The first evolution experiment consisted
of five rounds of screening the phage and resulted in only five sequenceable plasmids, each unique.
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These were cloned into the EGFP-STEPL construct used to validate the system and assayed in the
same way. Unfortunately, all of the clones either cleaved under all conditions or did not cleave under
any conditions.
Many of the sequenced plasmids had undergone recombination to delete the sortase sequence
entirely, so the cloning methods were altered to add stability and the screen was run again. After
another five rounds of screening, 26 sequences were returned, again all unique. Ten clones were
chosen to be assayed. None were modulated by the addition of glycine or manganese, the ion chosen
as a calcium replacement during the 4 hour reaction. When left overnight, one of the clones did
cleave only in the presence of high calcium. However, this was independent of glycine. This was
subjected to random mutagenesis to create a second generation screen, which returned no sequences.
The next library was screened under much harsher conditions to try and obtain a consensus
sequence. After five rounds of screening, seventeen sequences were obtained, all unique yet again.
All of the clones were assayed. None could be modulated by high calcium or manganese.
At this point, the screening method was altered to reduce non-specific dissociation from the
streptavidin-coated plates. This screen included a 20-fold increase in manganese concentration in
hopes of obtaining even a weakly dependent clone. After five rounds of screening, nine identical
sequences were obtained. However, the sequence yielded inactive sortase under all conditions.
Finally, a library of only random mutations to the entire sortase sequence was screened. After
five rounds, one sequence was obtained. This also was inactive under all conditions.
A constant bias for a cysteine at position 109, which was allowed to sample all twenty amino
acids, indicated that the screens were indeed selecting for something. Unfortunately, they did
not select for conditional sortase activity as intended. One theory is that the screens selected for
calcium- or manganese-mediated streptavidin binding. Many affinity ligands are evolved using a
similar randomization of two loops, so this was a distinct possibility. However, the SBP domain
should have still held inactive phage to the plate, which was the most common phenotype assayed.
Another possibility is that the screens selected for a metal-modulated SBP-binding domain, which
would explain why they no longer bound the streptavidin in the positive screening buffers. It is also
possible that this bound conformation was stabilized by a disulfide bond, explaining the consensus
cysteine found in most of the sequences.
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6.2 Future Directions
6.2.1 Extending STEPL to Other Expression Systems
An obvious next step in the development of STEPL is to extend it to other prokaryotic and eukaryotic
expression systems. While the E. coli cytoplasm is a convenient and scalable place to express
proteins, it is severely limited in the types of proteins that can be expressed. scFvs for example,
have much more complex structures than affibodies and often contain multiple disulfide bonds, which
cannot form in the reducing environment of the cytoplasm. When overexpressed proteins are poorly
folded, they can precipitate in vivo, forming occlusion bodies that complicate harvesting proteins
[268]. There are a few strategies for avoiding these precipitates, but the problem is usually best
solved by changing expression systems entirely.
The simplest change is to express the STEPL chimera in the bacterial periplasm, which is an
oxidizing environment that has been reported to be a favorable compartment for scFv expression
[269]. This is accomplished by fusing the OmpA or PelB signaling peptide to the N-terminus of
the chimera, before the targeting ligand. The peptide facilitates transport across the inner mem-
brane before being proteolyzed, resulting in the original STEPL chimera. During phage display,
the STEPL-pIII protein was transported to the periplasm via the OmpA signal peptide. Phage
displaying the sortase enzyme showed activity, which is a good indication that periplasmically ex-
pressed STEPL chimeras will also remain functional. We have already begun working on expressing
scFv-STEPL chimeras in the periplasm. The STEPL chimera has been cloned into the pET20(+)
expression plasmid, which directs periplasmic expression via the PelB signal. Initial experiments
resulted in poor yield of scFv fusion proteins, so the project has been delegated to the experts at
the Wistar Institute’s Protein Expression Facility.
When expressing complicated proteins, however, the best options are eukaryotic. Yeast, insect,
and mammalian cells all have a secretory system capable of folding and secreting complex proteins
with a myriad of post-translational modifications [270]. Yeast are particularly well suited for protein
expression because they can be grown to high densities and secrete the protein for easy isolation and
continuous manufacturing [271]. Although they grow slowly compared to bacterial cells, they outpace
other eukaryotic systems by a considerable amount. Currently, a collaborator in the Muzykantov
group at Penn is working to optimize expression of an scFv-STEPL fusion in the P. pastoris yeast
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strain. By optimizing STEPL in eukaryotic expression systems, its utility would grow enormously
as it could then be capable of expressing and conjugating full-length antibodies and enzyme-derived
therapeutic proteins.
6.2.2 Improved Directed Evolution Strategies
While the directed evolution attempts described in Chapter 5 were unable to produce sortase enzymes
with reduced background cleavage, this will still be necessary to accelerate adoption of the technology
throughout the scientific community. To that end, there are a few potential options for improving
the directed evolution strategy, depending on what the problem with the current system actually is.
In Section 5.5.4 we altered the screening protocol in an attempt to solve one potential problem,
that SBP-streptavidin binding affinity may be too low, resulting in random release of inactive phage.
Another solution to that problem is to change the affinity ligand from SBP to one with a stronger
interaction with its target. We are already in the process of doing this, cloning a phagemid that
displays a hexahistidine tag rather than SBP. The tight binding of His6 with immobilized metal
resins is well documented [272, 273, 274, 275]. Even in this thesis, we have shown that a cobalt
resin is capable of retaining protein for a full 24 hours. Using a His-tag for immobilization may also
reduce the potential to evolve a binding pocket for the affinity ligand because it is much shorter
than SBP and lacks any sort of structure necessary for protein-protein interactions.
Another way to avoid evolving an affinity ligand binding pocket is to use larger ligands, such as
monobodies or nanobodies. Even if a modulated, tight binder were to emerge, it would have a much
lower chance of binding the ligand in a configuration that impairs binding to an immobilized target.
To further ensure this, several copies of the ligand could be strung together one after another. Not
only would that greatly increase the overall avidity to the plate, it would also leave extra ligands
that are capable of binding the plate even if one of them was sequestered by an evolved binding
loop, making it much more difficult for that phage to pass the screen.
Phage display itself may be too complicated of a system for the delicate evolution of an enzyme.
If that is the case, a delicate screening system such as ribosome display may be more appropriate.
Ribosome display is entirely in vitro, so it removes many possible complications, such as STEPL-
phage interactions, the oxidizing environment of the periplasm, and transport across the inner
membrane. It would also allow much larger libraries that could increase the possibility of recovering
clones with the desired phenotype.
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6.2.3 Triggered Cleavage with Dual-Sortase Constructs
Creating a manganese-triggered sortase would allow for more than just higher protein yields. It
would also enable STEPL proteins with two independently active sortase domains. By creating
a fusion protein that consists of a targeting ligand, Sa-SrtA∆59Mn, the sortase motif LPEGT, a
flexible linker, Sa-SrtA∆59, and a His6 tag, it would be possible to use the Ca-triggered Sa-SrtA∆59
to perform the standard STEPL conjugation and purification and later use the Mn-triggered Sa-
SrtA∆59 to cleave that label off of the protein. This would be especially useful in nuclear imaging.
The radiotoxicity of PET and SPECT agents forces them to either use nuclides with short half-lives,
agents that can be excreted quickly, or low doses of contrast agent [1, 276]. With the dual-STEPL
system, a nuclide could be conjugated to the targeting ligand, which is then injected and allowed
to equilibrate for contrast. After an image is obtained, Mn is injected to trigger the cleavage of
the nuclide from the targeting ligand, allowing the toxin to be quickly excreted. Because the time
that the targeting protein spends in the patient would be decoupled from the length of time that
the radiolabel would be present, higher activities of more stable nuclei could be used. For example,
the major nuclide used for PET, 18F, has a half-life of 110 minutes. This short half-life allows high
activities to be used for imaging, while limiting the radiation dose to the patient. It also requires an
on-site cyclotron to produce the contrast agents, which greatly increases the expense of PET imaging
and limits it to only a handful of clinics. With the dual-STEPL approach, it would be possible to
produce the contrast agents off-site and in bulk with a different positron-emitter like 125I, which has
a half-life of 60 days, because the patient dose could be mitigated by cleavage rather than a short
life-span.
6.3 Concluding Remarks
In this thesis, we have documented the design, optimization, and initial applications of a novel
protein system capable of condensing protein purification and conjugation into a single enzymatic
step. By modeling the underlying chemical principles of the STEPL system, we proved that it is one
of the most efficient bioconjugation systems, capable of producing yields of more than 95% purity
while at the same time reducing the amount of conjugate needed to achieve that purity. We then
showed examples of STEPL’s inherent flexibility and modularity by making a panel of affibody-
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peptide conjugates that were used as monomeric and dimeric fluorescence imaging agents as well
as targeting ligands for magnetic nanoparticles. As proteins continue to become a larger portion
of the pharmaceutical portfolio, technologies like STEPL will become foundational to the future of
medicine and biotechnology in general. This will be even more likely once STEPL has been adapted
for use in eukaryotes and evolved to increase protein yields. The incredible flexibility of the sortase
enzyme coupled with STEPL’s cost-, material-, and time-efficient single-protein design give STEPL
the potential for widespread use in academic and industrial settings.
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